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Resumo 
 
Mutações no gene GJB2 são responsáveis por uma percentagem significativa de casos de 
surdez neurossensorial não sindrómica em várias populações. Este gene pertence à família de 
genes que codificam as conexinas, as subunidades dos hemi-canais (conexões) que formam os 
canais intercelulares das gap junctions existentes nos vertebrados e nos tunicados. A conexina-
26 (Cx26), codificada pelo gene GJB2, é expressa em vários tecidos, incluíndo tecidos específicos 
epiteliais e conjuntivos da cóclea, órgão auditivo localizado no ouvido interno. Na cóclea, a Cx26 
é co-expressa com a conexina-30 (Cx30), codificada pelo gene GJB6, em vários tipos de células. 
Duas extensas deleções afectando o gene GJB6 são também responsáveis por vários casos de 
surdez, sendo a maior parte deles devido a heterozigotia composta com uma mutação em GJB2. 
Dada a relevância dos genes GJB2 e GJB6 na etiologia da surdez em várias populações, o 
diagnóstico molecular de casos de surdez neurossensorial não sindrómica é habitualmente 
iniciado pela análise da região codificante do gene GJB2 (a maior parte das mutações 
patogénicas foram encontradas nesta região), seguida da investigação da presença das deleções 
do gene GJB6 quando nenhuma ou apenas uma mutação é encontrada no gene GJB2. Em certos 
casos, a atribuição da causa da surdez ao genótipo GJB2/GJB6 é complicada pelo facto de a 
patogenicidade de algumas mutações do gene GJB2 ser indeterminada ou controversa, quer por 
falta de evidência genética (segregação evidente da mutação com a surdez), quer devido a 
dados genéticos contraditórios (indivíduos com audição normal e indivíduos com surdez que 
apresentam o mesmo genótipo). Nesses casos, os estudos funcionais constituem um meio 
adequado de investigar a eventual patogenicidade dessas mutações, tendo várias sido já desde 
modo analisadas. 
Um dos primeiros objectivos deste trabalho foi o estudo da região codificante e local de 
splicing receptor do gene GJB2 em pacientes portugueses com surdez neurossensorial não 
sindrómica. Estendemos, seguidamente, a análise do gene a regiões não codificantes (promotor 
basal e os cerca de 700 pb imediatamente a montante, o exão 1, o local de splicing dador e toda 
a 3’UTR). Estas regiões não codificantes têm sido até agora raramente estudadas. No entanto, 
duas mutações patogénicas não codificantes tinham sido já identificadas, ambas no local dador 
de splicing. Inicialmente, analisámos apenas alguns indivíduos portadores de uma mutação 
xviii 
 
codificante, relativamente ao promotor basal, exão 1 e local dador de splicing. No decorrer 
desta análise inicial de regiões não codificantes, encontrámos uma nova mutação (c.-259 C>T) 
no promotor basal, num dos locais de ligação de factores de transcrição Sp1/Sp3. Esta mutação 
foi encontrada numa paciente com surdez profunda, em trans com p.Val84Met, por nós 
identificada anteriormente como uma nova mutação associada a surdez em GJB2. 
Posteriormente, analisámos todas as regiões não codificantes atrás referidas, num 
conjunto maior de pacientes (n=89), com apenas uma ou nenhuma mutação codificante em 
GJB2, e em 91 controlos, considerados como tendo audição normal. Os resultados decorrentes 
deste análise revelaram que, nos pacientes, está sobre-representado o genótipo 
c.[*168A>G(+)*931C>T], um duplo heterozigótico respeitante aos SNPs rs55704559 e rs5030700 
(ambos localizados na 3’UTR), respectivamente. A análise in silico prevê que a variante 
c.*168A>G (independentemente de estar uma citosina ou uma timina na posição c.*931) cause 
uma alteração da conformação do mRNA. Deste modo, os nossos dados sugerem que o alelo 
c.*168G poderá estar associado a surdez. 
Outro dos objectivos deste trabalho foi a elucidação da patogenicidade das referidas 
mutações c.-259C>T e p.Val84Met, assim como da mutação p.Met163Leu, também encontrada 
pela primeira vez, num trabalho prévio, numa outra família Portuguesa. Os dados genéticos 
disponíveis sobre as três mutações (os nossos e os publicados por outros autores) eram 
insuficientes para a confirmação da sua patogenicidade, e assim efectuámos estudos funcionais 
para investigarmos os seus efeitos. 
Os resultados obtidos sugerem que as três mutações são de facto patogénicas, exercendo 
o seu efeito de formas distintas. A mutação c.-259C>T reduz muito significativamente a 
actividade do promotor basal. Relativamente às mutações codificantes, enquanto a p.Val84Met 
altera as propriedades de permeabilidade iónica e molecular do canal intercelular, o que poderá 
in vivo traduzir-se num défice funcional, a p.Met163Leu causa a morte celular, possivelmente 
por outro mecanismo que não o funcionamento anómalo de conexões não emparelhados (já 
descrito na literatura), e apresenta um efeito dominante negativo parcial sobre a Cx26 e Cx30 
do tipo selvagem. 
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Abstract 
 
Mutations in the GJB2 gene are responsible for a considerable proportion of 
nonsyndromic sensorineural hearing loss (NSSHL), in several populations. This gene is a member 
of a gene family coding for connexins, the subunits of the hemichannels (connexons) which 
form the intercellular channels of the gap junctions existing in the vertebrates and tunicates. 
Connexin-26 (Cx26), encoded by the GJB2 gene, is expressed in several tissues, including specific 
epithelial and conjunctive tissues of the cochlea, the auditory organ which is localised to the 
inner ear. In the cochlea, Cx26 is co-expressed with connexin-30 (Cx30), encoded by the GJB6 
gene, in several cell types. Two large GJB6 deletions are involved in several hearing loss (HL) 
cases, as well, being most of these cases due to compound heterozygosity with a GJB2 
mutation. 
Given the relevance of both GJB2 and GJB6 genes to the HL etiology in several 
populations, the molecular diagnosis of NSSHL cases with probable genetic cause is usually 
initiated by the analysis of the GJB2 coding region (in which most pathogenic mutations have 
been found), followed by the investigation of the presence of the GJB6 deletions in the cases 
where none or only one GJB2 mutation is found. In some cases, attributing the cause of the HL 
to the GJB2/GJB6 genotype is complicated because some GJB2 mutations are of unclear or 
controversial pathogenicity, due to either lack of genetic evidence (evident segregation of the 
mutation with the HL) or contradictory genetic data (same genotype occurring in both normal-
hearing and hearing-impaired individuals). In those cases, functional studies constitute an 
adequate approach for the investigation of the putative pathogenicity of such mutations, 
several of which have already been studied in this way. 
One of the aims of this work consisted in the study of the coding region and acceptor 
splice site of the GJB2 gene in Portuguese individuals presenting with NSSHL. We have further 
extended the analysis of the gene to noncoding regions (basal promoter and about 700 bp 
immediately upstream, exon 1, donor splice site and the whole 3’UTR). These noncoding regions 
have rarely been studied. Nonetheless, two pathogenic noncoding mutations had previously 
been identified, both in the donor splice site. Initially, we analysed the basal promoter, exon 1 
and donor splice site in some patients who only harboured one coding mutation. We then found 
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a novel mutation (c.-259C>T) in the basal promoter, in one of the binding sites for Sp1/Sp3 
transcription factors. This mutation was found in a profoundly hearing-impaired patient, in trans 
with p.Val84Met, that we had identified as a novel mutation, in a previous work.  
Later, we analised all the fore mentioned noncoding regions in a larger sample, including 
monoallelic patients and also those harbouring no mutation in the GJB2 coding region (n=89) as 
well as 91 controls who reported to have normal hearing. The obtained data revealed that the 
c.[*168A>G(+)*931C>T] double heterozygous genotype, regarding the rs55704559 and 
rs5030700 SNPs (both localised to the 3’UTR), respectively, is overrepresented in the patients. 
In silico analysis predicts that the c.*168A>G variant (regardless of the fact that in position 
c.*931 is a cytosine or a thymine) causes an alteration of mRNA folding. Thus, our data suggest 
that the c.*168G allele might be associated with HL. 
Other aim of this work was to investigate the effects of the mutations c.-259C>T and 
p.Val84Met, mentioned above, and the mutation p.Met163Leu, also identified for the first time 
in a previous work, in other Portuguese family. The available genetic data regarding these 
mutations were insufficient to prove their pathogenicity, and thus we have performed 
functional studies on the three mutations. The obtained results suggest that the three 
mutations are indeed pathogenic, exerting their effect in distinct ways. The c.-259C>T mutation 
decreases very significantly the basal promoter activity. As regards the coding mutations, 
p.Val84Met alters the ionic and molecular permeability properties of the intercellular channel, 
which may compromise their function in vivo, while p.Met163Leu leads to cell death, possibly 
by a mechanism other than the malfunctioning of undocked hemichannels (already described in 
the literature), and has a partial dominant-negative effect on wild-type Cx26 (wtCx26) and Cx30 
(wtCx30). 
 
 
 CHAPTER 1 
 
General Introduction 
 
  
2 Chapter 1 
 
Section 1 - Physiology of Hearing 
 
The mammalian auditory system is capable of detecting and analyzing sounds over a wide 
spectrum of frequencies (humans can hear sounds between 20 Hz to 20 kHz) and over an 
intensity range of 12 orders of magnitude or 120 dB (Robles & Ruggero, 2001). 
 
Ear Anatomy 
The human auditory system, responsible for the complex process of hearing, is composed 
of the outer ear, middle ear and inner ear (fig. 1). 
 
 
 
Figure 1. Structure of the human ear. Reproduced from Encyclopædia Britannica Inc. (n.d.). 
 
The outer ear is composed of the external ear (auricle) and the ear canal (external 
auditory canal). The middle ear includes the tympanic membrane, at the end of the ear canal, 
and three ossicles (maleus, incus and stapes). The middle ear cavity is connected by the 
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Eustachian tube to the pharynx. The inner ear consists of the vestibular apparatus, responsible 
for the balance function, and the cochlea, the organ of hearing (Møller, 2006). 
The human cochlea is a structure coiled in the form of a snail (fig. 2), which number of 
turns is generally considered to be 2 ½. However, a study conducted by (Biedron, Westhofen, & 
Ilgner, 2009) suggests that the majority of individuals (65% in their study) has more than 2 ½ 
cochlear turns, of which a small fraction has more than 2 ¾ turns. The cochlea is composed of 
three contiguous, fluid-filled, membranous tubes, scala vestibuli, scala tympani and scala media 
(fig. 2), being enclosed by a bony shell, the otic capsule. 
The scala vestibuli and scala tympani, which communicate near the apex of the otic 
capsule, at helicotrema (fig. 2), are filled with perilymph, a fluid with an ionic composition 
similar to that of other extracellular fluids. The scala media is filled with endolymph, a fluid that, 
contrary to perilymph, has a high potassium concentration (Wangemann, 2006), which is 
necessary for the normal auditory function. 
 
 
 
Figure 2. Cochlea opened from the side. The three compartments (scala vestibuli, scala media, 
scala tympani) are shown. The arrows indicate the direction of the sound wave traveling through the 
perilymph along scala vestibuli and scala tympani, which are connected at helicotrema. The stirrup is 
also called the stapes. Figure reproduced from Hearing Central LLC (n.d.). 
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Transduction of sound into nerve impulses 
The sound is conducted through the outer ear to the tympanic membrane, which 
transmits vibration to the three ossicles of the middle ear. These ossicles impart the vibration to 
the oval window of the cochlea (fig. 2), creating a mechanical wave in the cochlear fluid and in 
the basilar membrane (fig. 3). The mechanical vibration is transduced into electric signals in the 
organ of Corti (fig. 3), which contains several cell types, including inner and outer hair cells (IHCs 
and OHCs, respectively) as well as supporting cells (e.g. inner and outer pillar cells, Claudius’, 
Hensen’s and Deiters’ cells) (fig. 3). 
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Figure 3. Representation of a cross-section of one turn of the cochlea, showing the three compartments, 
scala vestibuli, scala media and scala tympani, and the organ of Corti, resting on the basilar membrane. 
1. Inner hair cell; 2. Outer hair cell; 3. Interdental cell (IDC); 4. Inner sulcus cells; 5. Inner pillar cells; 6. 
Outer pillar cells; 7. Deiters’ cells; 8. Hensen’s cells; 9. Claudius’ cells; 10. Spiral ligament; 11. Spiral 
limbus; 12. Stria vascularis; 13. Spiral ganglion; 14. Auditory nerve; 15. Reissner’s membrane; 16. 
Tectorial membrane (TM); 17. Basilar membrane; 18. External sulcus cells; 19. Spiral prominence; 20. 
Bony spiral lamina; 21. Reticular lamina; 22. Between IDC and TM; 23. Scala vestibuli; 24. Scala media; 
25. Scala tympani. Reproduced from Van Camp & Smith (2011a). 
 
The OHCs play an active role in increasing sensitivity to low intensity acoustic stimuli, and 
in frequency selectivity (especially for weak sounds) while the IHCs are responsible for the 
transduction of mechanical vibration (caused by sound) into nerve impulses (Møller, 2006). The 
movement of the basilar membrane leads to the deflection of the stereocilia at the apical 
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surface of IHCs and OHCs, which elicits the opening of the transducer channels (Beurg, Evans, 
Hackney, & Fettiplace, 2006; Ricci, Kennedy, Crawford, & Fettiplace, 2005; Stauffer & Holt, 
2007). The current that then passes through these non-selective cation channels, carried by Ca2+ 
and mainly by K+ (LeMasurier & Gillespie, 2005), leads to depolarization of the cell’s membrane. 
Influx of calcium ions through IHCs’ voltage-gated Ca2+ channels elicits exocytosis (Brandt, 
Striessnig, & Moser, 2003; Moser & Beutner, 2000) and consequently the release of the 
neurotransmitter which stimulates type I afferent fibers via glutamatergic synapses, involving 
the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor and the glutamate-
aspartate transporter (GLAST) (Fuchs, Glowatzki, & Moser, 2003; Glowatzki et al., 2006). This 
primary acoustic input is then transmitted to the brain. 
 
K
+
 recycling 
The process of transduction requires K+ to be returned to the endolymph. It is believed 
that K+ ions that exit hair cells through K+ channels at their basolateral membrane into the 
perilymph may be taken up by supporting cells (Hibino & Kurachi, 2006; Zdebik, Wangemann, & 
Jentsch, 2009), and move either through supporting cells, epithelial cells, and fibrocytes of the 
spiral limbus back into the endolymph, or through supporting and epithelial cells to the spiral 
ligament, where they are taken up by fibrocytes and conducted via the fibrocyte network to the 
stria vascularis where they are then secreted back into the endolymph (Spicer & Schulte, 1998) 
(fig. 4). 
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Figure 4. A schematic representation of the proposed transcellular pathways of K+ ions, effluxed 
from hair cells during auditory transduction, back to the endolymph. B=basal cell; BP=border cell; 
Cap=capillary; C=Claudius’ cell; CI=central interdental cell; D=Deiters’ cell; H=Hensen’s cell; 
I=intermediate cell; IH=inner hair cell; IS=inner sulcus cell; M=marginal cell; MI=medial interdental cell; 
LF =light fybrocyte; LI=lateral interdental cell; OH=outer hair cell; OS=outer sulcus cell; RP=root process; 
SF =stellate fybrocyte; SL=supralimbal fybrocyte; T=tectal cell; Ia, Ib, II, IV, and V=types of lateral wall 
fybrocytes. Reproduced from Spicer and Schulte (1998). 
 
In addition to K+ circulation induced by acoustic stimulation, evidence supports the 
existence of standing currents in the cochlea (fig. 5), not depending on acoustic stimulation but 
being modulated by it (Zidanic & Brownell, 1990). 
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Figure 5. Model for standing currents in the cochlea in terms of current density field lines. The 
current leaks from scala media through the mechanically-sensitive transduction channels in the 
stereocilia of hair cells. Current leakage from scala media is thought to occur also through Reissner's 
membrane and through (or between) the supporting cells lateral to the organ of Corti. Reproduced from 
Zidanic and Brownell (1990). 
 
Stria vascularis and the endocochlear potential (EP) 
The stria vascularis, located in the cochlear lateral wall, is a tissue composed of two 
epithelial layers, with one composed of basal cells (BCs) and intermediate cells (ICs), and the 
other composed of marginal cells (MCs). The space that exists between the MCs and ICs is 
designated by intrastrial space (IS), and contains a dense capillary network (fig. 6). 
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Figure 6. Schematic diagrams illustrating the structure and location in the cochlea of the stria vascularis 
and the electrogenic machinery involved in the endocochlear potential generation. Inset: cross section of 
a cochlea’s turn. OC = organ of Corti; Sc.V = scala vestibuli; Sc.M = scala media; Sc.T = scala tympani; SL = 
spiral ligament; SV = stria vascularis. Red lines represent the vascular system of the cochlea lateral wall. 
Large diagram: stria vascularis in detail. B = basal cells; I = intermediate cells; M = marginal cells. Black 
boxes indicate tight junctions (TJs) between marginal cells and between basal cells. Endothelial cells of 
the SV capillaries are also linked by TJs (not represented). Intermediate and basal cells of the SV and 
fibrocytes (F) of the SL are connected by gap junctions (GJs) (double bars) composed of Cx26 and Cx30 
(Forge et al., 2003; Lautermann et al., 1998; W. Liu, Boström, Kinnefors, & Rask-Andersen, 2009; Y.-P. Liu 
& Zhao, 2008). The K+ concentration (in mM) and the electric potential (in mV) are indicated in each of 
the three extracellular fluid spaces, namely the perilymph, intrastrial fluid, and endolymph. Each electric 
potential is indicated relative to that of the perilymph, which is taken as reference (0 mV). Figure 
reproduced from Cohen-Salmon et al. (2007).  
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As mentioned previously, stria vascularis secretes K+ ions into the endolymph. 
Additionally, stria vascularis generates an EP of approximately +80 mV which constitutes the 
main driving force for sensory transduction (Wangemann, 2002), thus being critical for the 
normal auditory function. The EP comprises two different K+-diffusion potentials, one across the 
apical membrane of the ICs and the other across the apical side of the MCs (Nin et al., 2008). 
This EP is dependent on KCNJ10 (Kir4.1) (Marcus, Wu, Wangemann, & Kofuji, 2002; Nin et al., 
2008) and KCNQ1/KCNE1 (Nin et al., 2008) K+ channels, localised to the apical surfaces of ICs 
and MCs, respectively. The Na+,K+-ATPase and NKCC K+ transporters, that exist in the basolateral 
membrane of MCs, are also important for the generation of the EP (Nin et al., 2008). The gastric 
H+,K+-ATPase is expressed at the basolateral membrane of MCs as well, and may participate in 
EP formation (Shibata et al., 2006), but its role in the regulation of the electrochemical milieu of 
the IS remains unclear (Nin et al., 2008). 
 
Cochlear gap junction systems 
Two gap junction systems, the epithelial cell and the connective cell gap junction systems, 
exist in the cochlea and are thought to play a role in the recirculation of K+ by providing a 
mechanism for the uptake of the K+ released by the hair cells, its transcellular transport 
laterally, and its delivery to the stria vascularis (Kikuchi, Adams, Miyabe, So, & Kobayashi, 2000; 
Kikuchi, Kimura, Paul, & Adams, 1995; Kikuchi, Kimura, Paul, Takasaka, & Adams, 2000). Spicer 
and Schulte (1998) suggested the existence of a medial K+ recycling pathway from IHCs, in 
parallel with the formerly hypothesized lateral pathway (fig. 4), implicating the participation of 
gap junctions in both transcellular routes. Jagger and Forge (2006) presented evidence for the 
existence of two distinct compartments (medial and lateral) in the organ of Corti, which are 
isolated from each other, in terms of gap junctional intercellular communication. This finding 
supports Spicer and Schulte’s model of two distinct transcellular routes (medial and lateral) for 
the recirculation of K+, in which gap junctions would play a role, but it also demonstrated the 
existence of gap junction channels with different permeability properties, suggesting that the 
gap junction intercellular communication may play additional roles in the organ of Corti beyond 
its putative contribution for K+ recycling. 
General Introduction 11 
 
Section 2 - Hearing loss 
 
Hearing loss is the most common sensorial impairment being a major public health 
concern. In 2005, about 278 million people had moderate to profound hearing impairment, of 
whom 80% live in low- and middle-income countries (World Health Organization, 2011a). HL 
affects 6 to 8% of the population in developed nations (Schrijver, 2004). This condition can 
occur at any age. In children before speech, HL (prelingual HL) occurs in 1 in 800-1000 while in 
early childhood HL occurs in 1 in 400-500. The probability of impairment increases with age 
(phenomenon designated by age-related HL or presbyacusis), affecting 2.3 % of the population 
aged 40-50 years, and over 30% of the population above 70 years of age (Petit et al., n.d.). The 
auditory defect can be located in the external or middle ear (conductive HL), or in the inner ear 
(sensorineural HL), affecting the cochlea or the auditory nervous system. Mixed HL results from 
anomalies in both external/middle ear and inner ear. HL may present itself with variable grades, 
which are described in table 1. 
 
Table 1. Grades of hearing impairment, adapted from World Health Organization (2011b). Grades 2, 3 
and 4 are classified as disabling hearing impairment. The audiometric ISO values are averages of values 
at 500, 1000, 2000, 4000 Hz. 
 
Grade of 
impairment  
Corresponding audiometric 
ISO value  
Performance  
0 - None 25 dB or better 
(better ear)  
No or very slight hearing problems. Able to hear 
whispers.  
1 - Slight (Mild) 26-40 dB 
(better ear)  
Able to hear and repeat words spoken in normal 
voice at 1 metre.  
2 - Moderate 41-60 dB 
(better ear)  
Able to hear and repeat words spoken in raised 
voice at 1 metre.  
3 - Severe 61-80 dB 
(better ear)  
Able to hear some words when shouted into 
better ear.  
4 - Profound 81 dB or greater 
(better ear)  
Unable to hear and understand even a shouted 
voice.  
 
HL can be caused by environmental factors (infections, prematurity, trauma and 
exposition to ototoxic medications), however, in developed countries, most cases have a 
genetic cause. 
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Section 3 - Genetic hearing loss 
 
Genetic hearing loss can be syndromic (~30%) or nonsyndromic (~70%). About 80% of 
nonsyndromic hearing loss (NSHL) cases are autosomal recessive, 15-20% are autosomal 
dominant, about 1% are X-linked and at least 1% are due to mutations in the mitochondrial DNA 
(mtDNA) (Schrijver, 2004). 
To date 60 nuclear genes associated with NSHL have been cloned (Van Camp & Smith, 
2011b). While eight of them are associated with both autosomal recessive and dominant HL, 17 
genes have been strictly associated with autosomal dominant HL, and 32 other genes are so far 
related with autosomal recessive HL only. Three genes are implicated in X-linked NSHL. Two 
mitochondrial genes are also associated with NSHL. 
Mutations in one particular gene, GJB2, coding for the Cx26 protein, are a major cause of 
NSHL/NSSHL in several populations (Kenneson, Van Naarden Braun, & Boyle, 2002). As such, 
screening for mutations in this gene is generally the first step undertaken in the molecular 
diagnosis of this pathology. Two gross deletions involving one other connexin gene, GJB6 (Cx30) 
(F. J. del Castillo et al., 2005; I. del Castillo et al., 2002; Lerer et al., 2001; Pallares-Ruiz, Blanchet, 
Mondain, Claustres, & Roux, 2002) have also been associated with NSHL in several cases. 
 
 
Section 4 - The role of GJB2 (Cx26) and GJB6 (Cx30) genes in hearing loss 
 
The Connexins and Gap Junctions 
Connexins are transmembrane proteins, with four transmembrane domains (M1-M4), two 
extracellular loops (E1, E2), a cytoplasmic loop and cytoplasmic amino (N)- and carboxy (C)- 
termini (Kumar & Gilula, 1996). The N-terminus, transmembrane domains and extracellular 
loops are highly conserved among connexins, while the cytoplasmic loop and C-terminus are 
quite variable in both length and sequence (Haefliger et al., 1992). 
Connexins oligomerize into hemichannels termed connexons, which are assembled from 
six connexin subunits (Baker, Caspar, Hollingshead, & Goodenough, 1983; Makowski, Caspar, 
 Phillips, & Goodenough, 1977; Perkins, Goodenough, & Sosinsky, 1997; Unwin & Zampighi, 
1980; Yeager, 1998). Two connexons in adjacent plasma membrane
intercellular channel (fig. 7). 
 
 
 
Figure 7. Tri-dimensional representation of a connexon (A), and of two connexons docked to form 
a intercellular channel (B). Figure adapted from
 
Several of these intercellular channels cluster into structures termed gap ju
Channels formed by connexins have been shown to be permeable to atomic
glutathione, glutamate (Harris, 2001)
and even siRNAs (Valiunas et al
nervous system, respiratory epithelium, bone, lens, heart and vasculature, reproductive system, 
inner ear) (Harris & Locke, 2009)
proteins are of importance in kerati
wound healing (Aasen & Kelsell, 2009; Langlois 
Becker, 2007). Connexins are also involved in 
Saffitz, 2001), and in the electric signaling between 
tissue homeostasis (Mathias, White, & Gong, 2010)
subunits of the same connexin (homomeric connexons) or from different connexins 
(heteromeric connexons). The intercellular channels are homotypic if both connexons are 
identical, or heterotypic if they are composed of two different connexons. Heteromeric 
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connexons have been found in several tissues (Diez, Ahmad, & Evans, 1999; He, Jiang, Taffet, & 
Burt, 1999; Jiang & Goodenough, 1996; Locke et al., 2007, 2000), including cochlear tissues 
(Shoab Ahmad, Chen, Sun, & Lin, 2003; Forge et al., 2003; X. Z. Liu, Yuan, et al., 2009). 
Genomic data has provided evidence of the generalised presence of connexins in 
vertebrates (Cruciani & Mikalsen, 2006). Connexins have also been identified in tunicates 
(Sasakura et al., 2003; Seo et al., 2001; White, Wang, Mui, Litteral, & Brink, 2004). These 
findings, together with additional genomic data from other taxonomic groups obtained so far, 
suggest that this protein family may be specific to vertebrates and tunicates (Panchin, 2005; 
Shestopalov & Panchin, 2008; Sodergren et al., 2006). 
 
The GJB2 and GJB6 genes (DFNB1/DFNA3 loci) 
Twenty connexin genes have been identified in humans (Cruciani & Mikalsen, 2005). The 
genes GJB2 and GJB6, together with gene GJA3, which codes for connexin-46 (Cx46), form a 
connexin gene cluster which localise to chromosome 13q12.11 (fig. 8). 
 
 
 
Figure 8. GJA3, GJB2 and GJB6 connexin gene cluster in human chromosome 13q12.11. Adapted 
from The International HapMap Consortium (n.d.). 
 
The genomic region comprising the GJB2 and GJB6 genes is commonly known as the 
DFNB1 locus or the DFNA3 locus, when referring to mutations in these connexins causing 
 recessive or dominant HL, respectively
1998). 
The GJB2 gene comprises a first nonc
5’ capped cDNA sequences), a 3179 kb intron, and a second exon containing the whole coding 
region (fig. 9a). There is also supporting evidence for an unspliced transcript, containing a 
shorter ORF initiating at an AUG upstream of the main ORF (fig. 9b), which is likely to impair the 
efficacy of the translation of the Cx26 protein. Additionally, there are 
polyadenylation sites (figs. 9a, b). The possibility of alternative splicing, 
out of a 2357 pb intron (fig. 9c), is supported by one cDNA sequence 
Mieg, 2010). 
 
 
Figure 9. Scheme of human 
b represents an unspliced transcript. 
polyadenylation sites (three different sites)
2010). 
 
In the GJB6 gene the coding region is contained within a single exon, prece
upstream noncoding exons (Essenfelder, Larderet, Waksman, & Lamartine, 2005)
 
Cx26 and Cx30 in the cochlea
Cx26 and Cx30 are expressed 
et al., 2009) cochleae, in the supporting cells of the organ of Corti and in the lateral wall, where 
they are part of the two independent gap junction systems, the epithelial cell gap junction 
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system and the connective tissue cell gap junction system (Kikuchi et al., 1995). W. Liu, Boström, 
et al. (2009) also observed expression of the two connexins in human spiral ganglion neurons. 
Co-localisation of Cx26 and Cx30 at the same gap junction plaques was observed in 
supporting cells of the organ of Corti, in basal and intermediate cells of stria vascularis and in 
fibrocytes of the spiral ligament, in rodents (Forge et al., 2003). In the same study, an 
immunoprecipitation assay using mature mouse cochleae demonstrated the existence of 
heteromeric connexons comprising both Cx26 and Cx30. In humans, co-localisation was 
detected in the basal cell layer of the stria vascularis and in Deiters’ cells of the organ of Corti 
(W. Liu, Boström, et al., 2009). Therefore, it is very likely that heteromeric connexons, and/or 
heterotypic channels, comprising both Cx26 and Cx30 also exist in the human cochlea. 
Despite of being co-localised in certain cochlear regions, Cx26 and Cx30 display distinct 
localisation patterns in the cochlear sensory epithelium (W. Liu, Boström, et al., 2009; Zhao & 
Yu, 2006) and in the cochlear lateral wall (W. Liu, Boström, et al., 2009; Y.-P. Liu & Zhao, 2008). 
Since Cx26 and Cx30 are constituents of the cochlear gap junction systems, mutations in 
these genes have been considered to cause HL by interfering with the recirculation of K+ in the 
cochlea (Kikuchi, Adams, et al., 2000). However, a more complex role of both connexins in 
cochlear physiology has been emerging in the recent years. 
Loss of Cx30 in mice impairs the development of the EP (Teubner et al., 2003), through 
disruption of the endothelial barrier in the stria vascularis (Cohen-Salmon et al., 2007). Cx30-
null mice also present degeneration of the organ of Corti (Teubner et al., 2003). Shoeb Ahmad 
et al. (2007) observed that Cx30-null mice express a reduced Cx26 protein level in the cochlea 
and, interestingly, the consequent hearing impairment is prevented in Cx30-null mice 
overexpressing Cx26, which present levels of the protein close to the wild-type mice. A recent 
study has detected a reduction of Cx26 mRNA and protein levels in Cx30-null mice cochlea, 
particularly significant in cells from the region of the outer sulcus when compared to the whole 
cochlea. The authors presented evidence of co-regulation of Cx26 and Cx30 through NF-kB 
pathway as a feature of supporting cells in the outer sulcus region (Ortolano et al., 2008). 
Chang, Tang, Ahmad, Zhou, and Lin (2008) found that Cx30-null mice presented near normal 
ionic coupling but impaired metabolic coupling in outer sulcus and Claudius’ supporting cells, 
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which normally co-express Cx26 and Cx30, as assessed by Zhao and Yu (2006), in guinea-pig 
Claudius’ cells, and by Y.-P. Liu and Zhao (2008), in rat outer sulcus cells. The results of the fore 
mentioned studies suggest that ablation of Cx30 and the subsequent decrease of the Cx26 
protein levels in supporting cells, results in impaired metabolic coupling, which could explain 
cell death in the organ of Corti. 
Loss of expression of Cx26 in the mice epithelial gap junction network specifically does not 
seem to impair the EP development, but results in the degeneration of the organ of Corti soon 
after onset of hearing. It was proposed that the degeneration could be due to local extracellular 
accumulation of K+ near the basolateral region of IHCs (Cohen-Salmon et al., 2002). However, 
the fore mentioned finding of the co-regulation of Cx26 and Cx30 could suggest that a 
downregulation of Cx30 occurs in these conditional Cx26 knocked-out mice, leading to a 
defective epithelial gap junction system, and consequently to metabolic coupling impairment 
and cell death. 
Additional evidence suggesting the participation of Cx26 and Cx30 in cochlear 
homeostasis, beyond their putative role in the recirculation of K+, arises from functional studies 
of some Cx26 and Cx30 mutant proteins. It was found that some mutations in these connexins 
(p.Val84Leu, p.Ala88Ser in Cx26, and p.Thr5Met in Cx30) do not impair ionic permeability of 
intercellular channels but impair their permeability to the larger cationic molecule propidium 
iodide (PI), as well as to the anionic second messenger IP3, which initiated propagation of Ca2+ 
waves in organotypic cochlear cultures (Beltramello, Piazza, Bukauskas, Pozzan, & Mammano, 
2005; Y. Zhang et al., 2005). Also, the study of other Cx26 mutants (p.Thr8Met and p.Asn206Ser) 
showed that mutant and wild-type channels had similar unitary conductance, and that 
permeability to the anionic molecules cAMP and Lucifer yellow (LY) were retained by the 
mutant channels whereas their permeability to the cationic dye ethydium bromide (EtBr) was 
greatly reduced compared with that of the wild-type channel. This finding indicated differential 
selectivity to large molecules which suggested that altered permeability to large molecules of 
mutant channels between the supporting cells might be associated to HL (Meşe, Valiunas, Brink, 
& White, 2008). Moreover, faster intercellular Ca2+ signaling was observed in cells coupled by 
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heteromeric channels containing both Cx26 and Cx30 (Sun et al., 2005), suggesting that such 
channels may mediate and be important to Ca2+ signaling in cochlear tissue. 
Although HL in Cx30 null mice had been prevented by overexpression of Cx26 (Shoeb 
Ahmad et al., 2007), the distinct localisation of the two connexins in the cochlea (W. Liu, 
Boström, et al., 2009; Y.-P. Liu & Zhao, 2008; Zhao & Yu, 2006) might be a strong indication that 
the two connexins have non-redundant functions in the normal physiology of the cochlea, 
further supporting their function beyond the putative role in K+ recycling. 
Therefore, it is very likely that gap junctions play a crucial role in the cochlea by mediating 
the intercellular diffusion of large biological molecules, as part of biochemical and signaling 
pathways in vivo. 
 
GJB2 mutations 
There are over 200 pathogenic GJB2 mutations described (Stenson et al., 2009). Most of 
them are responsible for recessive NSHL, but a few others are dominant causing either NSHL or 
HL associated with dermatological disorders (syndromic HL). 
The spectrum and the prevalence of GJB2 mutations vary among different populations. 
The recessive mutation c.35delG is the most frequent GJB2 pathogenic mutation identified in 
NSHL European patients (Antoniadi et al., 2000; Gabriel et al., 2001; Janecke et al., 2002; T. 
Löppönen et al., 2003; Minárik, Feráková, Ficek, Poláková, & Kádasi, 2005; Roux et al., 2004; 
Santos et al., 2005; Seeman et al., 2004; Šterna et al., 2009), in other populations of 
predominantly European ancestry (Batissoco et al., 2009; Dalamón et al., 2005; Kelley et al., 
1998) and in the Mediterranean populations from Algeria (Ammar-Khodja et al., 2009), Egypt 
(Snoeckx, Hassan, Kamal, Van Den Bogaert, & Van Camp, 2005), Lebanon (Mustapha et al., 
2001), Morocco (Abidi et al., 2007) and Tunisia (Masmoudi et al., 2000). Two other recessive 
mutations, c.167delT and c.235delC, are the most frequent GJB2 pathogenic mutations found in 
NSHL affected individuals among Ashkenazi Jews (Lerer et al., 2000), and in Asian populations 
from Japan (Abe, Usami, Shinkawa, Kelley, & Kimberling, 2000; Fuse et al., 1999), Korea (H. J. 
Park, Hahn, Chun, Park, & Kim, 2000) and China (Dai et al., 2009), respectively. 
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The c.35delG mutation has a high carrier frequency in Europe in general (1.96%), but is 
higher (2.86%) in southern Europe (Gasparini et al., 2000). This deletion has also a high carrier 
frequency (2.08%) among Americans of European ancestry (Kelley et al., 1998). Regarding the 
c.167delT mutation, carrier frequencies of 2.78% (Sobe et al., 1999), 4.03% (Morell et al., 1998) 
and as high as 7.46% (Lerer et al., 2000) have been found among Ashkenazi Jewish individuals. 
Carrier frequencies for c.235delC mutation range from 0.5% to 2.08% in Eastern Asia (Abe et al., 
2000; S.-H. Han et al., 2008; Hwa et al., 2003; Kudo et al., 2000; Y. Liu, Ke, Qi, Li, & Zhu, 2002; H. 
J. Park et al., 2000; Shi et al., 2004). 
One other recessive mutation, p.Arg143Trp, firstly identified in Ghana (Brobby, Müller-
Myhsok, & Horstmann, 1998), is the prevalent mutation in congenital, profound NSSHL Ghanese 
cases (Hamelmann et al., 2001). Interestingly, this mutation has a high prevalence among NSHL 
Japanese cases, compatible with recessive inheritance (Abe et al., 2000; Hayashi et al., 2011). To 
a lesser extent, the p.Arg143Trp mutation has been identified in NSHL cases from other Asian 
countries, such as India (Maheshwari et al., 2003; Mani et al., 2009), Iran (Hashemzadeh 
Chaleshtori et al., 2005; Najmabadi et al., 2005), and Korea (H. J. Park et al., 2000). A significant 
frequency of p.Arg143Trp among moderate to profound NSSHL cases, compatible with recessive 
inheritance, was also found in Argentina, a country which has received major immigration fluxes 
from Italy and Spain (Gravina et al., 2010). Noteworthy, the p.Arg143Trp was among the most 
frequent GJB2 variants detected in North American HL patients of Hispanic ethnicity (Putcha et 
al., 2007). 
A different pathogenic mutation, p.Trp24X, was the predominant GJB2 mutation identified 
in NSHL cases in India (RamShankar et al., 2003), and in Gypsies (an ethnic group that traces 
back to the Indian subcontinent) from Eastern Slovakia (Minárik et al., 2003) and Spain (Álvarez 
et al., 2005). This mutation was also found to have a high carrier frequency (2.4%) in the Indian 
population (RamShankar et al., 2003), and in some subpopulations of Gypsies (Minárik et al., 
2003; Álvarez et al., 2005). 
As previously mentioned, due to the high frequency of GJB2 mutations among 
NSHL/NSSHL cases in several populations worldwide, this gene is routinely screened for 
mutations in patients with this pathology. However, only the coding region has been 
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systematically analysed. Nonetheless, several studies have also searched for mutations in exon 
1 (Al-Qahtani et al., 2010; Denoyelle et al., 1999; Godbole et al., 2010; Green et al., 1999; 
Hamelmann et al., 2001; Hashemzadeh Chaleshtori et al., 2002; Janecke et al., 2002; X. Z. Liu, 
Xia, et al., 2002; Mani et al., 2009; Marlin et al., 2005; Matos et al., 2008, 2007, 2011, 2010; 
Najmabadi et al., 2002, 2005; Pollak et al., 2008; Prasad, Cucci, Green, & Smith, 2000; 
RamShankar et al., 2003; Riazalhosseini et al., 2005; Roux et al., 2004; Seeman & Sakmaryová, 
2006; Sirmaci, Akcayoz-Duman, & Tekin, 2006; H.-Y. Tang et al., 2006; Y. Yuan et al., 2009, 
2010). The promoter region has also been screened, but in fewer studies (Hashemzadeh 
Chaleshtori et al., 2002; Houseman et al., 2001; Matos et al., 2008, 2007, 2011, 2010; Pollak et 
al., 2008; Sirmaci et al., 2006; Y. Yuan et al., 2009, 2010). As a result, a few noncoding 
pathogenic mutations have been described. Their identification contributed to the elucidation 
of the genetic etiology of the HL in some patients who harboured only one recessive mutation in 
the GJB2 coding region. 
The donor splice site c.-23+1G>A (commonly known as IVS1+1G>A) mutation has 
explained a high proportion of such unelucidated cases in some populations. This mutation, first 
identified by (Denoyelle et al., 1999), and later proven to prevent the transcription of the gene 
(Shahin et al., 2002), has been identified in 45% (9/20) of Czech and 23% (11/47) of Hungarian 
hearing-impaired individuals with only one GJB2 coding mutation (Seeman & Sakmaryová, 2006; 
Tóth et al., 2007). In one other study, 50% (8/16) of Turkish HL patients heterozygous for an 
exon 2 mutation, were also heterozygous for the c.-23+1G>A mutation (Sirmaci et al., 2006). 
Compound heterozygosity between the c.-23+1G>A mutation and a coding GJB2 mutation has 
also been detected in patients from other populations (Janecke et al., 2002; Medica, Rudolf, 
Balaban, & Peterlin, 2005; Najmabadi et al., 2005; Prasad et al., 2000; Y. Yuan et al., 2010). 
One other noncoding mutation, c.-23G>T, located at the position -1 in respect to the 
donor splice site, has been recently identified (Mani et al., 2009). This mutation, predicted to 
impair the splice site, was present in trans with p.Trp24X, in a severe to profound HL patient 
from India. 
Y. Yuan et al. (2010) reported a patient harbouring a novel exon 1 variant, c.-3175C>T, in 
compound heterozygosity with c.235delC. These variants were most likely in trans since the 
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patient’s father was simple heterozygous for the exon 1 variant. The pathogenicity of c.-
3175C>T, which was not present in 105 normal-hearing controls, is possible, but still unclear. 
A pathogenic mutation within the basal promoter has been found in the context of the 
present work (Matos et al., 2007). 
 
Gross deletions compromising GJB2/GJB6 
Pathogenic point mutations in the GJB2 gene are numerous and are a frequent cause of 
NSHL. In contrast, GJB6 point mutations are seemingly a rare cause of this pathology (Bhalla, 
Sharma, Khandelwal, Panda, & Khullar, 2011; Gürtler, Egenter, Bösch, & Plasilova, 2008; Nahili 
et al., 2008). Nonetheless, a few GJB6 variants have been identified in some NSHL cases. The 
GJB6 mutations p.Thr5Met (Grifa et al., 1999), and c.63delG (Pandya, personal communication 
in Ballana, Ventayol, Rabionet, Gasparini, & Estivill, 2011) have been associated with dominant 
NSHL, while two other GJB6 variants, c. 631T>G (p.Cys211Gly) and c.689insA, were identified in 
compound heterozygosity in two NSSHL cases (Putcha et al., 2007). The first one was 
accompanied by the rare c.110T>C (p.Val37Ala) GJB2 variant [firstly identified by Azaiez et al. 
(2004), in heterozygosity, in a NSHL patient born to normal-hearing parents; classified as 
pathogenic (Husami et al., 2011)] and the second one by the GJB2 c.35delG deletion. Y. Yuan et 
al. (2010) found a NSHL patient, with no GJB2 mutations identified, carrying one other GJB6 
variant, c.404C>A (p.Thr135Lys). While GJB6 point mutations are rare, two gross deletions, 
del(GJB6-D13S1830) (I. del Castillo et al., 2002; Lerer et al., 2001; Pallares-Ruiz et al., 2002) and 
del(GJB6-D13S1854) (F. J. del Castillo et al., 2005), localised upstream of the GJB2 gene, and 
disrupting the GJB6 gene, have been identified and shown to be associated with HL in several 
populations, most often due to compound heterozygosity with GJB2 mutations (Angeli, 2008; 
Cama et al., 2009; Chora et al., 2010; Cordeiro-Silva et al., 2011; Dalamón et al., 2005; F. J. del 
Castillo et al., 2005; I. del Castillo et al., 2003; Gravina et al., 2010; Marlin et al., 2005; Pandya et 
al., 2003; Piatto, Bertollo, Sartorato, & Maniglia, 2004; Roux et al., 2004; Santos et al., 2005; 
Seeman et al., 2005; Taitelbaum-Swead et al., 2006). Less frequently, homozygosity for 
del(GJB6-D13S1830), or compound heterozygosity for both deletions, have also been identified 
in HL patients (Angeli, 2008; F. J. del Castillo et al., 2005; I. del Castillo et al., 2003; Pandya et al., 
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2003; Roux et al., 2004). Interestingly, (Erbe, Harris, Runge-Samuelson, Flanary, & Wackym, 
2004) reported one hearing-impaired child, not harbouring any GJB2 coding mutations, who 
was compound heterozygous for del(GJB6-D13S1830) and for a GJB6 coding mutation 
(p.His124Gln). 
Common et al. (2005) observed loss of Cx26 expression from the allele bearing the 
del(GJB6-D13S1830) deletion, in ductal sweat gland epithelium, and suggested the existence of 
a regulatory element of Cx26 expression. Rodriguez-Paris and Schrijver (2009) demonstrated, by 
qualitative allele-specific RT-PCR analyses using total RNA isolated from buccal ephitelium, that 
del(GJB6-D13S1830) causes loss of expression of GJB2 gene in cis, providing further support for 
the hypothesis of existence of a cis-regulatory element regulating GJB2. Later, Rodriguez-Paris, 
Tamayo, Gelvez, and Schrijver (2011) showed that the del(GJB6-D13S1854) GJB6 deletion, which 
is smaller than, and included within, the del(GJB6-D13S1830) also causes loss of GJB2 expression 
in cis, as previously suspected. 
A third deletion, of 131.4 kbp, del(chr13:19,837,344-19,968,698), localised upstream of 
GJB2 and GJB6 has been identified segregating with HL and in trans with c.35delG, in one large 
American family of German descent. The GJB2 and GJB6 expression from alleles bearing the 
deletion was found to be reduced (Wilch et al., 2010, 2006). Wilch et al. (2010) hypothesized a 
similar mechanism for the pathogenic effect of this deletion, and the two deletions truncating 
GJB6, which would involve, in addition to loss or reduction in expression of GJB6, the loss of a 
GJB2 cis-regulatory element located within the deleted 95.4 kbp genomic interval shared by the 
three deletions. The expression of GJB6 gene might also be regulated by this element, or, 
instead, a distinct cis-regulatory element of this gene might exist and be deleted by 
del(chr13:19,837,344-19,968,698). Alternatively, the authors suggest that this third deletion 
could be in linkage disequilibrium (LD) with a pathogenic variant closer to both GJB2 and GJB6 
that disrupts cis-regulatory function of these genes. 
Feldmann et al. (2009) identified a large deletion, encompassing at least 920 kbp, which 
completely deletes the three connexin genes GJA3, GJB2 and GJB6, as well as at least four other 
genes. This deletion was identified in trans with the c.250G>A (p.Val84Met) GJB2 mutation in an 
individual presenting prelingual, profound HL. 
General Introduction 23 
 
Unelucidated GJB2 or GJB6 heterozygotes 
In some patients, after searching for mutations in the GJB2 coding region, splice sites and 
exon 1, and screening for the del(GJB6-D13S1830) and del(GJB6-D13S1854) GJB6 deletions, only 
one recessive GJB2 coding mutation is identified (F. J. del Castillo et al., 2005; I. del Castillo et 
al., 2003). Some of these individuals may indeed just be carriers of a GJB2 mutant allele but in 
some other patients a second mutation may exist in other regions of GJB2 gene, such as the 
promoter, as shown in this work (Matos et al., 2007), the intron or the 3’ UTR, or in the GJB6 
gene. The fore mentioned 131.4 kbp or the ~920 kbp GJB2/GJB6 gross deletions, other deletions 
truncating GJB2 or GJB6, or mutations disrupting a putative upstream regulatory element of 
these genes, may account for some of these unresolved cases. 
 
GJB2 mutations with unknown or controversial pathogenicity 
The pathogenicity of several GJB2 mutations is not always clear, due to the lack of 
evidence for or to existing contradictory data regarding the segregation of the mutation with 
the HL. Examples of such mutations are c.-684_-675del (Houseman et al., 2001; Zoll et al., 
2003), p.Met34Thr (Bicego et al., 2006; Cama et al., 2009; Feldmann et al., 2004; Griffith et al., 
2000; Houseman et al., 2001; Kenna, Wu, Cotanche, Korf, & Rehm, 2001; Pollak et al., 2007; 
Snoeckx, Huygen, et al., 2005; B.-L. Wu et al., 2002), p.Arg127His (Matos et al., 2010), 
p.Val153Ile (Cryns et al., 2004; Dalamón et al., 2005; Hashemzadeh Chaleshtori et al., 2005; 
Kenna et al., 2001; Marlin et al., 2001; RamShankar et al., 2003; Snoeckx, Hassan, et al., 2005; 
Snoeckx, Huygen, et al., 2005) and p.Gly160Ser (X. Cheng et al., 2005; Hashemzadeh 
Chaleshtori, Farhud, & Patton, 2007; Janecke et al., 2002; Löffler et al., 2001; Santos et al., 2005; 
Snoeckx, Huygen, et al., 2005; H.-Y. Tang et al., 2006). 
 
DFNB1 mutations and human evolution 
The high frequency of DFNB1-related HL, observed in several populations, has been 
hypothesized to be due to the combined effects of relaxed selection and assortative mating 
(Nance & Kearsey, 2004). Furthermore, it has been suggested that a carrier status for Cx26 
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mutations might confer advantages. Carriers of c.35delG and p.Arg143Trp have been shown to 
display increased epidermal thickening (Guastalla et al., 2009; Meyer et al., 2002) which might 
confer protection against infection. Common, Di, Davies, and Kelsell (2004) observed increased 
survival of cells expressing the p.Arg143Trp-Cx26 protein, other Cx26 mutants, or the 
p.Thr5Met-Cx30 mutant, compared with the wild-type proteins, which they suggested could 
account for the increased epidermal thickening in carriers. Increased cell migration and 
decreased susceptibility to cellular invasion by the enteric pathogen Shigella flexneri have also 
been shown for cells expressing the p.Arg143Trp-Cx26 mutant protein in comparison to cells 
expressing wtCx26 (Man et al., 2007). 
 
 
Section 5 - Functional Studies 
 
In order to elucidate the biological effect of Cx26 mutations (being some of them of 
unclear or controversial pathogenicity), functional studies have been conducted by several 
investigators. Consequently, a number of mechanisms for pathogenesis associated with 
mutations in this connexin have been described (reviewed in Hoang Dinh et al., 2009). 
Mutations in Cx26 have been shown to interfere with protein translation (D’Andrea et al., 
2002), oligomerization (P. E. M. Martin, Coleman, Casalotti, Forge, & Evans, 1999) and 
trafficking to the membrane (Bruzzone et al., 2003; Choi et al., 2009; Choung, Moon, & Park, 
2002; Haack et al., 2006; Mani et al., 2009; P. E. M. Martin et al., 1999; Melchionda et al., 2005; 
Oguchi et al., 2005), as well as with the intercellular channel conductance (Choi et al., 2009; 
Meşe, Londin, Mui, Brink, & White, 2004; Piazza et al., 2005; Y. Zhang et al., 2005) and 
permeability to tracers such as Cascade Blue (Marziano, Casalotti, Portelli, Becker, & Forge, 
2003), PI (Choi et al., 2009; Y. Zhang et al., 2005), LY (Mani et al., 2009; Piazza et al., 2005) and 
EtBr (Meşe et al., 2008), and to the second messenger IP3 (Beltramello et al., 2005; Y. Zhang et 
al., 2005). 
There is other group of mutations, associated with skin disease in addition to HL (Keratitis-
Ichthyosis-Deafness syndrome), which were observed to cause cell lysis and death through 
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abnormal hemichannel activity (Gerido, DeRosa, Richard, & White, 2007; J. R. Lee, Derosa, & 
White, 2009; Montgomery, White, Martin, Turner, & Holland, 2004; Stong, Chang, Ahmad, & 
Lin, 2006). 
The data obtained from the functional studies performed to date allowed the elucidation 
of the pathogenic mechanism of several Cx26 mutations, as well as a number of mutations in 
other connexins. Moreover, these studies have shown that, as already mentioned, some Cx26 
mutations do not exhibit significant change in ionic permeability, whereas they do display 
impaired permeability to some large molecules, including the second messenger IP3 
(Beltramello et al., 2005; Y. Zhang et al., 2005). This suggests that these mutations cause HL not 
by disrupting ionic cycling but possibly by disrupting biochemical and signaling pathways in vivo. 
It should be noted that care should be taken upon interpreting the results of functional 
studies since, in some instances, they produce different results. This situation was observed 
with some GJB2 mutations, such as p.Val95Met (Beltramello et al., 2005; H.-L. Wang et al., 
2003; Y. Zhang et al., 2005), p.Met34Thr (Bicego et al., 2006; D’Andrea et al., 2002; Palmada et 
al., 2006; Skerrett, Di, Kasperek, Kelsell, & Nicholson, 2004; White, Deans, Kelsell, & Paul, 1998) 
and p.Arg127His (Thönnissen et al., 2002; H.-L. Wang et al., 2003). 
 
 
Section 6 - Aims and outlines of the thesis 
 
The study of genetic deafness in Portuguese families and the molecular diagnosis of 
patients with sensorineural HL have been conducted by CGBM/BioFIG Deafness Group since 
1998. 
 
The work presented on this thesis aimed to two main goals: 
 
a) To continue the study of the GJB2 gene in Portuguese NSSHL patients, and to extend it 
in order to also include noncoding regions (promoter, exon 1, donor splice site and 3’UTR);  
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b) To investigate the functionality of three GJB2 mutations: two coding mutations for the 
first time identified during a previous study, and one occurring in the basal promoter, found 
during this work. 
 
To date, the study of GJB2 gene in HL cases worldwide has been mostly focused on the 
coding region. Some studies have also analysed the exon 1 and the splice sites. However, very 
few studies investigated the promoter and the whole 3’UTR, which are also potential locations 
for pathogenic mutations.  
We have thus analysed the GJB2 gene in Portuguese HL patients, focusing on: 
i) the coding region and acceptor splice site (Chapter 2); 
ii) the exon 1 and donor splice site (Chapters 3, 4, 5 and 6); 
iii) the basal promoter (Chapters 3, 4, 5 and 6) and the region upstream of the basal 
promoter (Chapter 6); 
iv) the whole 3’UTR (Chapter 6) 
 
The assessment of the functionality of GJB2 mutations has been essential for the 
investigation of the biological mechanisms through which these mutations cause HL. Therefore, 
we studied three GJB2 mutations, identified in Portuguese HL patients, and which pathogenic 
effect could not be conclusively demonstrated through the sparse genetic data available 
(Chapters 3 and 4). 
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ABSTRACT 
 
Objective: A variable proportion of nonsyndromic sensorineural hearing loss (NSSHL) 
cases are due to mutations in the GJB2 gene in several populations, which present distinct 
spectra and prevalence of such mutations. In order to assess the contribution of GJB2 mutations 
to this pathology in the Portuguese population we have been investigating the prevalence of 
GJB2 mutations in hearing impaired patients. We here present a first comprehensive molecular 
analysis focusing on 264 unrelated individuals (sporadic and familial cases) presenting with mild 
to profound bilateral NSSHL. 
Methods: PCR-RFLP, SSCP and sequencing were used in the screening of the coding 
region, basal promoter, exon 1 and donor splice site of the GJB2 gene. Multiplex PCR was used 
to screen for the two common GJB6 deletions. 
Results: At least one out of 21 different GJB2 variants (18 coding and three noncoding) 
was identified in 80 (30.2%) of the 264 patients. Biallelic mutations were found in 53 (20%) of 
the probands, of which 83% (44/53) harboured at least one c.35delG allele. The most prevalent 
mutated genotype was [c.35delG]+[c.35delG], accounting for 52.8% (28/53) of the biallelic 
individuals. Next to this genotype, [c.35delG]+[p.Glu47X] (3/53 = 5.7%), [c.35delG]+[p.Trp172X] 
(3/53 = 5.7%), and [c.35delG]+[p.Val37Ile] (2/53 = 3.8%) were the most represented genotypes 
among bilallelic patients. Twenty-seven out of 264 (10.2%) probands were monoallelic, 
harbouring only one GJB2 variant. Subsequent analysis revealed that the GJB6 deletion 
del(GJB6-D13S1854) was present in at least 7.4% (2/27) of these monoallelic patients. 
Conclusion: This study provides clear demonstration that mutations in the GJB2 gene are 
an important cause of hearing impairment in Portugal. With basis solely on coding mutations, a 
diagnosis of GJB2-associated NSSHL was assumed for 18.9% (50/264) of the cases. Five other 
cases, with only one GJB2 coding mutation, were elucidated by the identification of an 
additional DFNB1 mutation. Overall, 20.8% (55/264) of the patients were diagnosed as having 
DFNB1-related NSSHL, this representing a valuable indicator as regards therapeutical and 
rehabilitation options, as well as genetic counseling of these patients and their families. 
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INTRODUCTION 
 
Hearing loss (HL) is the most common congenital sensory impairment, and the most 
prevalent sensorineural disorder (Hilgert, Smith, & Van Camp, 2009), being a major public 
health concern. 
Regarding NSSHL, more than 140 genetic loci have been mapped, with more than 60 
genes identified to date (Alford, 2011; Smith & Van Camp, 1998). 
Despite this extreme genetic heterogeneity, mutations in the GJB2 gene, encoding the 
protein connexin 26 (Cx26), are a major cause of NSSHL in many world populations, which 
makes GJB2 the gene most frequently associated with this condition. Two gross deletions, 
del(GJB6-D13S1830) and del(GJB6-D13S1854), involving the GJB6 gene, which codes for 
connexin 30 (Cx30), have also been associated with nonsyndromic hearing loss (NSHL) in several 
cases, often in trans with a GJB2 mutation (Lerer et al., 2001; Pallares-Ruiz, Blanchet, Mondain, 
Claustres, & Roux, 2002; F J del Castillo et al., 2005; I del Castillo et al., 2002). Both genes, GJB2 
and GJB6, are localised to chromosome region 13q11, corresponding to the DFNB1 locus. 
Connexins associate in hexamers to form homo- or heteromeric connexons (Perkins, 
Goodenough, & Sosinsky, 1997; Yeager, 1998). Connexons of adjoining cells can bind forming 
intercellular channels which cluster into gap junctions (Perkins, Goodenough, & Sosinsky, 1998). 
Cx26 and Cx30 channels are believed to play a key role in the cycling of potassium (Kikuchi, 
Adams, Miyabe, So, & Kobayashi, 2000; Kikuchi, Kimura, Paul, & Adams, 1995; Kikuchi, Kimura, 
Paul, Takasaka, & Adams, 2000; Spicer & Schulte, 1998) which is critical for the normal sensory 
hair cell excitation. There is also evidence that cochlear gap junctions might be important for 
Ca2+ signaling (Sun et al., 2005) and the intracellular diffusion of large cationic molecules (Meşe, 
Valiunas, Brink, & White, 2008).  
About two hundred GJB2 mutations causing nonsyndromic HL have been reported 
(Stenson et al., 2009), most of them being recessive. A few specific mutations in GJB2 also have 
been described in families with autosomal dominant HL (Smith, Sheffield, & Van Camp, 1998). 
Some mutations are very common and others are extremely rare. The carrier rate in the general 
GJB2 mutations and NSSHL in Portugal 47 
 
population for a recessive deafness causing GJB2 mutation is approximately one in 33 (Smith, 
Shearer, Hildebrand, & Van Camp, 1999). 
The spectrum and the prevalence of GJB2 mutations vary among different populations. 
The recessive mutation c.35delG is the most frequent GJB2 pathogenic mutation identified in 
NSHL European patients (Antoniadi et al., 2000; Gabriel et al., 2001; Janecke et al., 2002; 
Löppönen et al., 2003; Minarik, Ferakova, Ficek, Polakova, & Kadasi, 2005; Roux et al., 2004; 
Santos et al., 2005; Seeman et al., 2004; Šterna et al., 2009), in other populations of 
predominantly European ancestry (Batissoco et al., 2009; Dalamón et al., 2005; Kelley et al., 
1998) and in the Mediterranean populations from Algeria (Ammar-Khodja et al., 2009), Egypt 
(Snoeckx, Hassan, Kamal, Van Den Bogaert, & Van Camp, 2005), Lebanon (Mustapha et al., 
2001), Morocco (Abidi et al., 2007) and Tunisia (Masmoudi et al., 2000). 
Three other recessive mutations, c.167delT, c.235delC, and p.Arg143Trp are the most 
frequent GJB2 pathogenic mutations found among Ashkenazi Jews (Lerer et al., 2000), in Asian 
populations from Japan (Abe, Usami, Shinkawa, Kelley, & Kimberling, 2000; Fuse et al., 1999), 
Korea (H. J. Park, Hahn, Chun, Park, & Kim, 2000) and China (Dai et al., 2009), and in Ghanian 
populations (Brobby, Müller-Myhsok, & Horstmann, 1998; Hamelmann et al., 2001), 
respectively. 
A different pathogenic mutation, p.Trp24X, was the predominant GJB2 mutation identified 
in NSHL cases in India (RamShankar et al., 2003), and in Gypsies (an ethnic group that traces 
back to the Indian subcontinent) from Eastern Slovakia (Minárik et al., 2003) and Spain (Álvarez 
et al., 2005). This mutation was also found to have a high carrier frequency (2.4%) in the Indian 
population (RamShankar et al., 2003), and in some subpopulations of Gypsies (Minárik et al., 
2003; Álvarez et al., 2005). 
Due to the high frequency of GJB2 mutations among NSHL cases in several populations 
worldwide, mutation analysis of this gene is a widely available genetic test, representing the 
first step in the molecular diagnosis of this pathology.  
Since most GJB2 mutations described so far localize to the GJB2 coding region (totally 
included within exon 2), only this region has been systematically analysed. Nonetheless, a few 
noncoding pathogenic mutations have already been identified, contributing to the elucidation 
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of the genetic etiology of the HL in some patients who harboured only one recessive mutation in 
the GJB2 coding region (Denoyelle et al., 1999; Mani et al., 2009; Matos et al., 2007). 
In this study, we investigated the spectrum and prevalence of GJB2 mutations in 264 
Portuguese patients, and confirmed the relevance of screening this gene as a first step in the 
molecular analysis of NSSHL cases in our population. 
 
 
MATERIALS AND METHODS 
 
1. Patients 
A total of 301 Portuguese unrelated individuals (sporadic and familial cases), presenting 
with mild to profound sensorineural hearing impairment were tested for the presence of 
mutations in the DFNB1 locus. They had been referred from various otolaryngology 
departments and genetic units. A recessive mode of inheritance was predominantly observed in 
the familial cases (at least one first- or second-degree affected relative).  
In the analysis here presented, we only have considered those individuals affected with 
bilateral NSSHL. So, individuals with syndromic, unilateral, or acquired types of HL were 
excluded from this study. Diagnosis of NSSHL was established by accepted clinical criteria. 
Infection, oto-trauma or neonatal diseases causing acquired deafness were excluded by 
collecting detailed clinical history. Interestingly, there were three patients clinically diagnosed as 
having Waardenburg syndrome, and thus excluded from this study, who carried GJB2/GJB6 
mutations. One of them was a GJB2/GJB6 compound heterozygous, with the 
[=]+[c.35delG]/[=]+[del(GJB6-D13S1854)] genotype, while the other two patients were 
heterozygous for the mutation p.Val153Ile in the GJB2 gene. Individuals referred as not having 
been born in Portugal were also not considered. As such, of the 301 patients referred above, 
264 were included in this analysis.  
Written Informed consent was obtained from all the participants or from parents in case 
of those younger than 18 years. 
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2. Audiological methods 
All patients involved in the study underwent otoscopic and audiometric examinations by 
using age-appropriate methods. Pure tone audiometry, tympanometry and auditory brainstem 
response were obtained in a sound proof room according to current clinical standards. We were 
not able to retrieve medical history and audiometric records for all the patients. For some 
patients family histories were unknown.  
 
3. Molecular analysis 
Blood samples were obtained from all the individuals and DNA was extracted using 
standard procedures. 
All DNA samples were first screened for the 35delG mutation by PSDM-RFLP (Storm, 
Willocx, Flothmann, & Van Camp, 1999).  
The 35delG homozygotes were diagnosed as having GJB2-related HL and, consequently, 
no other studies were performed. 
The 35delG heterozygotes and the negative cases were further screened by single-strand 
conformational polymorphism (SSCP) analysis, and/or direct sequencing, of the entire coding 
region and flanking acceptor splice site of the GJB2 gene, in order to detect whether other 
pathogenic/controversial GJB2 mutations were present.  
If the cause of deafness remained non-elucidated, the patients were then screened for the 
del(GJB6-D13S1830) and del(GJB6-D13S1854) GJB6 deletions using multiplex PCR, according to F 
J del Castillo et al. (2005) and I del Castillo et al. (2002). When obtaining no positive result, a 
number of patients were also screened by sequencing for mutations in the GJB2 basal 
promoter, exon 1 and donor splice site (most of these patients have been described in Matos et 
al. (2008, 2007, 2011, 2010). 
Some patients could not be analysed regarding the GJB6 deletions and/or the noncoding 
regions of GJB2. 
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RESULTS 
 
At least one out of 21 different GJB2 variants (18 coding and three noncoding) was found 
in 80 (30.2%) of the 264 patients (see Table 1). These include 12 missense, 3 nonsense and 2 
frameshift variants, 1 in frame deletion, 1 mutation in the donor splice site, 1 mutation in the 
basal promoter, and 1 polymorphism in the intron. All the variants here identified were 
previously described, with the exception of the novel variant c.24G>A, which results in a silent 
mutation at protein level (p.Thr8Thr). Two of the reported mutations (c.-259C>T and 
p.Met163Leu), listed in Table 1, were first found in Portuguese patients (Matos et al., 2008, 
2007) belonging to the sample under analysis. As expected, c.35delG was the mutation most 
frequently found amongst the NSSHL patients, being present in 84 of the 528 chromosomes 
analysed, which corresponds to a prevalence of 15.9% (see Table 1). 
Table 2 shows the frequencies of GJB2 genotypes identified in a total of 264 individuals 
presenting with bilateral NSSHL. GJB2 biallelic mutations were found in 53 (20%) of the 
probands, of which 83% (44/53) harboured at least one c.35delG allele. The most prevalent 
mutated genotype was [c.35delG]+[c.35delG], accounting for 52.8% (28/53) of the biallelic 
individuals. Next to this genotype, [c.35delG]+[p.Glu47X] (3/53 = 5.7%), [c.35delG]+[p.Trp172X] 
(3/53 = 5.7%), and [c.35delG]+[p.Val37Ile] (2/53 = 3.8%) genotypes were the most represented 
among bilallelic patients.  
Twenty-seven out of 264 (10.2%) probands were monoallelic, harbouring only one GJB2 
variant. Subsequent analysis revealed that the GJB6 deletion del(GJB6-D13S1854) was present 
in two of those patients (one heterozygous for c.35delG plus one heterozygous for p.Met34Thr), 
presenting with prelingual, profound HL, which was then considered to be due to their 
GJB2/GJB6 compound genotype. In one monoallelic patient, harbouring the dominant 
p.Met163Leu mutation, the GJB2 genotype was shown to be responsible for the HL (this patient 
and her mother were described in Matos et al. (2008). 
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DISCUSSION 
 
A wide spectrum of GJB2 pathogenic, unclear or controversial mutations was observed in 
the cohort of 264 NSSHL Portuguese individuals included in this study, among which two 
variants so far found in these patients only, c.-259C>T, of confirmed pathogenicity, and 
p.Thr8Thr, with unknown effects. 
The DFNB1 genotype explained the HL, or was a likely cause of the pathology, in 20.8% 
(55/264) of the cases. All but two of these cases (53/55), corresponding to 1 in 5 of the patients 
analysed, were due to a GJB2 genotype. The GJB2-related cases include one monoallelic patient 
harbouring the dominant p.Met163Leu mutation. The HL in three patients with one coding GJB2 
mutation was explained by the presence of a second GJB2 mutation, in the basal promoter or in 
the donor splice site, highlighting the relevance of screening those noncoding regions in 
addition to the coding region. 
The deletion c.35delG was the predominant GJB2 mutation among GJB2-related HL cases, 
in accordance with other Caucasian or of mainly Caucasian descent populations (Dalamón et al., 
2010; Pandya et al., 2003; Roux et al., 2004). Individuals homozygous for the c.35delG mutation 
accounted for about 53% of the GJB2-related HL cases, and represented 10.6% of the total 
Portuguese NSSHL patients. 
Interestingly, an excess of c.35delG heterozygotes (11/264) was observed. Their allelic 
frequency corresponds to 4.1%, which is very high when compared with the c.35delG carrier 
rate in the Portuguese general population (0.88%) (data not yet published). It should be noted 
that we were not able to analyse all the 11 patients for the GJB6 deletions and the GJB2 
noncoding regions considered in this study. So, although some of these individuals might just be 
coincidental carriers, some other patients may harbour a second DFNB1 mutation, even in other 
GJB2/GJB6 regions not here analysed, thus explaining the excess of c.35delG heterozygotes. 
As regards genotype-phenotype correlations, truncating (T) mutations, as is the case of 
c.35delG, are usually associated with a greater degree of HL than nontruncating (NT) mutations 
(Cryns et al., 2004; Putcha et al., 2007; Snoeckx, Huygen, et al., 2005). However, variability in 
the degree of the hearing loss in T/T genotypes has been noticed, and is well exemplified by the 
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significant intra- and inter-familial variation, ranging from mild to profound impairment, which 
has been observed in c.35delG homozygotes (Cryns et al., 2004; Murgia et al., 1999). In the 
present study, the majority (16) of homozygotes for c.35delG had severe or profound HL, as 
expected. However, in five of the homozygous patients the hearing impairment was moderate.  
As opposed to T/T GJB2 genotypes, NT/NT GJB2 genotypes appear to be often associated 
with mild or moderate HL (Putcha et al., 2007; Snoeckx, Huygen, et al., 2005). As regards NT/NT 
genotypes including at least one p.Met34Thr or p.Val37Ile allele, it was observed that they were 
usually, but not always, associated with less severe HL (Snoeckx, Huygen, et al., 2005). 
Noteworthy, in our sample, two sporadic cases were compound heterozygous for p.Val37Ile 
plus one of two other NT mutations, p.Arg184Trp and p.Asn206Ser, and both presented with 
severe HL.  
In which concerns T/NT GJB2 genotypes, the variability on HL degree seems to depend on 
the NT mutation, at least when the T mutation is c.35delG (an early frameshift mutation). The 
two patients who were compound heterozygous for the p.Val37Ile and c.35delG displayed mild 
and moderate HL, respectively, which is in accordance with the phenotypes previously found 
associated with this compound genotype by Cryns et al. (2004). The association of the 
[c.35delG]+[p.Val37Ile] genotype with less severe HL phenotypes was corroborated by Pollak et 
al. (2007) and Snoeckx, Huygen, et al. (2005). One other T/NT GJB2 genotype, 
[c.35delG]+[p.Leu90Pro], is most commonly associated with mild or moderate HL (Cryns et al., 
2004; Pollak et al., 2007; Snoeckx, Huygen, et al., 2005). Our patient presenting this genotype 
had a moderate hearing impairment. As regards the genotype [c.35delG]+[p.Asn206Ser], it 
apparently follows the same trend as the [c.35delG]+[p.Leu90Pro] genotype (Marlin et al., 2005; 
Snoeckx, Huygen, et al., 2005). The [c.35delG]+[p.Asn206Ser] patient here reported presented 
with moderate HL. On the contrary, the [c.35delG]+[p.Val95Met] genotype, here found in two 
patients with severe HL, effectively appears to be more often associated with severe to 
profound HL (Cryns et al., 2004; Snoeckx, Huygen, et al., 2005) than with less severe HL (Cheng 
et al., 2005). 
Interestingly, the dominant GJB2 mutation p.Met163Leu, causing mild/moderate high-
frequency HL (Matos et al., 2008) has meanwhile also been found in one Argentinean patient 
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presenting with prelingual, profound NSSHL (Dalamón et al., 2010), suggesting that the severity 
of the HL due to the p.Met163Leu mutation might be variable and/or progressive. 
The pathogenicity of four GJB2 coding mutations found in our sample has been regarded 
as unclear or controversial in different studies. These mutations are p.Met34Thr (Bicego et al., 
2006; Cama et al., 2009; Feldmann et al., 2004; Griffith et al., 2000; Kenna, Wu, Cotanche, Korf, 
& Rehm, 2001; Pollak et al., 2007; Snoeckx, Huygen, et al., 2005; Wu et al., 2002), p.Arg127His 
(Matos et al., 2010), p.Val153Ile (Cryns et al., 2004; Dalamón et al., 2005; Hashemzadeh 
Chaleshtori et al., 2005; Kenna et al., 2001; Marlin et al., 2001; RamShankar et al., 2003; 
Snoeckx, Hassan, et al., 2005; Snoeckx, Huygen, et al., 2005) and p.Gly160Ser (Cheng et al., 
2005; Hashemzadeh Chaleshtori, Farhud, & Patton, 2007; Janecke et al., 2002; Löffler et al., 
2001; Santos et al., 2005; Snoeckx, Huygen, et al., 2005; Tang et al., 2006).  
In our study, p.Val153Ile and p.Gly160Ser were the sole GJB2 mutations identified in two 
individuals with mild and moderate hearing impairment, respectively. These two patients were 
also analysed in respect to both GJB6 deletions and the basal promoter, exon 1 and donor splice 
site of GJB2 gene, and no mutation was identified. So, no conclusion could be drawn. On the 
contrary, mutations p.Met34Thr and p.Arg127His were identified in biallelic patients, whose 
genotype we have considered to be the likely cause of the HL, with some reservations regarding 
the only p.Arg127His homozygous patient. Effectively, the [p.Arg127His]+[p.Arg127His] 
genotype was found segregating with HL (Tóth et al., 2004) but it was also identified in normal 
hearing individuals in the Indian population (RamShankar et al., 2003). Also, in one of the 
families included in this study, the p.Arg127His homozygous genotype is not segregating with HL 
(Matos et al., 2010). As regards the referred p.Arg127His homozygous patient, he doesn’t 
harbour any of the GJB6 deletions. Since other hearing impaired relatives of this patient were 
not available for study, we cannot know whether the p.Arg127His homozygous genotype is 
segregating with HL in the family.  
In general, our data meet the view that severity of GJB2-related HL can be correlated with 
specific mutation combinations (Cryns et al., 2004; Snoeckx, Huygen, et al., 2005). Variation in 
the phenotype for a given genotype would likely be dependent on more than one major 
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modifier gene, as suggested by the study of Hilgert, Huentelman, et al. (2009), as well as on 
environmental factors.  
Finally, our study is suggestive of genetic influx from other populations, since we found in 
the Portuguese patients some mutations particularly frequent in certain populations: c.-
23+1G>A (Eastern Europeans, Turkish, and Kurdish population of Iran), p.Trp24X and 
p.Arg127His (Indians/Gypsies), p.Val37Ile (East Asians), c.167delT (Ashkenazi Jews), c.-22-12C>T 
(Sub-Saharan Africans). It should be noted that the patients in this study harbouring p.Trp24X 
mutation are of Gypsy or Indian ethnicity/ancestry. This fact may account for the observed high 
frequency of this mutation. 
 
CONCLUSION 
 
GJB2 mutations are an important cause of NSSHL in the Portuguese population, being 
c.35delG the predominant mutation, with each of the 19 other pathogenic/controversial 
variants occurring at much lower frequencies. 
With basis solely on coding mutations, a diagnosis of GJB2-associated hearing loss was 
confirmed for 18.9% of the cases. Screening for the GJB2 donor splice site and the basal 
promoter, as well as for the two common GJB6 deletions, allowed the elucidation of the 
etiology of the HL in some of the cases with only one coding mutation identified. Therefore, 
such screening, in monoallelic patients, is advisable and should be performed. 
Overall, 20.8% of the patients were diagnosed as having DFNB1-related NSSHL, which 
represents a valuable indicator as regards therapeutical and rehabilitation options, as well as 
genetic counseling of Portuguese patients and their families. 
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TABLES 
 
 
Table 1. Frequency of the GJB2 mutated alleles (n= 528 chromosomes). 
 
Variant 
Location Effect 
Aleles, 
No. 
Frequency 
% 
DNA level Protein Level (n=528) 
c.35delG p.Gly12Valfs*2 
N-terminus 
(frameshift) 
Pathogenic 84 15.9 
c.101T>C p.Met34Thr M1 Controversial 7 1.3 
c.380G>A p.Arg127His IC Controversial 6 1.1 
c.71G>A p.Trp24X M1 (nonsense) Pathogenic 5 0.9 
c.109G>A p.Val37Ile M1 Pathogenic 5 0.9 
c.139G>T p.Glu47X E1 (nonsense) Pathogenic 3 0.6 
c.358_360delGAG p.Glu120del IC Pathogenic 3 0.6 
c.516G>A p.Trp172X E2 (nonsense) Pathogenic 3 0.6 
c.617A>G p.Asn206Ser M4 Pathogenic 3 0.6 
c.-23+1G>A NA Donor splice site Pathogenic 2 0.4 
c.283G>A p.Val95Met M2 Pathogenic 2 0.4 
c.-259C>Ta, b NA Basal promoter Pathogenic 1 0.2 
c.-22-12C>T NA Intron Polymorphism 1 0.2 
c.24G>A p.Thr8Thr N-terminus Novel 1 0.2 
c.167delT p.Leu56Argfs*26 E1 (frameshift) Pathogenic 1 0.2 
c.250G>A p.Val84Met M2 Pathogenic 1 0.2 
c.269T>C p.Leu90Pro M2 Pathogenic 1 0.2 
c.457G>A p.Val153Ile M3 Controversial 1 0.2 
c.468G>A p.Gly160Ser E2 Unclear 1 0.2 
c.487A>Ca p.Met163Leu E2 Pathogenic 1 0.2 
c.550 C>G p.Arg184Trp E2 Pathogenic 1 0.2 
 
a. Mutations identified for the first time in the Portuguese population; b. Mutation up to now private of 
one Portuguese family. 
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Table 2. GJB2 genotypes of the 80 patients carrying GJB2 mutations. 
 
GJB2 genotype Probands Frequency  % 
(n=264) 
HL 
 better ear 
History 
Biallelic      
[c.35delG]+[c.35delG] 28 10,6 5 Moderate 6 FC; 8 SC; 14 Un 
5 Severe 
11 Profound 
7 Unknown 
[c.35delG]+[p.Glu47X] 3 1,1 1 Profound 1 FC; 2 Un 
2 Unknown 
[c.35delG]+[p.Trp172X] 3 1,1 1 Moderate 1 FC; 1 SC; 1 Un 
2 Profound 
[c.35delG]+[p.Val37Ile] 2 0,8 1 Mild 1 FC; 1 SC 
1 Moderate 
[c.35delG]+ [c.-23+1G>A] 1 0,4  Profound Un 
[c.35delG]+[p.Trp24X] 1 0,4  Moderate SC 
[c.35delG]+[p.Met34Thr] 1 0,4  Unknown Un 
[c.35delG]+[c.167delT] 1 0,4  Severe FC 
[c.35delG]+[p.Leu90Pro] 1 0,4  Moderate SC 
[c.35delG]+[p.Val95Met] 1 0,4  Profound SC 
[c.35delG]+[delE120] 1 0,4  Moderate SC 
[c.35delG]+[p.Asn206Ser] 1 0,4  Moderate FC 
[p.Trp24X]+[p.Trp24X] 1 0,4  Moderate FC 
[p.Trp24X]+[p.Arg127His] 1 0,4  Moderate FC 
[p.Met34Thr]+[p.Val95Met] 1 0,4  Unknown Un 
[p.Val37Ile]+[p.Arg184Trp] 1 0,4  Severe SC 
[p.Val37Ile]+[p.Asn206Ser] 1 0,4  Severe SC 
[p.Val84Met]+ [c.-259C>T] 1 0,4  Profound FC 
[p.delE120]+[p.delE120] 1 0,4  Moderate SC 
[p.Arg127His]+[c.-23+1G>A] 1 0,4  Profound SC 
[p.Arg127His]+[p.Arg127His] 1 0,4  Unknown FC 
Total 53 20,1    
      
Monoallelic      
[=]+[c.35delG] 12 4,5 1 Mild 4 FC; 5 SC; 2 Un 
3 Moderate 
3 Severe 
3 Profound 
2 Unknown 
[=]+[p.Met34Thr] 5 1,9 1 Moderate 4 FC; 1 Un 
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1 Severe 
2 Profound 
1 Unknown 
[=]+[p.Arg127His] 2 0,8 2 Moderate 1 FC; 1 SC 
[=]+[c.-22-12C>T] 1 0,4  Severe Un 
[=]+[p.Thr8Thr] 1 0,4  Unknown Un 
[=]+[p.Trp24X] 1 0,4  Severe FC 
[=]+[p.Val37Ile] 1 0,4  Profound SC 
[=]+[p.Val153Ile] 1 0,4  Mild FC 
[=]+[Gly160Ser] 1 0,4  Moderate SC 
[p.Met163Leu]+[=] 1 0,4  Mild FC 
[=]+[p.Gln206Ser] 1 0,4  Moderate Un 
Total 27 10,2    
 
FC=Familiar Case; SC=Sporadic Case; Un=Unknown 
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ABSTRACT 
 
Mutations in the GJB2 gene are a major cause of nonsyndromic recessive hearing loss in 
many countries. In a significant fraction of patients, only monoallelic GJB2 mutations known to 
be either recessive or of unclear pathogenicity are identified. This paper reports a novel GJB2 
mutation, -3438C→T, found in the basal promoter of the gene, in trans with V84M, in a patient 
with profound hearing impairment. This novel mutation can abolish the basal promoter activity 
of GJB2. These results highlight the importance of extending the mutational screening to 
regions outside the coding region of GJB2. 
 
 
INTRODUCTION 
 
Hereditary hearing loss is a genetically heterogeneous disorder with 85 loci and 39 nuclear 
disease genes reported to date.1 Most of the cases of genetic hearing loss are non-syndromic, 
and of these, most are autosomal recessive. In some populations, up to 50% of cases of 
prelingual, non-syndromic sensorineural hearing loss (NSSHL) are due to mutations in a single 
gene, GJB2,2 which codes for connexin 26 protein (Cx26). Therefore, GJB2 is normally the first 
gene to be tested in patients with hearing loss. Mutational screening performed to date has 
usually focused on the coding region. Few studies have been conducted on the non-coding exon 
1 of GJB2, and even fewer on the promoter region of this gene. As a result of the GJB2 screening 
performed to date, the majority of patients in various populations have been reported with only 
one GJB2 mutation, either recessive or of unclear pathogenicity. Some of these cases were 
elucidated upon screening for the two common GJB6 deletions.3–5 The remaining cases possibly 
have pathogenic mutations yet to be found in the promoter region or other non-coding regions 
of GJB2. Notably, pathogenic mutations have been identified in the 5’ untranslated region (UTR) 
and promoter region of GJB1 (Cx32),6–8 another gene of the connexin family. In this paper, we 
report the genetic identification and functional analysis of the first GJB2 promoter mutation. 
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METHODS 
 
Subjects and audiometry 
We studied a Portuguese family with NSSHL: the 35-year oldmother and her two 
daughters (fig 1A). The mother (I-2) and the 12-year proband (II-2), had the hearing evaluated in 
both ears using pure-tone audiometry. Both presented with bilateral sensorineural hearing loss, 
but while the mother was only moderately affected, the proband had profound hearing 
impairment (fig 1B). The other child (II-1) had normal hearing. No biological or audiological data 
was available for the father (I-1). 
Eight unrelated patients, presenting with different degrees of hearing loss, and with only a 
monoallelic GJB2 variant previously identified, were also part of this study. Six of them have one 
controversial GJB2 variant (M34T, R127H or G160S), and the other two patients harbour one 
recessive GBJ2 allele (35delG). None of these eight patients has either of the two GJB6 
deletions, del(GJB6-D13S1830) and del(GJB6-D13S1854). 
The control population used comprised 70 non-related, hearing people from the 
Portuguese general population. 
Informed consent was obtained from each participant before collecting blood for DNA 
extraction. 
 
Screening of the GJB2 coding region and receptor splice site 
The coding region and receptor splice site of GJB2 gene were analysed by single-strand 
conformational polymorphism (SSCP) in both affected members of the family (I-2 and II-2). 
Sequencing of all the GJB2 coding region and receptor splice site was performed to identify the 
sequence variation detected by SSCP and to exclude other possible mutations in that genomic 
region. Before analysis of GJB2 basal promoter, both I-2 and II-2 were screened for the common 
GJB6 deletions, del(GJB6-D13S1830) and del(GJB6-D13S1854), following the method used by del 
Castillo et al.4 
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Screening of the GJB2 donor splice site, exon 1 and basal promoter 
For the three members of the family under study, the 70 Portuguese controls and the 
eight patients with only a monoallelic GJB2 variant, a GJB2 region of 1009 bp, comprising the 
donor splice site, exon 1 and part of the 5’ upstream sequence, was amplified by PCR using the 
forward primer 5’-CgTTCgTTCggATTggTgAg-3’ and the reverse primer 5’-
CAgAAACgCCCgCTCCAgAA-3’. The PCR products from the proband and one control patient were 
sequenced using the internal forward primer 5’-ggCTCAAAggAACTAggAgATCg-3’, with the same 
reverse primer as that used for amplification. These primers, used for sequencing, delimit a 539 
bp GJB2 region (from nucleotides -3573 to -3034 relative to the initiator methionine), which 
includes the 128 bp basal promoter, exon 1 and the donor splice site. 
The presence of the -3438C→T mutation identified in the proband was investigated in her 
mother and sister, and in the 70 Portuguese controls, by restriction analysis of the PCR products 
with the enzyme BsrBI (New England Biolabs, Quinta do Paizinho, Carnaxide, Portugal). The 
eight patients who had only a monoallelic GJB2 variant were assessed by sequencing for the 
presence of this mutation or other mutations in the donor splice site, exon 1 or basal promoter. 
The basal promoter, exon 1 and donor splice site of GJB2 gene can be found in GenBank 
(accession number U43932.1). 
 
Reporter-gene assay for assessment of wild-type and mutant GJB2 basal promoter 
activity 
A fragment of the promoter region from GJB2 alleles containing either a cytosine or a 
thymine at position -3438 relative to the initiator methionine was amplified by PCR using the 
forward primer 5’-ATACAgAgCTCACAgAggACAACgACCACAg-3’, designed to contain a SacI site, 
and the reverse primer 5’-TTAgTACCATggAgggCCgCAACACCTgTC-3’, designed to contain a NcoI 
site. The PCR products were cloned into the vector pCR2.1-topo using a commercial kit (TOPO 
TA pCR 2.1, TOPO Cloning Kit (ref. 45-064); Invitrogen, Prat de Llobregat, Barcelona, Spain). The 
SacI–NcoI fragment was excised by double digestion with the enzymes SacI and NcoI, and was 
then directionally cloned into pGL3-basic vector (Promega, Lisbon, Portugal) using its SacI and 
NcoI sites. A fragment upstream of the basal promoter and downstream of the SacI site was 
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then removed by digestion with SacI and XmaI followed by selfligation of the remaining plasmid. 
The resulting constructs contained, therefore, a fragment of the GJB2 promoter region ranging 
from nucleotides -3348 to -3490, which includes the entire basal promoter, cloned upstream of 
the firefly luciferase coding sequence. The constructs termed -3438C-pGL3 (wildtype sequence) 
and -3438T-pGL3 (containing the mutation -3438C→T) were assessed by sequencing and a 
diagnostic digestion with BsrBI to confirm sequence integrity. HEK-293 or Caco-2 cells were 
transfected with equimolar amounts of pRLTK 
vector (Promega) and -3438C-pGL3, -3438T-pGL3 or pGL3-basic, using a commercial 
transfection reagent (FuGENE 6.0; Roche, Basel, Switzerland). The transfected cells were lysed 
48h post-transfection. Luminescence of firefly luciferase (coded by pGL3-basic vector and by the 
pGL3 constructs) and Renilla luciferase (coded by pRL-TK vector) was assessed (Dual-LuciferaseH 
Reporter Assay System; Promega) by a multilayer counter plate reader (Victor(2) 1420-002; 
Perkin Elmer Wallack, Norton, Ohio, USA). The reporter gene assay was performed five times on 
HEK-293 cells and four times on Caco-2 cells. The firefly luciferase luminescence values were 
normalised against the Renilla luciferase luminescence values for each sample in each 
experiment. For each construct the average value of normalised luciferase luminescence was 
calculated and plotted in a histogram and analysed using the t test and Microsoft Excel 
software. 
 
Dye-transfer assay for assessment of wtCx26 and p.Val84Met-Cx26 function 
Gap-junctional communication in Wt-Cx26 and V84M-Cx26- expressing cells was assessed 
by intercellular spread of Lucifer yellow (LY) and neurobiotin (NBN). LY and NBN were delivered 
to HeLa cells using the whole-cell configuration of the patch-clamp technique. HeLa cells were 
transiently transfected with 500 ng Wt-Cx26-enhanced green fluorescent protein (EGFP) cDNA 
or V84M-Cx26-EGFP cDNA, using a commercial transfection reagent (Lipofectamine LTX; 
Invitrogen) according to the manufacturer’s recommendations. Transfected HeLa cells grown on 
9 mm coverslips were transferred to a recording chamber 24 hours after transfection. Cells in 
which significant EGFP-positive gap junction plaques were identified were selected for dye 
transfer. Following 5-minute whole-cell recordings, cells were fixed in 4% paraformaldehyde for 
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20 minutes and washed in phosphate-buffered saline. LY and NBN were detected and imaged as 
previously described.9 
 
 
RESULTS 
 
Analysis of the coding region of the GJB2 gene revealed that the proband and her mother 
were heterozygous for the V84M mutation (fig 1C). No other coding GJB2 variants were found. 
The V84M mutation has been previously reported to be associated with profound hearing 
loss.10 11 In the latter study, V84M was in trans with the 35delG mutation or M34T, suggesting 
that the V84M mutation is a recessive GJB2 mutation associated with profound hearing loss. As 
the proband analysed in our study was heterozygous for V84M and had profound hearing 
impairment, we hypothesised that she could yet possess either one of the two common GJB6 
deletions, del(GJB6-D13S1830) and del(GJB6-D13S1854), or a non-coding GJB2 mutation. 
Therefore, we tested the proband and her mother for the presence of del(GJB6-D13S1830) or 
del(GJB6-D13S1854). The deletions were not detected in either patient. We then sequenced the 
GJB2 donor splice site, exon 1 and basal promoter of the proband. A previously unreported 
substitution, -3438C→T, was found in the heterozygous state within the basal promoter. 
Restriction analysis with the enzyme BsrBI revealed that the proband’s normal-hearing sister 
also had one allele -3438C→T, but their mother, who had moderate hearing impairment, did 
not (data not shown). This variation was not found in the 70 hearing individuals from the 
Portuguese general population. Neither this nor other mutations were found in the donor splice 
site, exon 1 or basal promoter of seven of the eight monoallelic patients analysed. However, 
one monoallelic patient, heterozygous for the controversial R127H variant, was shown to be 
heterozygous for the donor splice-site recessive mutation IVS1+1G→A. 
The novel -3438C→T mutation is localised 3438 nucleotides upstream of the initiator 
methionine, in the GC box at position -81 relative to the transcription start point (TSP). This GC 
box and another at position -93 relative to the TSP, regulate GJB2 basal transcription by 
interacting with the transcription factors Sp1 and Sp3, but the -81 box is the most important.12 
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Because the -3438C→T mutation disrupts this GC box, we considered it to be potentially 
pathogenic, and reporter-gene assays were performed to confirm this. They revealed that the -
3438C→T mutation abolishes the GJB2 basal promoter activity in HEK-293 cells (fig 2), and 
greatly reduces it in Caco-2 cells (fig 3). Figure 2 shows that the mean normalised value of firefly 
luciferase luminescence from cells transfected with the plasmid containing the wild-type basal 
promoter (-3438C-pGL3) was higher than and significantly different from the value obtained 
from cells transfected with the promoterless pGL3-basic vector, which indicates promoter 
activity of the wild-type basal promoter (p<0.01), as expected. In contrast, there was no 
significant difference of the mean normalised values of firefly luciferase luminescence between 
cells that were transfected either with the mutant basal promoter (-3438T-pGL3) or with the 
pGL3-basic vector (p=0.29). This means that the mutation -3438C→T abolishes the activity of 
the GJB2 basal promoter in HEK-293 cells. In Caco-2 cells, the mutant GJB2 basal promoter 
showed some activity compared with the pGL3-basic vector (p<0.001), but was much less active 
than the wild-type basal promoter (p<<0.001) (fig 3). 
To confirm the suspected pathogenic effect of the V84M mutation we performed a dye-
transfer assay in HeLa cells. This experiment revealed clear differences between Wt-Cx26 and 
V84M-Cx26 function in the permeability of gap junctions to LY and NBN. In both groups of cells, 
there were detectable gap junction plaques between adjacent cells (fig 4). In all Wt-Cx26 
recordings (6/6) there was LY and NBN transfer to at least one adjacent cell (fig 4A). Conversely, 
in all V84M-Cx26 recordings (8/8) there was no transfer of LY or NBN (fig 4B). The membrane 
capacitance (an approximation of the total continuous membrane area in contact with the 
recording pipette) was significantly larger in Wt-Cx26 recordings (mean (SD) 54.8 (8.7) pF, n=6) 
compared with V84M-Cx26 recordings (29.6 (2.9) pF, n=8, p<0.01; unpaired t test). These results 
suggest that cells expressing V84M-Cx26 can form gap junction-like aggregates at the plasma 
membrane, but this does not allow intercellular electrical or molecular coupling. 
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DISCUSSION 
 
Connexin 26, a transmembrane protein coded by the gene GJB2, and a component of gap 
junctions, is strongly expressed in the cochlea, both in epithelial and connective tissues, where it 
is believed not only to have a role in the recirculation of the ion K+,13 which is a crucial 
mechanism for the transduction of sound waves into nervous impulses and consequently for 
proper hearing function, but also in the permeability to signalling molecules and metabolites.14 
The gene GJB2 is composed of two exons separated by an intron, and the coding region is 
entirely contained in exon 2. The basal promoter activity resides in the first 128 nucleotides 
upstream of the TSP and has two GC boxes, at positions -81 and -93 from the TSP, which are 
important for transcription.12 
Most of the GJB2 sequence variations described to date are localised in the coding region, 
and only a few have been reported in non-coding regions of the gene.15–19 Among the latter, 
there are two donor splice-site recessive mutations.15 19 The rest of the non-coding variations 
reported to date are localised upstream of the exon 1, in exon 1, the intron, the 5’ UTR of exon 
2, or the 3’ UTR, but none of these have yet been proven to be pathogenic. One is the -493del10 
deletion,16 located upstream of the basal promoter region, which occurs in most of the GJB2 
alleles harbouring the M34T mutation. This deletion disrupts a MGF-like sequence that is 
strongly homologous to the MGF binding site of the mouse β-casein gene.20 It was found that 
GJB2 alleles containing both -493del10 and M34T were expressed in cultured keratinocytes,16 
but it is not known whether the deletion altered the gene’s normal expression and whether it 
has an effect in the cochlea. 
We found a novel sequence variation in the gene GJB2 within the basal promoter, more 
specifically, in the -81 GC box. This novel mutation, -3438 C→T, was found in trans with the 
V84M mutation in a patient with profound hearing impairment, the proband of this study. Her 
mother, who had moderate hearing impairment, harboured V84M as the sole mutation in the 
coding region of GJB2, and tested negative for the -3438C→T mutation. The proband’s normal-
hearing sister did not have the V84M, but was found to be heterozygous for the -3438C→T 
mutation. The V84M mutation has been reported in other cases of profound hearing loss,10 11 
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and one of these cases was a patient also harbouring the 35delG,11 which suggests that when 
V84M-Cx26 is the only variant of Cx26 being produced, profound hearing loss can result. As the -
81 GC box was found to be crucial for the transcription of the gene in both the MCF-12A (human 
immortalised mammary epithelial) and RL95-2 (human endometrial) cell lines,12 we 
hypothesised that the -3438 C→T mutation could cause loss of function of the GC box, impairing 
or abolishing the GJB2 transcription in the cochlea. In this way, the profound hearing loss of the 
proband analysed here could be due to expression of only the V84MCx26 protein. To confirm 
that the GJB2 genotype -3438C→T/V84M could indeed be the cause of the profound hearing 
loss of the proband analysed in this study, we performed functional studies on both mutations. 
The reporter-gene assay, performed to assess the functionality of the basal promoter 
containing the -3438C→T mutation, revealed that this mutation abolishes the GJB2 basal 
promoter activity in the HEK-293 cell line and greatly reduces it in the Caco-2 cell line. 
The dye-transfer assay of V84M-Cx26 gap-junction properties revealed that this mutation 
results in communicationincompetent cells. A recent study has suggested that homomeric 
expression of V84L-Cx26 results in gap-junction channels that have unitary channel conductance 
and LY permeability that is indistinguishable from that of Wt-Cx26 channels.14 However, the 
basis of the hearing impairment caused by thismutation has been ascribed to impaired 
permeability to inositol trisphosphate. This would result in dysfunctional Ca2+ mobilisation in 
affected cochlear epithelial cells. In our study, HeLa cells expressing V84M-Cx26 also formed 
morphologically normal gap-junction plaques, but appeared to be uncoupled both electrically 
(based on membrane capacitance measurements), and metabolically (based on impaired LY and 
NBN transfer). 
In conclusion, this study describes the first pathogenic, hearing loss-related mutation 
impairing the basal promoter activity of the gene GJB2. It also shows that this or other basal 
promoter mutations, or even mutations in other non-coding regions, may be present in some 
patients with hearing loss with only a monoallelic GJB2 recessive mutation. Thus, screening of 
the basal promoter and other non-coding regions of the GJB2 gene, such as exon 1, UTRs and 
both splice sites, are important and necessary for improving genetic diagnosis regarding these 
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monoallelic patients, and for subsequent genetic counselling. We also present the first 
functional evidence for the pathogenicity of the previously described V84M mutation. 
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FIGURES 
 
 
 
 
Figure 1. (A) Pedigree of the family here analysed. Black symbols, affected family members; GJB2 
genotypes are displayed below the patients’ symbols. (B) Audiograms from right ear (RE) and left ear (LE) 
78 Chapter 3 
 
of the affected members (II-2 and I-2), at the ages of 12 and 35 years, respectively. Patient II-2 has 
bilateral profound hearing loss, and patient I-2 has bilateral moderate hearing impairment. The hearing 
ability of both patients decreases across the frequencies tested, being most compromised at the high 
frequencies. (C) Electrophoreograms showing a heterozygous nucleotide change, +250 G→A, resulting in 
the V84M mutation, in I-2 and II-2; this substitution is not present in II-1, Patient II-2 is also heterozygous 
for the -3438C→T mutation in the basal promoter region, changing the GC box sequence from CCGCCC 
to CCGCTC. This alteration is not present in the control individual, A209. 
 
 
 
 
Figure 2. Reporter-gene assay in HEK-293 cells. 
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Figure 3. Reporter-gene assay in Caco-2 cells. 
 
 
 
 
 
Figure 4. Dye-transfer assay of connexin (Cx) 26 function in Hela cells. (A) In cells expressing Wt-
Cx26, enhanced green fluorescent protein (EGFP)-labelled gap junction plaques (arrow) were seen. 
Following whole-cell dye injections, neurobiotin and Lucifer yellow were seen to transfer to adjacent 
cells. (B) In cells expressing V84M-Cx26, EGFP-labelled gap junction plaques (arrow) were also apparent. 
There was no spread of neurobiotin or Lucifer yellow in these cells. Scale bars, 20 μm. 
  
     Cx26-EGFP                    NBN      LY          Overlay 
A 
B 
wtCx26 
V84M-Cx26 
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SUPPLEMENTARY INFORMATION 
 
Materials and Methods 
 
Cell culture 
Three cell lines were used: HeLa, HEK-293 and NEB1. The first two cell lines were cultured 
in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and L-
glutamine; they were incubated in 10% CO2, at 37°C. NEB1 cells were cultured in DMEM/F12 
(1:1) medium supplemented with 10% FBS, and L-glutamine; they were incubated in 5% CO2, at 
37°C. 
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Figure 1. Microscopy images of the
wtCx30 at gap junction-like structures in NEB1 cells.
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Figure 2. Microscopy images showing the cellular localisation of EGFP
p.Val84Met-Cx26 in HeLa and NEB1 cells. wtCx26 and 
forming gap junction-like structures, although the latter protein sometimes appears to be partially 
retained in the cytoplasm (arrow). 
 
 
 
p.Val84Met-Cx26 both traffic to cell membrane, 
Alpha-tubulin is seen in red, and the nucleus is seen in blue.
 
-tagged wtCx26 and 
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Figure 3. Multiple alignment by ClustalW 2.1(Larkin et al., 2007) of Cx26 sequences from 23 
mammalian species, visualized in JalView 2.6.1(Waterhouse, Procter, Martin, Clamp, & Barton, 2009). 
The valine at position 84 (highlighted in red) of Cx26 is conserved. The sequences were retrieved from 
Ensembl database (Flicek et al., 2011). 
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Figure 4. Multiple alignment of connexin sequences in ClustalW 2.1 (Larkin et al., 2007), visualized in 
JalView 2.6.1 (Waterhouse et al., 2009). The sequences are a subset of the full core composed of 424 
connexin partial sequences, containing a connexin signature, therefore grouped as the PF00029 family, 
in Pfam database (Finn et al., 2010). This subset consists in those sequences that included the position 
equivalent to the Val84 of Cx26 (highlighted residue column), and to which a classification as to the type 
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of connexin (alpha, beta, delta, epsilon or gamma: CXA, CXB, CXD, CXE, CXG, respectively) was assigned. 
The accession name of each sequence (and its length) is provided. 
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ABSTRACT 
 
Mutations in GJB2 gene (encoding connexin 26) are the most common cause of hereditary 
non-syndromic sensorineural hearing loss (NSSHL) in different populations. The majority of GJB2 
mutations are recessive, but a few dominant mutations have been associated with hearing loss 
either isolated or associated with skin disease. We describe a novel dominant pathogenic GJB2 
mutation, identified in a Portuguese family affected with bilateral mild/moderate high-
frequency NSSHL. In vitro functional studies demonstrate that the mutant protein (p.M163L) has 
defective trafficking to the plasma membrane and is associated with increased cell death. 
 
 
1. INTRODUCTION 
 
The GJB2 gene encodes for connexin 26 (Cx26) which belongs to the connexin protein 
family. This protein oligomerizes in groups of six subunits making up the connexons. Each 
connexon docks into another one from an apposing cell, forming an intercellular channel. These 
channels cluster into structures named gap junctions, which allow metabolites and messenger 
molecules to pass between cells for synchronised function and ionic homeostasis of tissues and 
organs. 
In the cochlea, Cx26 is expressed in the supporting cells of the organ of Corti, the 
fibrocytes of the spiral ligament and the basal cells of stria vascularis (Forge et al., 2003) and 
may play a role in K+ recycling (Wangemann, 2002). This cyclic ionic flux is crucial for the 
auditory process since it enables the transduction of sound into nerve impulses which are then 
directed to the brain for processing. 
A broad spectrum of GJB2 mutations associated with hearing loss have been reported 
(Cooper et al., 2007), accounting for up to 50% of the cases of NSSHL occurring in many 
populations. Most of the GJB2 mutations described so far are recessive but a few dominant 
variants associated to both syndromic and non-syndromic hearing impairment have also been 
identified (Ballana et al., 2008).The identification of additional dominant GJB2 mutations might 
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help in understanding the relationship between this gene and disease phenotypes. Here we 
report a novel apparently dominant GJB2 mutation identified in a Portuguese nuclear family 
with bilateral NSSHL. Functional aspects of the corresponding Cx26 protein variant (p.M163L) 
have been investigated. 
 
 
2. MATERIALS AND METHODS 
 
A nuclear Portuguese family with a possible dominant form of NSSHL (Fig. 1) was studied. 
The three family members underwent otoscopic examination and audiometric testing. Hearing 
levels were determined by pure-tone audiometry with a diagnostic audiometer in a soundproof 
room. Environmental causes (for example, infectious diseases and ototoxic drugs) were 
excluded by interview. Individual I-2 had unilateral hearing loss associated with chronic otitis. 
The affected individuals I-1 and II-1 presented with similar audiological phenotypes (Fig. 1). 
 
2.1. Mutation screening 
The members of this Portuguese family were first tested for the 35delG mutation, and 
then screened for mutations in the whole GJB2 coding region and flanking sequences, including 
the acceptor splice site, by Single-Strand Conformational Polymorphism (SSCP), according to 
Scott et al. (1998). Following detection of sequence variations by SSCP, direct sequencing of the 
GJB2 coding region and acceptor splice site was performed. The novel M163L mutation was 
confirmed by PCR, using the primers Cx26-17(F) and Cx26-5(R) (Scott et al., 1998), followed by 
enzymatic restriction with the enzyme PstI (New England Biolabs) in a 20 μL reaction volume at 
37°C for 3 h. The same enzymatic restriction analysis was carried out in 103 non-related normal 
hearing control individuals from the Portuguese population. Mutational screening of GJB2 basal 
promoter, exon 1 and donor splice site was performed according to Matos et al. (2007). 
The GJB6 deletions del(GJB6-D13S1830) and del(GJB6-D13S1854) and the A1555G and 
A7445G hearing loss related mtDNA mutations were assessed as described by Del Castillo et al. 
(2005), Estivill et al. (1998) and Fischel-Ghodsian et al. (1995), respectively. 
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2.2. Residue conservation analysis 
The evolutionary conservation of the Cx26 methionine residue at position 163 was 
assessed by performing a multiple sequence alignment of the Cx26 sequences from 23 
mammalian species, which were retrieved from either Ensembl (http://www.ensembl.org) or 
UniProt (http://www.uniprot.org) databases. The software ClustalW 
(http://www.ebi.ac.uk/Tools/clustalw2/index.html) was used for generating the multiple 
sequence alignment, and Jalview (Clamp et al., 2004) was used for its visualization. 
 
2.3. Functional studies 
The behaviour and effects of the mutant M163L-Cx26 protein upon exogeneous 
expression in HeLa cells, HEK-293 cells (immortalized human embryonic kidney cells) and NEB1 
cells (immortalized normal keratinocytes) were studied using microscopy and Fluorescence 
Activated Cell Sorting (FACS) techniques. All transfection experiments were performed using the 
Fugene 6 reagent (Roche). 
The c.487A>C mutation (p.M163L) was created by Site Directed Mutagenesis, using a 
QuickChange® Site-Directed Mutagenesis Kit (Stratagene), in the wild-type coding sequence of 
the GJB2 gene, previously cloned by Common et al. (2004) into the pEGFP-N3 (Clontech) 
expression vector, in C-terminal fusion with eGFP. The sequence of the resulting vector was 
confirmed by enzymatic restriction and by sequencing. The construct encoding wild-type Cx26 
and constructs encoding eGFP, eGFP-tagged V84M-Cx26, eGFP-tagged D50N-Cx26 and eCFP-
tagged wtCx26 or wtCx30, were also used. V84M is a Cx26 non-syndromic hearing loss mutation 
(Matos et al., 2007) and D50N is a Cx26 syndromic skin disease-associated mutation that 
induces cell death in vitro (Common et al., 2004). 
The cellular localization of the M163L mutant protein was investigated and compared with 
that of wtCx26 by microscopy following transfection into HeLa and NEB1 cells. Co-localization 
studies with wtCx26 or wtCx30 and M163L-Cx26 were also performed in NEB1 cells. Cells used 
for cellular localization experiments were cultured at physiological extracellular calcium 
concentrations (1.8 mM for HeLa cells and 1.05 mM for NEB1 cells). For assessment of cell 
death, cells were first transfected with the constructs and maintained either at a physiological 
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or a high extracellular calcium concentration, prior to being analysed by FACS. Cell sorting was 
based on the fluorescence of eGFP, and also on the fluorescence of propidium iodide (PI) which 
was administrated to the cells 2 minutes before being analysed in the FACS machine. Since PI is 
uptaken by dead cells only, it was possible to sort and quantify the cells into four groups based 
on eGFP and PI fluorescence (positive or negative), and therefore calculate the percentage of 
eGFP positive cells which were dead. 
The death rates of HEK-293 cells transiently expressing eGFP-tagged M163L-Cx26, V84M-
Cx26, D50N-Cx26, or wtCx26, maintained at either a physiological (1.8 mM) or a high (3.6 mM) 
extracellular calcium concentration, were first determined. In addition, the death rates of NEB1 
cells transfected with the same constructs, and maintained at an extracellular calcium 
concentration within the physiological range (1.05 mM), were also assessed. Vectors encoding 
eGFP only, eGFP-tagged V84M-Cx26 and D50N-Cx26 were used as controls in these two 
experiments. Another cell death determination assay was performed using HEK-293 cells 
transfected with eGFP-tagged M163L-Cx26, wtCx26 and wtCx30, maintained at a physiological 
(1.8 mM) extracellular calcium concentration. In this latter assay, the total DNA transfected 
each time was 1 μg; when two constructs were co-transfected the ratio used was 1:1, and when 
cells were co-transfected with M163L-Cx26, wtCx26 and wtCx30 the ratio used was 1:1:2, 
respectively. NEB1 cells were cultured at a distinct physiological extracellular calcium 
concentration (1.05 mM) since this is the calcium concentration present in the standard media 
used to grow this cell line. 
 
 
3. RESULTS 
 
3.1. Audiological findings 
The audiogram shapes of mother (I-1) and daughter (II-1) are quite similar, showing a ‘‘ski-
slope” hearing loss (Fig. 1). Both present with high-frequency hearing loss, which is bilaterally 
moderate in the mother, and is mild in the left ear/moderate in the right ear in the daughter. 
The father (I-2) has unilateral profound hearing loss linked with chronic otitis. 
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3.2. Mutational screening 
The father (I-2) was heterozygous for c.35delG. However, a novel GJB2 mutation, the 
transversion c.487A > C, was identified in heterozygosity in the mother (I-1) and daughter (II-1), 
but not in the father (I-2). This mutation caused the substitution of the methionine amino acid 
residue at position 163 of the Cx26 protein for a leucine (p.M163L) has not previously been 
reported in the literature and was not found in the normal hearing control samples tested 
(0/206 control alleles). DNA from the mother and daughter was also screened for mutations in 
the basal promoter, exon 1 and donor splice site of the GJB2 gene, as well as for the deletions 
del(GJB6-D13S1830) and del(GJB6-D13S1854) in the GJB6 gene. As maternal inheritance could 
not be excluded, the presence of A1555G and A7445G mutations in the mtDNA was assessed. 
No further mutations were detected in these patients. 
 
3.3. Residue conservation analysis 
The Cx26 sequences from 23 mammalian species were aligned using ClustalW, in order to 
investigate the evolutionary conservation of the methionine residue, changed by the M163L 
mutation, located at position 163 of the protein. The multiple alignment revealed a total 
conservation of this residue across all the species, while some of its nearest residues show 
interspecific variation. 
 
3.4. Functional studies 
The M163L mutant protein was studied by microscopy, in regard to its trafficking and 
cellular localization, in HeLa and NEB1 cells. Contrary to wtCx26-EGFP, nearly no trafficking to 
the plasma membrane was observed with the M163L mutant having a predominantly punctate 
pattern in the cytoplasm (Fig. 2). However, when co-expressed with wtCx26-CFP or wtCx30-CFP, 
the mutant connexin was able to traffic to cell membrane, co-localizing with the CFP-tagged 
wild type connexins (Fig. 3) similar to other non-trafficking Cx26 mutations previously studied 
(Marziano et al., 2003; Di et al., 2005). 
Microscopic observation also revealed that cells expressing M163L-Cx26 alone acquired a 
rounded and detached morphology which suggested the cells were dying (Fig. 2). This 
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microscopic observation and a report on another hearing loss associated Cx26 mutation, G45E, 
which forms abnormally open hemi-channels and thus causes cell death at physiological but not 
at high extracellular calcium concentrations (Stong et al., 2006), raised the possibility that 
M163L mutation induces the same kind of hemichannel anomaly. Therefore, FACS analysis was 
used to investigate the effect of M163L-Cx26 on cell viability, under physiological and high 
extracellular calcium concentrations. It was observed that in both extracellular calcium 
conditions higher cell death occurred in HEK-293 cells expressing M163L-Cx26 or D50N-Cx26 in 
comparison to cells expressing wtCx26 or V84M-Cx26, and no rescue of the increased cell death 
phenotype associated with M163L and D50N mutations occurred at the high extracellular 
calcium concentration (Fig. 4A). FACS analysis was also performed to investigate the effect of 
expressing M163L-Cx26 in the keratinocyte cell line, NEB1 cells, at a physiological extracellular 
calcium concentration. In NEB1 keratinocytes, cells expressing M163L-Cx26 or D50NCx26 
exhibited more cell death than those cells expressing wtCx26 or V84M-Cx26 (Fig. 4B). Cell death 
was also analysed in HEK-293 cells transfected with M163L-Cx26, wtCx26, and wtCx30 (Fig. 4C). 
The mutant M163L alone caused the highest cell death. When the mutant was co-transfected 
with wtCx26 or wtCx30 the cell death rates decreased but were still statistically higher than the 
ones observed with wtCx26 either alone (p = 0.036) or in combination with wtCx30 (p = 0.011). 
Finally, the combination of M163L, wtCx26 and wtCx30 (1:1:2 ratio) resulted in a cell death rate 
not statistically different (p = 0.085) from the one obtained with cells co-transfected 
equimolarly with wtCx26 and wtCx30, although a small increase could be observed. 
 
 
4. DISCUSSION 
 
We have identified a novel, apparently dominant, Cx26 mutation, p.M163L, in a 
Portuguese nuclear family presenting with bilateral NSSHL. This mutation was identified in 
heterozygosity in two mild/moderate high-frequency hearing impaired individuals (mother and 
daughter) and was not found in normal hearing controls from the Portuguese population, which 
suggested it might be a pathogenic variant. This hypothesis was further supported by the 
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residue conservation analysis, which revealed total conservation of the methionine residue at 
position 163 across the 23 mammalian species represented at Ensembl and Uniprot databases, 
and also by reports of another mutation at the same position, M163V, having been found in 
heterozygosity in hearing loss patients (Marlin et al., 2001; Bayazit et al., 2003; Dalámon et al., 
2005). This latter mutation was shown to be translated but failed to induce the formation of 
homotypic junctional channels (Bruzzone et al., 2003). 
In order to elucidate the pathogenicity of M163L mutation we performed functional 
studies regarding its ability to traffic to the cell membrane as well as its effect on cell viability. 
The trafficking of M163L-Cx26 to the cell membrane was clearly impaired. However, 
trafficking to cell membrane with formation of gap junction-like structures was observed when 
this mutant was co-expressed with either wtCx26 or wtCx30. 
As regards cell viability, it was observed that expression of M163L-Cx26 in HEK-293 and 
NEB1 cells caused an increased cell death when compared to that seen upon expression of 
wtCx26. Moreover, this phenotype was not rescued by a high extracellular calcium 
concentration, as it was reported to happen with the G45E mutation, which yielded abnormally 
open hemi-channels at a physiological range of extracellular calcium concentration, but closed 
channels at higher concentrations, thus preventing cell death. This result, plus the trafficking 
defect, suggests that the increased cell death phenotype associated with M163L mutation is not 
due to abnormal hemi-channels. 
It was also observed that the increased cell death associated with the expression of 
M163L-Cx26 was lowered by equimolar co-expression of wtCx26 or wtCx30. However, co-
expression of M163L-Cx26 and wtCx26 still resulted in a higher cell death rate than the one 
obtained upon transfection with the same amount of total plasmid DNA, solely coding wtCx26. 
Similarly, equimolar co-expression of M163L-Cx26 and wtCx30 yielded a higher cell death rate 
than the one observed with cells equimolarly co-expressing wtCx26 and wtCx30. This suggests 
that the M163L mutant might exert a partially dominant-negative effect on wtCx26 and wtCx30 
as regards cell survival. 
Previously it has been reported that the second and third rows of Hensen’s cells of guinea 
pigs express Cx26 but almost no Cx30 (Zhao and Yu, 2006). Therefore it is possible that the 
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viability of cells solely expressing Cx26 in the M163L heterozygous patients might be diminished. 
As there is a gradient of expression of Cx26 and Cx30 in the cochleae of guinea pigs, with less 
expression at the base compared to the apex (Zhao and Yu, 2006), it is likely that the putative 
decreased viability of the patients’ Hensen’s cells causes more damage to the base of the 
cochlea, the region responsible for hearing at high-frequencies, than to its apex, the region 
responsible for hearing at low-frequencies. This hypothesis could explain the high-frequency 
hearing loss displayed by the patients. Additionally, it is possible that the M163L mutant protein 
impairs the function of Cx26 and/or Cx26/Cx30 channels, leading to decreased coupling, which 
also can have more severe consequences in the basal turn than in the apex due to the lower 
connexin expression. 
In conclusion, we have presented functional evidence supporting the pathogenicity and 
mode of the transmission of the novel dominant Cx26 mutation, p.M163L, therefore 
contributing to a better understanding of the molecular mechanisms underlying GJB2 related 
hearing loss. 
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FIGURES 
 
 
 
 
Figure 1. Pedigree and audiograms of the members of the family. A dominant form of NSSHL is 
apparently segregating in this family, affecting mother (I-1) and daughter (II-1), who are represented in 
the pedigree by blue symbols. These individuals have similar audiogram shapes and similar degrees of 
hearing loss. The slightly milder degree of hearing loss in the daughter might indicate either progressive 
deafness or intra-familial variability of the phenotype. I-2 presents with unilateral profound hearing loss 
apparently due to chronic otitis. 
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Figure 2. Microscopy images showing the cellular localization of wtCx26 and M163L-Cx26 proteins 
in HeLa and NEB1 cells. Wild-type Cx26 traffics to cell membrane, forming gap junction-like aggregates of 
protein. M163L-Cx26 does not traffic to cell membrane, being only visible in the cytoplasm. Note, also, 
the rounded, detaching morphology of NEB1 cells expressing the M163L mutant protein. 
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Figure 3. Microscopy images showing the co-localisation of M163L-Cx26 with either wtCx26 or 
wtCx30, at gap junction-like structures in NEB-1 cells. 
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Figure 4. (A) FACS analysis of HEK-293 cells at a physiological (1.8 mM) and at a high (3.6 mM) 
extracellular calcium concentrations. (B) FACS analysis of NEB1 cells at a physiological extracellular 
calcium concentration (1.05 mM). (C) FACS analysis of HEK-293 cells at a physiological extracellular 
calcium concentration (1.8 mM). 
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SUPPLEMENTARY INFORMATION 
 
 
Materials and Methods 
 
Cell Culture 
See Supplementary Information in Chapter 3. 
 
Western Blot 
HeLa cells, previously transfected with pEGFP-N3 constructs encoding wtCx26, 
p.Val84Met-Cx26 and p.Met163Leu-Cx26 were washed twice with PBS, and then lysed in lysis 
solution (5% 2-Mercaptoethanol in SDS sample buffer with protease inhibitor) with the aid of a 
syringe plunger. The lysates were sonicated to reduce viscosity. The samples were loaded into 
10% polyacrylamide gels, and the protein size marker used was the Full-Range Rainbow 
Molecular Weight Marker (GE Wealthcare). The samples were run, at 110V, until the loading 
buffer had just got off the gel. The proteins in the gel were then transferred to a membrane 
(Amersham Hybond™ ECL™). After the transfer, the membrane was blocked in PBS with 5% milk 
powder. The membrane was hybridized with the primary antibody (GFP antibody ab290, 
Abcam), diluted 1:1000 in PBS with 5% milk powder, during 1h at room temperature, with 
shaking, and then, after three 5min washes in PBS 1% Tween, it was incubated with the 
secondary antibody (goat anti-rabbit HRP P0448, DAKO) in the same conditions. Following three 
washes with PBS-1% Tween, the membrane was developed using the Amersham ECL™ Western 
Blotting Detection Reagents. After development, the membrane was stripped and hybridized 
with a mixture of antibodies against GAPDH (ab8245, Abcam) and β-actin (A5441, Sigma) first, 
and then with a goat anti-mouse secondary antibody (1:1000) and was revealed. 
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ANNEX 
 
 
Figures 
 
 
 
Figure 1. Western Blot of HeLa whole cell lysates revealed similar wild-type and p.Val84Met-Cx26 
(V84M) protein amounts, but only a small amount of p.Met163Leu-Cx26 (M163L) protein was detected. 
 
 
 
 
Figure 2. HEK-293 transfected with either wtCx26 or p.Met163Leu-Cx26 (M163L). Expression of 
the p.Met163Leu-Cx26 protein led to increased cell death.  
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Figure 3. Multiple alignment of the Cx26 sequences from 23 mammalian species. The sequences were 
derived from the Ensembl database (Flicek et al., 2011). The multiple alignment was performed in 
ClustalW 2.1 (Larkin et al., 2007) and visualized in JalView 2.6.1 (Waterhouse, Procter, Martin, Clamp, & 
Barton, 2009). The methionine at position 163 (highlighted in red) is invariant across the aligned 
sequences. This multiple alignment serves to illustrate the conservation of the amino acid residue at 
position 163 of Cx26, mentioned in the article of this chapter, but it is not the alignment mentioned in 
the article, as it was done by using sequences derived from the Ensembl database only. 
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ABSTRACT 
 
Mutations in the GJB2 gene account for up to 50% of hereditary nonsyndromic hearing 
loss in several populations. Over 200 mutations are already described in this gene, and three of 
them, c.35delG, c.167delT, and c.235delC, are the most frequent in Caucasians, Ashkenazi Jews, 
and Asians, respectively. Most of GJB2 hearing loss-related mutations are recessive, but a few 
dominant alleles have also been described. Apart from the clearly pathogenic mutations, there 
are some other variants whose pathogenicity is still controversial, such as p.Met34Thr, 
p.Val37Ile, p.Arg127His, and p.Val153Ile. The p.Arg127His allele has been found in some mono- 
and biallelic hearing-impaired patients from several countries. In this article we report on some 
Portuguese patients harboring this mutation. Taking into consideration the analysis of these 
Portuguese cases as well as the genetic and functional data regarding p.Arg127His available in 
the literature, we conclude that this variant may be a cause of hearing loss depending on 
environmental factors and/or genetic background. 
 
 
INTRODUCTION 
 
Genetic hearing loss is a common sensorial disorder in humans. There are many genes 
that, when mutated, can cause this disease. However, mutations in the gene encoding the gap 
junction protein connexin 26 (GJB2) account for up to 50% of hereditary nonsyndromic hearing 
loss in several populations. The Human Genome Mutation Database contains over 200 
mutations described in the GJB2 gene, most of them considered pathogenic (Stenson et al., 
2009) (www.hgmd.org). However, there are some variants, such as p.Met34Thr, p.Val37Ile, 
p.Arg127His, and p.Val153Ile, whose pathogenicity is still controversial, since their role in 
hearing impairment is not yet clearly understood (Marlin et al., 2001; Wu et al., 2002; Bayazit et 
al., 2003; Meşe et al., 2004; Bicego et al., 2006; Huculak et al., 2006; Guerci et al., 2007; Pollak 
et al., 2007). 
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Here we report on three Portuguese families affected with hearing loss, in which we have 
identified p.Arg127His. This variant is common in both deaf and hearing Indians, presenting 
allele frequencies of 0.123 and 0.175, respectively, in the study by RamShankar et al. (2003). 
Similar frequencies were reported by Ramchander et al. (2004) in a different sample of Indian 
patients and hearing controls. The p.Arg127His variant was also identified in 19.4% of the 
chromosomes of 54 hearing-impaired Slovak Romany (Gypsies), a people with Indian ancestry 
(Minárik et al., 2003; Álvarez et al., 2005). Interestingly, two of the families here presented 
belong to the Gypsy community. We discuss the pathogenicity of p.Arg127His taking into 
consideration our results as well as the information available in the literature on genetic and 
functional aspects of this mutation. In this way, this work may contribute to a better 
understanding of the role of p.Arg127His mutation in hearing loss. 
 
 
MATERIALS AND METHODS 
 
Patients 
This study focuses on three Portuguese families (coded as BS, DM, and EL), presenting 
with bilateral nonsyndromic, sensorineural hearing loss, whose analysis was performed when 
screening Portuguese affected families for GJB2 mutations. All patients were audiologically 
evaluated by pure tone audiometry. Informed consent was obtained from all the participants. 
 
Genetic analysis 
Blood samples were taken from the participants, and genomic DNA was extracted. The 
GJB2 gene coding region and acceptor splice site was amplified, and sequenced using the newly 
designed forward primer 2aF 5’-AAGTCTCCCTG TTCTGTCCT-3’ and reverse primer 2bR 5’-
GGCATCTGGAGTTTCACC-30. All the patients, except I:2 from family DM, were further studied in 
regard to the del(GJB6-D13S1830) and del(GJB6-D13S1854) GJB6 deletions using the same 
methodology as del Castillo et al. (2005). Afterward, these individuals were also screened by 
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sequencing for mutations in the GJB2 basal promoter, exon 1, and donor splice site, according 
to Matos et al. (2007). 
 
 
RESULTS 
 
The hearing-impaired individuals belonging to three Portuguese families were analyzed in 
respect to GJB2 coding region and acceptor splice site. With the exception of individual I:2 
belonging to family DM, these patients were also tested for both the common GJB6 deletions 
and screened for mutations in the GJB2 basal promoter, exon 1, and donor splice site. The 
variant p.Arg127His (R127H) was found in the three families analyzed, but in two of them a 
second GJB2 mutation, p.Trp24X (W24X) or c.-23+1G>A (often referred as IVS1+1G>A), was also 
identified (Fig. 1). No further GJB2 mutation, or GJB6 deletion, was found. 
In one of the families (EL), of Gypsy ethnicity, the proband, his affected sibling, and the 
normal-hearing father are compound heterozygous for p.Trp24X/p.Arg127His; the normal-
hearing mother is homozygous for p.Arg127His. In the second family (DM), consanguineous and 
also of Gypsy ethnicity, the p.Arg127His mutation does not seem to segregate with hearing loss 
since the two affected siblings are heterozygous for p.Arg127His, with no accompanying GJB2 
mutation or GJB6 deletion, while their unaffected sibling is homozygous for this mutation. In the 
third family (BS), of unknown ethnicity, the proband is heterozygous for p.Arg127His as well as 
for the recessive, donor splice-site mutation c.-23+1G>A. Genetic analysis on the parents’ DNA 
was performed to determine whether the two mutations are in trans. It was observed that each 
parent is a carrier of one of the mutations, so the child is effectively compound heterozygous. 
 
 
DISCUSSION 
 
We have analyzed three Portuguese families (BS, DM, and EL) presenting with 
sensorineural hearing loss, and having in common the controversial p.Arg127His mutation in 
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GJB2. However, this variant does not seem to be a cause of hearing impairment in all the three 
families. 
In family DM, the results obtained suggest that the hearing loss is not likely to be related 
to the p.Arg127His mutation since both affected siblings are heterozygous for this variant, with 
no accompanying GJB2 mutation or GJB6 deletion, while the normal-hearing sibling is 
homozygous for p.Arg127His. The cause of the hearing loss might probably lie in recessive 
alleles of other genes brought together by consanguinity. 
In the other two families, BS and EL, the p.Arg127His mutation could be involved in the 
hearing loss observed, since it occurs in compound heterozygosity with two well established 
recessive mutations, p.Trp24X and c.-23+1G>A, in the affected individuals (although other gene 
or environmental factors cannot be excluded as causes for the hearing loss). In family BS, the 
p.Arg127His variant seems to behave as a recessive allele since the proband is a c.-
23+1G>A/p.Arg127His compound heterozygote, and the parents, each one a carrier of one of 
the mutations, have normal hearing. In family EL, the proband and his affected sibling are both 
compound heterozygous for p.Trp24X and p.Arg127His, a similar situation to the one observed 
in a hearing loss case reported by Roux et al. (2004). The mutation p.Arg127His has also been 
found, in other cases of hearing loss, associated with the pathogenic recessive mutation 
p.Glu47Lys (Prasad et al., 2000), and also with the controversial variants p.Met34Thr (Roux et 
al., 2004; Snoeckx et al., 2005), p.Val37Ile (Yaeger et al., 2006) and p.Val153Ile (Najmabadi et 
al., 2005, Santos et al., 2005). Noteworthy, in the study by Roux et al. (2004), the three 
p.Arg127His alleles identified in the patient cohort occurred in compound heterozygosity with 
p.Met34Thr (two probands) and with p.Trp24X (one proband), while in the general population 
no compound heterozygosity involving p.Arg127His was reported. The authors considered 
significant the fact that compound heterozygosity for p.Met34Thr and p.Arg127His - identified 
twice among the patients - had not been observed in the general population controls. In other 
study (Tóth et al., 2004), p.Arg127His was shown to segregate in homozygosity with hearing 
loss. All these findings would support the pathogenicity of the p.Arg127His variant. 
However, some observations reported in the literature seem to argue against the 
pathogenic nature of p.Arg127His. In family EL and in the case described by Roux et al. (2004) 
The controversial p.Arg127His mutation 115 
 
mentioned above, compound heterozygosity for p.Trp24X and p.Arg127His was also observed in 
normal-hearing relatives. A puzzling behavior of the p.Arg127His variant is again evident when 
considering the reports of normal-hearing individuals (Marlin et al., 2001) and hearing-impaired 
individuals (Uyguner et al., 2003) who are compound heterozygotes for the c.35delG and 
p.Arg127His mutations. Moreover, normal-hearing individuals homozygous for p.Arg127His 
have been reported (RamShankar et al., 2003; Roux et al., 2004; Dahl et al., 2006), and studies 
have been published in which the frequency of the p.Arg127His variant in hearing-impaired and 
normal-hearing individuals is not significantly different, in comparison to clearly pathogenic 
mutations such as p.Trp24X and c.35delG (RamShankar et al., 2003; Ramchander et al., 2004; 
Roux et al., 2004). 
Given the discrepancies observed in the genetic studies, investigating the functionality of 
the p.Arg127His-Cx26 protein could provide further insight into the role of this variant in 
hearing loss. With this objective, some functional studies were already performed by other 
groups. 
Palmada et al. (2006) investigated the role of p.Arg127His mutation on hemichannel 
conductance in noncoupled oocytes. Western blotting ensured that p.Arg127His-Cx26 was 
inserted in the oocytes’ membranes at a degree similar to wtCx26. In the subsequent 
measurements of hemichannel activity, p.Arg127His-Cx26 displayed a partially defective 
phenotype when expressed alone. Although coexpression of p.Arg127His-Cx26 with wtCx26 at 
equimolar levels (mimicking p.Arg127His heterozygosity) revealed no significant current 
difference relative to wtCx26 expressed alone, coexpression of p.Arg127His-Cx26 with wtCx30 
or wtCx31 at equimolar levels (mimicking p.Arg127His homozygosity) revealed a strong 
dominant negative effect of the p.Arg127 His-Cx26 mutant on each of the wild-type connexins. 
Wang et al. (2003) performed dual whole-cell voltage-clamp assays in N2A cells stably 
transfected with cDNA encoding p.Arg127His-Cx26, and demonstrated that transjunctional 
current and macroscopic junctional conductance of p.Arg127 His-Cx26 channels were greatly 
reduced. The authors also reported impaired neurobiotin transfer between pairs of N2A cells 
expressing p.Arg127His-Cx26 (n=1 out of six pairs). These results seem not to be due to 
impaired translation or protein trafficking to the membrane, since Western blot revealed strong 
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expression of the p.Arg127His-Cx26, and this mutant protein was predominantly expressed in 
the cell membrane being its immunocytochemical staining pattern indistinguishable from that 
of wtCx26. Bicego et al. (2006) and D’Andrea et al. (2002) also observed immunocalization of 
p.Arg127His-Cx26 similar to wtCx26, with junctional plaques in zones of cell-to-cell apposition, 
and Western blotting revealed that levels of p.Arg127His-Cx26 expression were comparable 
(small or no significant difference) with those of wtCx26. In these two studies, p.Arg127His-Cx26 
channels have been found to have a much reduced permeability to Lucifer yellow, but 
p.Arg127His-Cx26 did not show a dominant negative effect on wtCx26, regarding permeability 
to this tracer, when both variants were cotransfected at 1:1 ratio. p.Arg127His-Cx26 channels 
were also shown to fail diamidino-2-phenylindole (DAPI) transfer (D’Andrea et al., 2002). 
Thönnissen et al. (2002) observed an elevated permeability of p.Arg127His-Cx26 channels 
to neurobiotin, contrary to the results obtained by Wang et al. (2003) above referred. It should, 
however, be noticed that in the study by Thönnissen et al. (2002), p.Arg127His-Cx26 was 
considerably more expressed than wtCx26; therefore, the high intercellular diffusion of 
neurobiotin observed with p.Arg127His-Cx26 channels (three times more than that obtained 
with wtCx26 channels) might not reflect the real permeability of each p.Arg127His-Cx26 
channel; instead, it may be due to the very high number of p.Arg127His-Cx26 channels with 
reduced permeability to neurobiotin, as suggested by the results of Wang et al. (2003). This 
notoriously higher expression of p.Arg127His-Cx26 relative to wtCx26, which was not observed 
by D’Andrea et al. (2002) or by Bicego et al. (2006), might result from a different degree of 
purity of the constructs used for transfection, or it may have happened that the stably 
transfected p.Arg127His-Cx26 expressing clones chosen for subsequent analyses expressed, by 
chance, more Cx26 protein than the ones expressing wtCx26. It is also possible that the silent 
base change, from G to A, that the authors refer to exist at position 237 in the Cx26 sequence in 
all the constructs used might have altered protein expression levels in a manner that changed 
the relative expression of p.Arg127His-Cx26 and wtCx26. 
In summary, the overall results clearly indicate an abnormal behavior of this mutation. 
It is not known whether the alterations in the properties of p.Arg127His-Cx26 channels 
observed in vitro are meaningful at the biological level and, if so, at what extent or under which 
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circumstances. If any in vivo effect exists, it might be potentiated or attenuated by other genetic 
and/or environmental factors. These still unknown interactions would explain the differences 
observed in the audiological phenotypes (normal or impaired) of the compound heterozygotes 
for p.Arg127His and p.Trp24X in family EL and in the family referred by Roux et al. (2004). This 
explanation could be extended to other cases of compound heterozygosity involving 
p.Arg127His and to the p.Arg127His homozygotes. 
In the light of the genetic and functional data here analyzed, including the three 
Portuguese cases, we conclude that p.Arg127His mutation may in some cases be a cause of 
hearing loss, depending on environmental and/or genetic factors yet to be elucidated. 
Therefore, p.Arg127His should not be disregarded when providing genetic counseling to the 
families. 
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FIGURES 
 
 
 
 
Figure 1. Pedigrees of the three Portuguese families under study, family BS, family DM, and family 
EL. Black symbols represent hearing-impaired individuals, and open symbols represent normal-hearing 
individuals. W24X and R127H are abbreviations for the p.Trp24X and p.Arg127His mutations, 
respectively. 
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ABSTRACT 
 
Involvement of GJB2 noncoding regions in hearing loss (HL) has not been extensively 
investigated. However, three noncoding mutations, c.-259C>T, c.-23G>T, and c.-23+1G>A, were 
reported. Also, c.-684_-675del, of uncertain pathogenicity, was found upstream of the basal 
promoter. We performed a detailed analysis of GJB2 noncoding regions in Portuguese HL 
patients (previously screened for GJB2 coding mutations and the common GJB6 deletions) and 
in control subjects, by sequencing the basal promoter and flanking upstream region, exon 1, and 
3’UTR. All individuals were genotyped for c.-684_-675del and 14 SNPs. Novel variants (c.-
731C>T, c.-26G>T, c.∗45G>A, and c.∗985A>T) were found in controls. A hearing individual 
homozygous for c.-684_-675del was for the first time identified, supporting the 
nonpathogenicity of this deletion. Our data indicate linkage disequilibrium (LD) between SNPs 
rs55704559 (c.∗168A>G) and rs5030700 (c.∗931C>T) and suggest the association of 
c.[∗168G;∗931T] allele with HL. The c.∗168A>G change, predicted to alter mRNA folding, might 
be involved in HL. 
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1. INTRODUCTION 
 
About two hundred GJB2 mutations causing nonsyndromic hearing loss (NSHL) have been 
reported (http://www.hgmd.org/) [1]. Most GJB2 mutations described so far localize to the 
coding region (totally included within exon 2), which is routinely analysed upon the study of 
GJB2 in HL patients. Also involved in HL, two deletions, del(GJB6-D13S1830) [2–4] and del(GJB6-
D13S1854) [5] disrupt the GJB6 gene which codes for connexin-30, and it is thought that they 
may ablate a GJB2 cis-regulatory sequence [5-7]. This putative element is likely to be ablated by 
a third deletion, del(chr13 : 19,837,344–19,968,698), localized upstream of GJB2 and GJB6 [8, 
9]. 
Along with GJB2 coding region, the noncoding first exon and donor splice site have been 
analysed in several studies, and two pathogenic mutations, c.-23G>T (exon 1) [10] and c.-
23+1G>A (intron) [11], both in the donor splice site, have been identified. The c.-23+1G>A 
mutation (commonly known as IVS1+1G>A), shown to impair splicing [12], has been identified in 
several cases, being particularly frequent in Czech Republic, Turkey, and Hungary [13–15]. 
A few studies have investigated, in addition to exon 1, the noncoding region immediately 
upstream of this exon, including the basal promoter [14, 16–21]. 
Houseman and coworkers [16] analysed HL patients heterozygous for c.101T>C 
(p.Met34Thr), in which no second GJB2 coding mutation had been detected, and identified a 
monoallelic 10 bp deletion, c.-684_-675del (firstly designated -493del10), upstream of the basal 
promoter. The deletion was also present in other hearing impaired individuals as well as in 
control individuals, with or without c.101T>C. However, c.-684 -675del homozygosity was only 
observed in c.101T>C homozygous patients. The fact that in the control population 22 of the 25 
(88%) c.101T>C heterozygotes carried the deletion suggested the existence of LD between 
c.101T>C and c.-684 -675del, later demonstrated by Zoll and coworkers [22]. Transcription was 
observed from alleles harbouring in cis the deletion and the variant c.101T>C, derived from 
keratinocytes and cell lines. However, eventual subtle differences would not have been 
detected, since this was not a quantitative analysis [16]. To date, the role of c.-684_-675del in 
HL has remained uncertain. 
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More recently, a pathogenic basal promoter mutation, c.-259C>T (firstly designated -
3438C>T) was identified, in trans with c.250G>A (p.Val84Met), in a Portuguese HL patient, 
highlighting the relevance of screening GJB2 noncoding regions in nonelucidated cases [18]. 
In the present study, we have analysed the basal promoter and the flanking upstream 
region, as well as the exon 1 and the 3’UTR of the GJB2 gene in 89 Portuguese HL patients. The 
same analysis was conducted on 91 normal hearing control individuals from the Portuguese 
population. 
 
 
2. METHODS 
 
2.1. Subjects 
Eighty-nine Portuguese HL patients previously screened for mutations in the GJB2 coding 
region and acceptor splice site (by SSCP and/or sequencing) and for the del(GJB6-D13S1830) 
and del(GJB6-D13S1854) GJB6 deletions (using the methodology described in [5]) were enrolled 
in this study. Eight patients were heterozygous for a GJB2 coding mutation: c.71G>A (p.Trp24X; 
n = 1), c.35delG (n = 3), c.109G>A (p.Val37Ile; n = 1), c.380G>A (p.Arg127His; n = 1), c.457G>A 
(p.Val153Ile; n = 2), and one patient was heterozygous for the c.-22-12C>T variant (apparently a 
polymorphism; dbSNP accession number rs9578260). No patient harboured either of the known 
GJB6 deletions. The HL was nonsyndromic in all patients, except for one of them, who 
presented with Waardenburg syndrome. The patient was heterozygous for the controversial 
c.457G>A mutation and was thus included in the study. The patients presented with bilateral, 
mild to profound HL, and were either familial or sporadic cases. The familial cases 
predominantly showed a recessive pattern of inheritance. All patients were audiologically 
evaluated by pure tone audiometry. 
The control sample was composed of 91 Portuguese individuals with apparent normal 
hearing. The status regarding c.101T>C GJB2 variant of those control individuals harbouring the 
c.-684_-675del, here referred, had been previously investigated, by sequencing, as part of an 
unpublished work. The status of the entire GJB2 coding region is not known for the vast 
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majority of the 91 control individuals, which were blindly included in this study (and not based 
on their eventually available GJB2 coding region status). 
Informed consent was obtained from all the participants. 
 
2.2. Genetic Analysis 
In all individuals, we have sequenced a region of about 0.7 kb immediately upstream of 
the exon 1 (which includes the basal promoter), the exon 1, and the whole 3’UTR. The region 
upstream of the exon 1, plus exon 1 and donor splice site, was amplified in a 1009 bp amplicon, 
using the pair of primers PF2 5’-CgTTCgTTCggATTggTgAg-3’ and PR1 5’-
CAgAAACgCCCgCTCCAgAA-3’, as previously described [18]. The amplicons were sequenced using 
the primers PF2 and PF1 5’-ggCTCAAAggAACTAggAgATCg-3’. When necessary, primers PR1 and 
PR2 5’-ggAgACTgggAAAgTTACgg-3’ were used for sequencing. The 3’UTR (plus the last 90 
nucleotides and stop codon) was amplified in three overlapping fragments using the following 
three pairs of primers: 3UTRaF 5’-gCAgTgTCTggAATTTgCATC-3’, 3UTRaR 5’-
AggCACTggTAACTTTgTCC-3’, 3UTRbF 5’-CACgTTAAAggTgAACATTgg-3’, 3UTRbR 5’-
CgACAgAAACTTCTCCCTC-3’, 3UTRcF 5’-gTAgCCAgCATCggAAAgAAC-3’, 3UTRcR 5’-
ACTCTggCAACTTACCCATTg-3’. The 3’UTR PCR products were sequenced using the respective 
amplification forward primers. 
 
2.3. DNA Sequence Variants and SNPs Description 
Description of variants follows the HGVS recommendations, and is based on the GJB2 
reference sequences accessed through the following links: 
 
(1) https://research.cchmc.org/LOVD/refseq/GJB2codingDNA.html; 
(2) https://research.cchmc.org/LOVD/refseq/GJB2intron 01.html; 
(3) https://research.cchmc.org/LOVD/refseq/GJB2upstream.html; 
(4) https://research.cchmc.org/LOVD/refseq/GJB2downstream.html. 
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These sequences show 100% identity with the NM 004004.5 (link 1) and NG 008358.1 
(links 2, 3, and 4) NCBI reference sequences. 
Novel variants were submitted to dbSNP and the respective reference SNP (rs) accession 
numbers are provided within the text. 
SNPs are referred to by the dbSNP reference SNP (rs) accession number whenever it was 
available, and by the HGVS recommended designation, relative to the forementioned reference 
sequences. 
 
2.4. Genotyping and Statistical Analysis 
We have genotyped all individuals for the c.-684_-675del deletion; three SNPs in the 
promoter (rs9550621 (c.-484T>C), rs73431557 (c.-410T>C), rs9552101 (c.-369A>G)); ten SNPs in 
the 3’UTR (c.∗1C>T, rs3751385 (c.∗84T>C), rs7337074 (c.∗104A>T), rs7329857 (c.∗111C>T), 
rs55704559 (c.∗168A>G), rs5030700 (c.∗931C>T), rs1050960 (c.∗1067G>T), rs7623 
(c.∗1152G>A), rs11841182 (c.∗1197T>A), and rs7988691 (c.∗1277T>C)); one SNP downstream of 
the 3’UTR (rs11839674 (c.∗1447G>A)). 
For the sake of simplicity, when describing the composite genotypes regarding SNPs 
rs73431557 (c.-410T>C), rs3751385 (c.∗84T>C), rs55704559 (c.∗168A>G), and rs5030700 
(c.∗931C>T), the genotype at each position, indicated in order from 5’ to 3’, is designated by A, 
C, G, or T if homozygous, or by a code letter, according to IUPAC nucleotide ambiguity code, if 
heterozygous. 
The allelic frequencies regarding deletion c.-684_-675del and the 14 SNPs, were 
determined in the control population and used to test for Hardy-Weinberg equilibrium. The chi-
square test was used to compare the allelic frequencies of the patients with those of the normal 
hearing individuals. Allelic frequencies of the control sample for the 14 SNPs were used to 
calculate pairwise linkage disequilibrium values. Testing for Hardy-Weinberg equilibrium, 
calculation of pairwise linkage disequilibrium values, and haplotype estimation (through the 
expectation maximization algorithm), were performed using SNPAnalyzer 1.2A online software 
(http://snp.istech.info/snp/SNPAnalyzer.html). 
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2.5. Analysis of mRNA Folding 
Mfold (http://mfold.rna.albany.edu/?q=mfold/RNA-Folding-Form) [23] was used to assess 
the effect of alleles c.[∗168A;∗931C], c.[∗168G;∗931T], c.[∗168A;∗931T], and c.[∗168G;∗931C] 
on the folding of GJB2 mRNA (template sequence: ENST00000382848, retrieved from Ensembl). 
For each sequence the lowest free-energy structure was considered. 
 
 
3. RESULTS AND DISCUSSION 
 
In the current study, 89 Portuguese HL patients, previously screened for mutations in the 
GJB2 coding region and acceptor splice site (80 patients presenting no mutation, plus eight 
heterozygous for coding mutations and one heterozygous for the noncoding variant c.-22-
12C>T), and 91 hearing individuals were analyzed as regards the noncoding region immediately 
upstream of the exon 1 (which includes the basal promoter), the exon 1, and the whole 3_UTR 
of GJB2 gene. All individuals were also genotyped for c.-684_-675del and 14 SNPs localized 
therein. 
 
3.1. DNA Sequence Variants 
No additional GJB2 variant was found in any of the eight patients previously found to be 
heterozygous for a coding GJB2 mutation or in the patient heterozygous for the c.-22-12C>T 
noncoding variant. 
Among the remaining 80 patients, six of them presented noncoding variants, which had 
already been reported (Table 1). 
One patient, presenting with profound HL was heterozygous for the donor splice site c.-
23+1G>A mutation. The patient may just be a carrier, or other GJB2 or GJB6 mutation might 
remain undetected. One other patient, presenting with moderate to severe HL, harboured in 
heterozygosity the c.-216T>G variant, located within the basal promoter, between two GT boxes 
[24, 25]. This variant was previously identified in two HL patients, also in heterozygosity [26]. 
The c.-45C>A variant in exon 1 was found in heterozygosity in one individual with severe HL. 
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This variant was referred, by Wilch and coworkers [8], as an SNP at position +94 in exon 1. These 
authors observed expression of the GJB2 allele harbouring the variant but, since a quantitative 
comparison with wild-type allele was not performed, a possible contribution to HL cannot be 
excluded. Three affected individuals (two heterozygous and one homozygous) harboured the 
deletion c.-684_-675del. 
No novel putative pathogenic noncoding mutation has been found in the patients, which 
might be due to the low number of monoallelic individuals and the small sample size. It is also 
possible that, simply, such mutations are very rare in our population. 
Among controls, four novel noncoding variants were identified: c.-731C>T, c.-26G>T, 
c.∗45G>A, and c.∗985A>T (rs112400198, rs112875543, rs112399473, and rs111729919, 
respectively). Each of these variants was identified only once, in heterozygosity, and in different 
individuals (Table 1). The hearing individual harbouring the novel c.-731C>T variant was also 
heterozygous for the recessive c.670A>C (p.Lys224Gln) mutation 
(https://research.cchmc.org/LOVD/; phase unknown). One control individual harboured the c.-
45C>A exon 1 variant in heterozygosity (Table 1). Interestingly, we found one control subject 
homozygous for c.-684 -675del (Table 1), which is, to our knowledge, the first case described to 
date of a normal hearing individual presenting this genotype. This individual did not harbour the 
c.101T>C mutation. Our finding, together with the previous report of transcription from alleles 
harbouring c.-684 -675del [16] suggests the nonpathogenicity of the deletion. In addition, six 
normal hearing heterozygotes for the deletion were also identified (Table 1), with one also 
heterozygous for c.101T>C. 
It should be noted that the pathogenic basal promoter mutation c.-259C>T, identified for the 
first time in a Portuguese family [18], was not found among the 89 patients and 91 normal 
hearing individuals here analysed, and neither was it identified in the other studies which 
analysed the basal promoter [14, 16–21]. Therefore, known occurrence of c.-259C>T continues 
to be restricted to that Portuguese family. 
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3.2. Genotypic Data and Statistical Analysis 
The allelic frequencies and Hardy-Weinberg equilibrium status regarding the deletion c.-
684_-675del and the 14 noncoding SNPs were determined (Table 2; see Supplementary Table 1 
in Supplementary Material available online at doi:10.4061/2011/827469). 
The allelic frequencies of the deletion c.-684_-675del in patients and controls are not 
statistically different (Table 2). The allelic frequency observed for this deletion in our control 
population is close to the one found among the British control population [16], and higher than 
the one determined in the German control population [22]. 
The allelic frequencies regarding SNPs c.-410T>C, c.∗84T>C, c.∗168A>G, and c.∗931C>T, 
were statistically different between patient and control groups (Table 2). 
By sorting both patients and controls into groups reflecting the genotypes for these four 
SNPs altogether, eleven composite genotypes were evidenced (Figure 1). Comparison of the 
genotypic frequencies in controls and patients promptly revealed an increased frequency in 
patients of the genotypes YYRY and CTRY, both heterozygous for SNPs c.∗168A>G and 
c.∗931C>T. Also, the genotype YCAC was identified in four patients but not found in controls. On 
the contrary, a decrease was observed in the frequency of the three genotypes that are most 
represented in controls-TCAC, TYAC, and YYAC. Each of the remaining genotypes was scarcely 
represented in both controls and patients (0%-2%), and their frequency did not varymore than 
2%between the two groups; only 3% of controls and 4% of patients belong to one of these 
genotypes. 
We also observed that, regarding SNPs c.∗168A>G and c.∗931C>T, nearly all individuals 
analysed (178/180) were either c.[=;=]+[=;=] or c.[∗168A>G(+)∗931C>T], which results from LD 
between these two SNPs (Supplementary Table 2, SNP pair 8 : 9). Interestingly, the 
overrepresentation of c.[∗168A>G(+)∗931C>T] genotype among patients, when comparing to 
hearing controls, is statistically very significant (χ2 = 28.159; P = 3.4 E-06), thus accounting for 
the statistically significant differences in the allelic frequencies of these two SNPs between 
patients and hearing controls. 
The statistically significant differences also observed in the allelic frequencies of SNPs c.-
410T>C and c.∗84T>C seems to be due to the differential association of their variants with the 
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estimated predominant alleles c.[∗168A+∗931C] and c.[∗168G+∗931T] (Tables 3(a) and 3(b)). 
This fact is in accordance with the observed LD between the two SNPs and SNPs c.∗168A>G and 
c.∗931C>T (Supplementary Table 2, SNP pairs 2 : 8, 2 : 9, 5 : 8, and 5 : 9). 
It should be noticed that the presence of genotype YCAC among patients lends some 
contribute to the difference in allelic frequencies between patients and controls regarding SNP 
c.-410T>C. 
The fact that YCAC genotype is not represented in 91 control individuals while it occurs in 
4/89 patients is noteworthy. The presence of genotype YCAC implies the presence of haplotype 
CCAC, which frequency is of at least 2,2% among patients, and estimated to be null in the 
control population (as inferred from Table 3(a)). In order to validate a possible association of 
haplotype CCAC with HL analysis of larger samples of patients and normal hearing individuals is 
necessary. Interestingly, one of the four patients with the referred composite genotype is a 
c.457G>A heterozygote (phase unknown). 
 
3.3. 3’UTR Variants and mRNA Folding 
Our findings suggest that the c.[∗168G;∗931T] allele might have a deleterious effect, 
contributing to HL. We have used Mfold [23] to predict the effect of alleles c.[∗168A;∗931C], 
c.[∗168G;∗931T], c.[∗168A;∗931T], and c.[∗168G;∗931C] on mRNA folding. The change 
c.∗168A>G, regardless of genotype at position c.∗931, was predicted to alter mRNA folding. On 
the contrary, the change c.∗931C>T, regardless of genotype at position c.∗168, is not predicted 
to alter mRNA folding (Figure 2). 
The c.∗168A was predicted to be located in an internal loop of a stem-loop structure 
(Figure 2). Regulatory motifs in mRNA 3’UTR seem to function in the context of specific 
secondary structure [27]. Stem-loop structures occurring in the 3’UTR have been implicated in 
gene expression, with roles at the level of mRNA stability (e.g., the SLDE of G-CSF gene [28], the 
CDE of TNF-alpha gene [27, 29], the complex structure integrating three C-rich elements of 
alpha-globin gene, the histone mRNA 3’ terminal stemloops, and the IRE of TFRC gene [27]) or 
translation (e.g., the common 30–37 nucleotide long element present in the target mRNAs of 
TIA-1, a translational repressor [30], and the SECIS element [27]). The disruption of the 
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predicted stem-loop structure and/or other adjacent stem-loop structures (Figure 2), induced by 
the c.∗168A>G change, might lead to deregulation of the GJB2 gene expression, thus being a 
contributor to the hearing loss phenotype. It should be stressed that mRNA folding predictions 
are fallible. This fact notwithstanding, the simple change of sequence, without affecting the 
secondary structure, could conceivably disrupt a binding site for a trans-acting factor, also 
leading to gene expression deregulation. Regarding the c.∗931C>T variant, despite the 
predictions that c.∗931C occurs in a helix and that the change from C to T does not have 
structural implications, the in vivo situation might be different. Functional studies involving 
constructs containing a reporter gene’s coding sequence fused with GJB2 3’UTR could help 
elucidating the functional significance of these two sequence variants. 
In this study, of a total of 15 patients presenting either a GJB2 coding mutation or a 
noncoding variant, 14 do not harbour either the c.∗168A>G or the c.∗931C>T changes, whereas 
one patient, heterozygous for the controversial c.380G>A mutation, is a compound 
heterozygote regarding SNPs c.∗168A>G and c.∗931C>T (phase unknown). Therefore, our data 
do not allow withdrawal of conclusions concerning a putative role of the two 3_UTR variants in 
the HL of some monoallelic patients. In this regard, the investigation of the genotypes regarding 
c.∗168A>G and c.931C>T variants in larger samples of monoallelic patients would be interesting. 
Finally, the finding of one c.∗168G homozygote (a c.∗931C>T heterozygote, and carrying no 
GJB2 sequence variant) in our patient cohort, might further support a possible role of c.∗168G in 
HL. 
 
 
4. CONCLUSION 
 
This study suggests the association of the noncoding SNPs c.∗168A>G and c.∗931C>T with 
HL. The c.∗168A>G change is predicted to alter mRNA folding, suggesting a putative role of this 
SNP in the pathology.Our data also point to a possible association with HL of the haplotype 
CCAC, comprising SNPs c.-410T>C, c.∗84T>C, c.∗168A>G, and c.∗931C>T, respectively. However, 
this observation requires validation through analysis of a larger number of subjects. The 
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technique of targeted sequence capture and massively parallel sequencing makes it very easy 
and cost-effective to screen large numbers of genes, and might cover noncoding sequences of 
some of them, such as GJB2. This approach could prove to be very useful for genetic diagnosis in 
cases of NSHL [31], with predictable benefits for genetic counseling of the affected families. 
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FIGURES 
 
 
 
 
Figure 1. Frequencies, in patients (n=89) and controls (n=91), of the composite genotypes 
concerning SNPs c.-410T>C, c.*84T>C, c.*168A>G and c.*931C>T; R = A/G heterozygosity; Y = C/T 
heterozygosity (based on IUPAC nucleotide ambiguity code). 
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Figure 2. Effect of c.*168A>G and c.*931C>T changes in the 3’UTR on 
c.*168A and c.*168G; B: c.*931C and c.*931T. The mRNA folding associated with each variant is the 
same regardless of the allele present at the other position, therefore only one example for each variant 
is provided. 
 
GJB2 mRNA folding. A: 
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TABLES 
 
 
Table 1. GJB2 variants identified in this study. Novel variants are in italic. BP- basal promoter; Ex 1 
– exon 1; DSS – donor splice site; Ex 2 – exon 2; CR – coding region; 3’ UTR – 3’ unstranslated region. 
 
Variant Location Patients (n=89) Controls (n=91) 
Heterozygote Homozygote Heterozygote Homozygote 
c.-731C>T 5’ of the BP 0 0 1 0 
c.-684_-675del 5’ of the BP 2 1 6 1 
c.-216T>G BP 1 0 0 0 
c.-45C>A Ex 1 1 0 1 0 
c.-26G>T Ex 1 0 0 1 0 
c.-23+1G>A DSS 1 0 0 0 
c.670A>C (p.Lys224Gln) Ex 2 (CR) 0 0 1 0 
c.*45G>A 3’ UTR 0 0 1 0 
c.*985A>T 3’ UTR 0 0 1 0 
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Table 2. Differences in the allelic frequencies, regarding c.-684_-675del and 14 SNPs, between 
patient and control samples (chi-square test). ND – Not determined: chi-square test could not be 
performed for SNPs with an expected value <5, or for SNPs which both alleles were observed in only one 
sample. Four SNPs present statistically significant differences in allelic frequencies between patients and 
controls (P values <0.05, in bold). 
 
Variant/SNP Alleles 
Patients (n=178 alleles) Controls 
(n=182 
alleles) 
P value 
Observed Expected 
c.-684_-675del 
wt 174 170.18 174 
0,162043 
c.-684_-675del 4 7.82 8 
rs9550621 
c.-484 C 162 165.29 169 
0,338941 
c.-484 T 16 12.71 13 
rs73431557 
c.-410 C 41 26.41 27 
0,002089 
c.-410 T 137 151.59 155 
rs9552101 
 c.-369 A 20 19.56 20 
0,916103 
c.-369 G 158 158.44 162 
c.*1C>T 
c.*1 C 177 178 182 
ND 
c.*1 T 1 0 0 
rs3751385 
c.*84 C 129 139.86 143 
0,04734 
c.*84 T 49 38.14 39 
rs7337074 
c.*104 A 174 177.02 181 
ND 
c.*104 T 4 0.98 1 
rs7329857 
c.*111 C 174 177.02 181 
ND 
c.*111 T 4 0.98 1 
rs55704559 
c.*168 A 154 170.18 174 
3,33E-09 
c.*168 G 24 7.82 8 
rs5030700 
c.*931 C 155 169.20 173 
9,18E-07 
c.*931 T 23 8.80 9 
rs1050960 
c.*1067 G 19 19.56 20 
0,893155 
c.*1067 T 159 158.44 162 
rs7623 c.*1152 A 165 165.29 169 0,93373 
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Table 3a. Estimated haplotype frequencies, based on the control population, concerning SNPs c.-
410 T>C, c.*84T>C, c.*168A>G and c.*931C>T. 
 
Haplotype Frequency 
TCAC 0.7802 
CTAC 0.0989 
TTAC 0.0714 
CTGT 0.0440 
CCAT 0.0055 
 
 
Table 3b. Relationship between the estimated prevalent alleles regarding positions c.*168 and 
c.*931, and SNPs c.-410T>C and c.*84T>C. 
 
Allele [c.*168; c.*931]  c.-410 T>C c.*84T>C  
AC  89.6% T  82.1% C  
GT  100% C  100% T  
 
  
c.*1152 G 13 12.71 13 
rs11841182 
c.*1197 A 2 0 0 
ND 
c.*1197 T 176 178 182 
rs7988691 
c.*1277 C 178 176.04 180 
ND 
c.*1277 T 0 1.96 2 
rs11839674 
c.*1447 A 2 0 0 
ND 
c.*1447 G 176 178 182 
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SUPPLEMENTARY TABLES 
 
 
Supplementary table 1. Analysis of Hardy-Weinberg equilibrium for c.-684_-675del and 14 SNPs. 
Calculations were based on the control population. ND – Not determined due to lack of genetic 
variability regarding the concerned SNP. 
 
Variant/SNP P value 
c.-684_-675del 0.02972810 
c.-484 T>C 0.39134875 
c.-410 T>C 0.08837465 
c.-369 A>G 0.32767174 
c.*1C>T ND 
c.*84T>C 0.45797172 
c.*104A>T 0.95828080 
c.*111C>T 0.95828080 
c.*168A>G 0.65802073 
c.*931C>T 0.61631805 
c.*1067G>T 0.91543627 
c.*1152G>A 0.45797190 
c.*1197T>A ND 
c.*1277T>C 0.91543627 
c.*1447G>A ND 
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Supplementary table 2. Analysis of pair-wise linkage disequilibrium regarding the 14 SNPs studied. 
Calculations were based on the control population. The P value and the scores for five measures of 
linkage disequilibrium (D, D’, Delta, Delta squared and Fisher's) are presented for each pair of SNPs. Pair-
wise linkage disequilibrium involving SNPs 4, 12 and 14 could not be determined due to lack of genetic 
variability regarding these SNPs. Correspondence: 1 - c.-484 T>C; 2 - c.-410 T>C; 3 - c.-369 A>G; 4 – 
c.*1C>T; 5 - c.*84T>C; 6 - c.*104A>T; 7 - c.*111C>T; 8 - c.*168A>G; 9 - c.*931C>T; 10 - c.*1067G>T; 11 - 
c.*1152G>A; 12 - c.*1197T>A; 13 - c.*1277T>C; 14 - c.*1447G>A. 
 
SNPs Pair P value D D' Delta (Δ) Delta squared (Δ
2
) Fisher's 
1:2 0.1099 -0.0106 -1.0000 -0.1158 0.0134 1.1146 
1:3 0.0000 0.0636 1.0000 0.7894 0.6231 2.0000 
1:5 0.0000 0.0495 0.8812 0.4680 0.2190 2.0000 
1:6 0.0000 0.0051 1.0000 0.2680 0.0718 2.0000 
1:7 0.0000 0.0051 1.0000 0.2680 0.0718 2.0000 
1:8 0.4167 -0.0031 -1.0000 -0.0595 0.0035 1.5460 
1:9 0.3875 -0.0035 -1.0000 -0.0633 0.0040 1.5053 
1:10 0.0000 0.0578 0.9094 0.7179 0.5153 2.0000 
1:11 0.0000 0.0608 0.9167 0.9167 0.8403 2.0000 
1:13 0.7716 -0.0004 -1.0000 -0.0207 0.0004 1.8619 
2:3 0.0390 -0.0163 -1.0000 -0.1466 0.0215 1.0331 
2:5 0.0000 0.1107 0.9495 0.7588 0.5758 2.0000 
2:6 0.6723 -0.0008 -1.0000 -0.0310 0.0010 1.8516 
2:7 0.6723 -0.0008 -1.0000 -0.0310 0.0010 1.8516 
2:8 0.0000 0.0374 1.0000 0.5138 0.2639 2.000 
2:9 0.0000 0.0421 1.0000 0.5465 0.2987 2.0000 
2:10 0.0715 0.0144 0.1540 0.1297 0.0168 1.9467 
2:11 0.1099 -0.0106 -1.0000 -0.1158 0.0134 1.1146 
2:13 0.5484 -0.0016 -1.0000 -0.0440 0.0019 1.7246 
3:5 0.0000 0.0470 0.5440 0.3660 0.1340 2.0000 
3:6 0.0000 0.0049 1.0000 0.2115 0.0448 2.0000 
3:7 0.0000 0.0049 1.0000 0.2115 0.0448 2.0000 
3:8 0.3029 -0.0048 -1.0000 -0.0753 0.0057 1.3864 
3:9 0.2726 -0.0054 -1.0000 -0.0801 0.0064 1.3420 
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3:10 0.0000 0.0518 0.5294 0.5294 0.2802 2.0000 
3:11 0.0000 0.0578 0.9098 0.7182 0.5158 2.0000 
3:13 0.7057 -0.0007 -1.0000 -0.0273 0.0007 1.7918 
5:6 0.4675 0.0016 0.3671 0.0529 0.0028 2.0000 
5:7 0.4675 0.0016 0.3671 0.0529 0.0028 2.0000 
5:8 0.0000 0.0345 1.0000 0.4106 0.1686 2.0000 
5:9 0.0000 0.0389 1.0000 0.4368 0.1908 2.0000 
5:10 0.0000 0.0863 1.0000 0.6728 0.4527 2.0000 
5:11 0.0000 0.0561 1.0000 0.5311 0.2821 2.0000 
5:13 0.0000 0.0086 1.0000 0.2018 0.0407 2.0000 
6:7 0.0000 0.0055 1.0000 1.0000 1.0000 2.0000 
6:8 0.8281 -0.0002 -1.0000 -0.0159 0.0003 1.9560 
6:9 0.8173 -0.0003 -1.0000 -0.0170 0.0003 1.9505 
6:10 0.1877 0.0022 0.4414 0.0958 0.0092 2.0000 
6:11 0.0715 0.0024 0.4645 0.1296 0.0168 2.0000 
6:13 0.9150 -0.0001 -1.0000 -0.0078 0.0001 1.9890 
7:8 0.8281 -0.0002 -1.0000 -0.0159 0.0003 1.9560 
7:9 0.8173 -0.0003 -1.0000 -0.0170 0.0003 1.9505 
7:10 0.1877 0.0022 0.4414 0.0958 0.0092 2.0000 
7:11 0.0715 0.0024 0.4645 0.1296 0.0168 2.0000 
7:13 0.9150 -0.0001 -1.0000 -0.0078 0.0001 1.9890 
8:9 0.0000 0.0418 1.0000 0.9401 0.8838 2.0000 
8:10 0.8877 0.0007 0.0170 0.0104 0.0001 1.7853 
8:11 0.4167 -0.0031 -1.0000 -0.0595 0.0035 1.5460 
8:13 0.7580 -0.0005 -1.0000 -0.0226 0.0005 1.9138 
9:10 0.9903 0.0001 0.0014 0.0009 0.0000 1.7417 
9:11 0.3875 -0.0035 -1.0000 -0.0633 0.0040 1.5053 
9:13 0.7431 -0.0005 -1.0000 -0.0240 0.0006 1.9033 
10:11 0.0000 0.0636 1.0000 0.7894 0.6231 2.0000 
10:13 0.0000 0.0098 1.0000 0.3000 0.0900 2.0000 
11:13 0.0000 0.0102 1.0000 0.3801 0.1444 2.0000 
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Figures 
 
 AAGTCAAAAAAGCCAGTTTAA                                               c.681 
  K  S  K  K  P  V  X                                                p.226 
c.*1C>T           c.*45G>A 
          .         .         .         .         .         .       g.5135 
 cgcattgcccagttgttagattaagaaatagacagcatgagagggatgaggcaacccgtg        c.*60 
        c.*84T>C          c.*104A>T   c.*111C>T 
          .         .         .         .         .         .       g.5195 
 ctcagctgtcaaggctcagtcgctagcatttcccaacacaaagattctgaccttaaatgc       c.*120 
                    c.*168A>G 
          .         .         .         .         .         .       g.5255 
 aaccatttgaaacccctgtaggcctcaggtgaaactccagatgccacaatggagctctgc       c.*180 
 
          .         .         .         .         .         .       g.5315 
 tcccctaaagcctcaaaacaaaggcctaattctatgcctgtcttaattttctttcactta       c.*240 
 
          .         .         .         .         .         .       g.5375 
 agttagttccactgagaccccaggctgttaggggttattggtgtaaggtactttcatatt       c.*300 
 
          .         .         .         .         .         .       g.5435 
 ttaaacagaggatatcggcatttgtttctttctctgaggacaagagaaaaaagccaggtt       c.*360 
 
          .         .         .         .         .         .       g.5495 
 ccacagaggacacagagaaggtttgggtgtcctcctggggttctttttgccaactttccc       c.*420 
 
          .         .         .         .         .         .       g.5555 
 cacgttaaaggtgaacattggttctttcatttgctttggaagttttaatctctaacagtg       c.*480 
 
          .         .         .         .         .         .       g.5615 
 gacaaagttaccagtgccttaaactctgttacactttttggaagtgaaaactttgtagta       c.*540 
 
          .         .         .         .         .         .       g.5675 
 tgataggttattttgatgtaaagatgttctggataccattatatgttccccctgtttcag       c.*600 
 
          .         .         .         .         .         .       g.5735 
 aggctcagattgtaatatgtaaatggtatgtcattcgctactatgatttaatttgaaata       c.*660 
 
          .         .         .         .         .         .       g.5795 
 tggtcttttggttatgaatactttgcagcacagctgagaggctgtctgttgtattcattg       c.*720 
 
          .         .         .         .         .         .       g.5855 
 tggtcatagcacctaacaacattgtagcctcaatcgagtgagacagactagaagttccta       c.*780 
 
          .         .         .         .         .         .       g.5915 
 gtgatggcttatgatagcaaatggcctcatgtcaaatatttagatgtaattttgtgtaag       c.*840 
 
          .         .         .         .         .         .       g.5975 
 aaatacagactggatgtaccaccaactactacctgtaatgacaggcctgtccaacacatc       c.*900 
         c.*931C>T 
          .         .         .         .         .         .       g.6035 
 tcccttttccatgactgtggtagccagcatcggaaagaacgctgatttaaagaggtcgct       c.*960 
         c.*985A>T 
          .         .         .         .         .         .       g.6095 
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 tgggaattttattgacacagtaccatttaatggggaggacaaaatggggcaggggaggga       c.*1020 
                  c.*1067G>T 
          .         .         .         .         .         .       g.6155 
 gaagtttctgtcgttaaaaacagatttggaaagactggactctaaagtctgttgattaaa       c.*1080 
          CS1 CS2         U-tract 
          .         .         .         .         .         .       g.6215 
 gatgagctttgtctacttcaaaagtttgtttgcttaccccttcagcctccaattttttaa       c.*1140 
       c.*1152G>A                    c.*1197T>A 
          .         .         .         .         .         .       g.6275 
 gtgaaaatatagctaataacatgtgaaaagaatagaagctaaggtttagataaatattga       c.*1200 
 
          .         .         .         .         .         .       g.6335 
 gcagatctataggaagattgaacctgaatattgccattatgcttgacatggtttccaaaa       c.*1260 
       c.*1277T>C 
          .         .         .         .         .         .       g.6395 
 aatggtactccacatatttcagtgagggtaagtattttcctgttgtcaagaatagcattg       c.*1320 
                   CS3 CS4           U-tract 
          .         .         .         .         .         .       g.6455 
 taaaagcattttgtaataataaagaatagctttaatgatatgcttgtaactaaaataatt       c.*1380 
                      CS5 
          .         .         .         .         .                 g.6510 
 ttgtaatgtatcaaatacatttaaaacattaaaatataatctctataataattta /          c.*1435 
 
 
 
             CS6 
         .         .         .         .         .               g.6515 
        / aaatc   c.*1440 
  c.*1447G>A 
         .         .         .         .         .         .    g.6575 
taatatggttttaatagaacagcaaattttaatttcatctatcactttttatataaatac     c.*1500 
 
         .         .         .         .         .         .     g.6621 
attaatgttttatatttcataacaccaatgggtaagttgccagagt                   c.*1546 
 
Figure 1. Human GJB2 genomic sequence including the whole 3’UTR, and the further downstream 
sequence analysed in this work. The six inferred cleavage sites (CS1-6), highlighted in blue, were assigned 
based on the human sequences deposited at Genbank with the following accession numbers: CS1 - 
CA310936.1 (lung epithelial cells), AW086214.1 (ovarian carcinoma); CS2 - BC071703.1 (adult colon, 
kidney and stomach pool); CS3 - AA613715.1 (colon tumor); CS4 - AA461087.1 (total 8-9 weeks fetus); 
CS5 - BI492740.1 (fetal cochlea), BC017048.1 (colon adenocarcinoma), BU686041.1 (lung epithelial cells), 
CD370089.1 (lung alveolar macrophage); CS6 - BI491091.1 (fetal cochlea); corresponds to the 
NM_004004.5 mRNA reference sequence. CS1, CS4 and CS5 correspond to the three alternative 
polyadenylation sites in AceView (D. Thierry-Mieg & Thierry-Mieg, 2010), although the exact location of 
each CS seems to differ from those here presented. The counting criteria of the number of bases 
between the UPCAS and the poly-A site did not seem to be uniform but, apparently, AceView (D. Thierry-
Mieg & Thierry-Mieg, 2010) considered the CS to be the last non-A residue before the poly-A tail even if 
it included genomic As. Here, in such cases, since it is possible that the first nucleotide of the poly-A tail 
might be template encoded (Zhao, Hyman, & Moore, 1999), we have considered a genomic A (arbitrarly 
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the last) to be the CS. The 11 investigated SNPs within the 3’UTR are highlighted in yellow, while the two 
novel SNPs, within the same region, identified in this work, are highlighted in green (the names of the 
SNPs are provided above their locations). The UPCAS are in red and bold font. The potential DCPAS (U-
stretches in the corresponding pre-mRNA) are in orange and bold font. The presented sequence was 
accessed through **Public** CCHMC Molecular Genetics Laboratory Mutation Database - gap junction 
protein, beta 2, 26kDa (GJB2) (Husami et al, 2009a, 2009b). 
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 Figure 2. Partial DNA sequencing electrophoretograms showing the novel 
identified in this study. The designation of each sequence variant is provided above the corresponding 
electrophoretogram. 
 
 
 
Figure 3. Conservation of the 3’UTR of the 
considerable degree of conservation, and do not include the SNPs c.*168A>G (rs55704559) and 
c.*931C>T (rs5030700). Adapted from Encode database (Birney 
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GJB2 gene. Some regions within the 3’UTR show 
et al., 2007). 
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The initial part of the work leading to this PhD thesis consisted in searching for 
mutations in the coding region and acceptor splice site of the GJB2 gene in over 140 
Portuguese individuals, presenting with NSSHL and already screened for the c.35delG 
mutation. Since mutations in this single gene were shown to account for a significant 
fraction of the NSSHL cases in many populations (Kenneson, Van Naarden Braun, & Boyle, 
2002), GJB2 molecular analysis has been the first step of the studies on hereditary HL led by 
our group in Portugal since 1998. 
During this past activity, two novel coding GJB2 mutations, p.Val84Met and 
p.Met163Leu were identified (Matos, 2002; Matos, Caria, O’Neill, Correia, & Fialho, 2003). A 
short time after, the p.Val84Met mutation was also found by other group (Pandya et al., 
2003). Additionally, the less frequently studied basal promoter, exon 1 and donor splice site 
were investigated in some patients, found to be heterozygous for a recessive, controversial 
or unclear mutation. As a result of this additional mutational screening, a previously 
unreported mutation (c.-259C>T) was found within the basal promoter, in trans with the 
p.Val84Met mutation (Matos et al., 2007).  
The results obtained were integrated in the overall genetic data concerning the 
prevalence of GJB2 mutations in 264 Portuguese sporadic and familial NSSHL cases (Chapter 
2). The results pertaining three of the families analysed in this first stage of the study, all 
carrying the controversial p.Arg127His mutation, were discussed in more detail in Chapter 5. 
The second part of this work consisted in the functional characterization of the fore 
mentioned c.-259C>T, p.Val84Leu and p.Met163Leu mutations, in order to elucidate their 
suspected pathogenicity and contribute for a better understanding of the effects of the 
different GJB2 mutations and of how they conduce to HL (Chapters 3 and 4). 
The final part of this work, presented in Chapter 6, included the extension of the pilot 
study concerning noncoding regions, by screening the GJB2 donor splice site, exon 1 and the 
immediately 0.7 Kb upstream region (including the basal promoter), and the whole 3’UTR, in 
a larger sample of HL patients (n=89) who harboured none or just one GJB2 coding mutation. 
Furthermore, a total of 14 SNPs across the fore mentioned noncoding regions were 
genotyped in these patients. The same methodology was followed to study 91 individuals 
with self-reported normal hearing from the Portuguese general population. 
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1. Spectrum of mutations in the GJB2 gene in Portuguese NSSHL patients 
 
We have found a wide spectrum of GJB2 pathogenic/controversial mutations among 
the 264 Portuguese NSSHL families analysed (Chapter 2). Most of these mutations had 
already been identified in other populations. Three novel mutations (c.-259C>T, p.Val84Met 
and p.Met163Leu) were found in two of these Portuguese families (Matos, 2002; Matos et 
al., 2003, 2008, 2007). One of these three mutations (c.-259C>T) has, until now, not been 
reported in any family other than the one in which it was identified (Matos et al., 2007). 
Taking into consideration the overall results regarding the 264 families, some 
important conclusions can be drawn.  
GJB2 mutations, in coding and noncoding regions, were found in 80 (30.2%) of the 264 
patients. Patients with two GJB2 mutations represented 20% of the probands analysed, 
while 10.2% harboured only one GJB2 variant. 
The c.35delG deletion was, as expected, the GJB2 mutation most frequently found 
amongst the NSSHL patients, comprising 63.2% of the mutant alleles, and being present in 
over 80% of the biallelic individuals. The c.35delG homozygous genotype was by far the most 
prevalent GJB2 mutated genotype, being present in 10.6% of the Portuguese NSSHL 
patients. In accordance with other studies (Cryns et al., 2004; Murgia et al., 1999), we also 
noticed variability in the degree of HL in the patients homozygous for c.35delG. 
The HL of the patients could be attributed, or assumed to be due, to the GJB2 
genotype in all biallelic patients, with the exception of the only p.Arg127His homozygous 
patient, since we could not determine whether this controversial genotype (Chapter 5) was 
segregating with the HL in the family. 
The GJB2 genotype of one monoallelic patient also explained the HL, since the patient 
harboured one dominant GJB2 mutation (p.Met163Leu). Interestingly, the dominant GJB2 
mutation p.Met163Leu, causing mild/moderate high-frequency HL in the Portuguese patient 
and her mother (Chapter 4), has meanwhile also been found in one Argentinean patient 
presenting with prelingual, profound NSSHL (Dalamón et al., 2010), suggesting that the 
severity of the HL due to the p.Met163Leu mutation might be variable and/or progressive. 
Further screening for the GJB6 deletions, and GJB2 basal promoter and donor splice 
site, contributed to the elucidation of the HL in five other patients with only one coding 
mutation, since the del(GJB6-D13S1854) was found in two of these patients, the basal 
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promoter (c.-259C>T) mutation was identified in another one, and the donor splice site (c.-
23+1G>A) mutation was present in the remaining two individuals. 
Interestingly, an excess of c.35delG heterozygotes (11/264) was observed. Their allelic 
frequency corresponds to 4.1%, which is very high when compared with the c.35delG carrier 
rate in the Portuguese general population (0.88%) (data not yet published). It should be 
noted that we were not able to analyse all the 11 patients for the GJB6 deletions and the 
GJB2 noncoding regions considered in this study. So, although some of these individuals 
might just be coincidental carriers, some other patients may harbour a second DFNB1 
mutation, even in other GJB2/GJB6 regions not here analysed, thus explaining the excess of 
c.35delG heterozygotes. 
In conclusion, with basis solely on coding mutations, a diagnosis of GJB2-associated HL 
was confirmed for 18.9% of the cases. Thus, GJB2 mutations are an important cause of 
NSSHL in the Portuguese population, being c.35delG the predominant mutation, with each 
of the 19 other pathogenic/controversial variants occurring at much lower frequencies. 
Screening for the GJB2 donor splice site and the basal promoter, as well as for the two 
common GJB6 deletions, allowed the elucidation of the etiology of the HL in some of the 
cases with only one coding mutation identified. Therefore, such screening, in monoallelic 
patients, is advisable and should be performed. 
Overall, 20.8% of the patients were diagnosed as having DFNB1-related NSSHL, which 
represents a valuable indicator as regards therapeutical and rehabilitation options, as well as 
genetic counseling of Portuguese patients and their families. 
 
1.1 Genetic influx from other populations 
The identification, in Portuguese HL patients, of certain variants (c.-23+1G>A, c.-22-
12C>T, p.Trp24X, p.Val37Ile, c.167delT and p.Arg127His) which are particularly frequent in 
certain populations, is suggestive of genetic influx. 
p.Thr24X. The p.Trp24X mutation is a frequent variant among NSHL patients in India, 
where high carrier frequencies were observed, although the prevalence among normal-
hearing control individuals seemed to vary with the geographic region (Joseph & Rasool, 
2009; Khandelwal, Bhalla, Khullar, & Panda, 2009; Maheshwari et al., 2003; G. Padma, 
Ramchander, Nandur, & Padma, 2009; RamShankar et al., 2003). This mutation is also 
frequent among NSHL cases in Gypsies, an ethnic group tracing their origins to the Indian 
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subcontinent (Minárik et al., 2003; Álvarez et al., 2005), and presents with high carrier 
frequencies in several European Gypsy subpopulations (Bouwer et al., 2007). In line with 
these data, in our patient sample those harbouring the p.Trp24X mutation are of Indian or 
Gypsy descent. 
p.Arg127His. The p.Arg127His mutation is a common variant in the Indian population 
(G. Padma et al., 2009; RamShankar et al., 2003), having also been identified in Gypsy NSHL 
patients (Minárik et al., 2003; Álvarez et al., 2005). In our study, this mutation was identified 
in five families, three of which are described in Chapter 5. Two of these five families belong 
to the Gypsy ethnicity, being the ethnicity of the other three families unknown.  
p.Val37Ile. As regards p.Val37Ile, its prevalence is high in Eastern Asians (Abe, Usami, 
Shinkawa, Kelley, & Kimberling, 2000; Han et al., 2008; Huculak, Bruyere, Nelson, Kozak, & 
Langlois, 2006; Hwa et al., 2003; Kudo et al., 2000; Ohtsuka et al., 2003; Wattanasirichaigoon 
et al., 2004). Although this mutation presented a high allelic frequency (15.3%) among Asian 
patients, significant allelic frequencies were found among Hispanic (1.1%) and White (5.5%) 
hearing-impaired individuals in the study conducted by Putcha et al. (2007). Therefore, the 
presence of p.Val37Ile at considerable frequencies in HL patients, across distinct ethic 
groups, might reflect ancient migrations. 
c.-23+1G>A. The c.-23+1G>A donor splice site mutation has been frequently identified 
in NSHL cases in Eastern Europe, Turkey and the Kurdish population of Iran (Mahdieh et al., 
2004; Seeman & Sakmaryová, 2006; Sirmaci, Akcayoz-Duman, & Tekin, 2006; Tóth et al., 
2007).  
c.167delT. The carrier frequency of c.167delT is very significant in Ashkenazi Jews 
(Lerer et al., 2000; Morell et al., 1998; Sobe et al., 1999). This mutation was also found at 
relatively high frequency in Palestinian NSSHL patients, and is thought to have occurred a 
single time in Middle Eastern antiquity (Shahin et al., 2002). Given the presence of Jews in 
Portugal since many centuries ago, it is not surprising to find the c.167delT mutation in 
Portuguese patients.  
c.-22-12C>T. The c.-22-12C>T variant (dbSNP accession number rs9578260) seems to 
be mostly associated with subsaharian Africans (Bethesda (MD): National Center for 
Biotechnology Information National Library of Medicine, n.d.). The finding of this variant 
among Portuguese patients is also not surprising due to the historic relation between 
Portugal and some subsaharian African countries (former Portuguese colonies). 
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1.2. Controversial mutations 
The mutations p.Met34Thr, p.Arg127His, p.Val153Ile and p.Gly160Ser, identified in this 
study, are of controversial pathogenicity. 
p.Met34Thr. Heterozygosity for p.Met34Thr occurring in normal-hearing individuals 
has been reported by Scott et al. (1998) and several other studies, including the present one 
(Chapter 2), while all p.Met34Thr homozygotes described so far showed HL, most often 
ranging from mild to moderate (R. A. Cucci et al., 2000; Dietz, Löppönen, Valtonen, 
Hyvärinen, & Löppönen, 2009; Houseman et al., 2001; Marlin et al., 2001; Snoeckx, Huygen, 
et al., 2005; Teek et al., 2010; B.-L. Wu et al., 2002). Altogether, these reports support the 
view of p.Met34Thr being a recessive mutation. 
Skerrett, Di, Kasperek, Kelsell, and Nicholson (2004) presented electrophysiological 
evidence that also supports a recessive role for the p.Met34Thr allele. Impaired function of 
intercellular channels composed of p.Met34Thr-Cx26 was further supported by other 
studies, as assessed by single channel conductance measurements, intercellular neurobiotin 
(NBN) and LY transfer and Ca2+ waves spreading assays (Bicego et al., 2006; D’Andrea et al., 
2002; Thönnissen et al., 2002).  
Normal-hearing individuals who were compound heterozygous for p.Met34Thr and 
c.35delG or del(GJB6-D13S1830) have been described (Feldmann et al., 2004). Nonetheless, 
these and other compound heterozygous genotypes involving p.Met34Thr, have also been 
found in individuals with some degree of hearing impairment, most often presenting with 
mild to moderate HL (Bicego et al., 2006; Cama et al., 2009; Griffith et al., 2000; Kenna, Wu, 
Cotanche, Korf, & Rehm, 2001; Snoeckx, Huygen, et al., 2005; B.-L. Wu et al., 2002). Pollak et 
al. (2007) found a clear association of c.35delG/p.Met34Thr genotype with HL, but of 
relatively mild severity, and with weaker penetrance compared with c.35delG homozygotes. 
The authors found that the HL associated with c.35delG/p.Met34Thr genotype was often 
detected only at > 7 years old, and provided evidence supporting the progressiveness of the 
impairment. Thus, penetrance of DFNB1 compound genotypes involving the p.Met34Thr 
mutation might depend on genetic modifiers and/or environmental factors.  
In two patients of this study we have found the p.Met34Thr mutation in compound 
heterozygosity with the c.35delG and p.Val95Met recessive mutations, respectively. Thus, 
both compound genotypes were assumed to be the likely causes of the HL. 
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p.Arg127His. Regarding the p.Arg127His variant, identified in this study in a total of 
five families, we have performed a detailed review of the literature aiming at clarifying its 
role. Many authors argue that evidence plays in favor of it being a polymorphism. However, 
considering our genetic data, as well as the genetic and functional data available in the 
literature, our opinion is that the p.Arg127His mutation might exert a pathogenic effect, 
depending on the genetic background and/or environmental factors (Chapter 5). 
p.Val153Ile. The p.Val153Ile mutation, which we found as the sole GJB2 mutation in 
Portuguese patients (Chapters 2 and 6), has been considered as either a polymorphism or a 
recessive allele. Marlin et al. (2001) refer two cases in which two individuals with normal 
hearing (at least at conversational frequencies) had the c.35delG/p.Val153Ile genotype, and 
RamShankar et al. (2003) refer two hearing individuals homozygous for p.Val153Ile as well as 
similar frequencies of p.Val153Ile in hearing-impaired and in hearing individuals. 
Nonetheless, several studies reported the identification, in HL patients, of the p.Val153Ile 
mutation in compound heterozygosity with the recessive GJB2 mutations c.35delG, 
p.Thr8Met and p.Leu90Pro (Cryns et al., 2004; Dalamón et al., 2005; Hashemzadeh 
Chaleshtori et al., 2005; Kenna et al., 2001; Marlin et al., 2001; Snoeckx, Hassan, Kamal, Van 
Den Bogaert, & Van Camp, 2005), or with p.Met34Thr (Snoeckx, Huygen, et al., 2005). 
Noteworthy, the genotype p.Thr8Met/p.Val153Ile has been reported, in HL patients, in four 
different studies (in distinct genetic backgrounds). Moreover, the p.Val153Ile mutant protein 
was unable to form functional intercellular channels in Xenopus oocytes (Meşe, Londin, Mui, 
Brink, & White, 2004). However, a more recent study, this time in a mammalian expression 
system (HeLa cells), reported that channels composed of the p.Val153Ile mutant connexin 
were targeted to the membrane and formed intercellular channels permeable to LY (Guerci 
et al., 2007). It should be noted that normal permeability to LY has been reported for the 
pathogenic p.Val84Leu mutation, which displayed impaired permeability to IP3 (Beltramello, 
Piazza, Bukauskas, Pozzan, & Mammano, 2005). Considering all these data, a pathogenic 
effect of the p.Val153Ile mutation remains a possibility, and should not be disregarded. 
p.Gly160Ser. Mutation p.Gly160Ser was identified in a proband (sporadic case) 
presenting with bilateral moderate NSSHL at the age of 11 years old (Chapters 2 and 3). This 
mutation seems to be a rare variant (<1/~150 alleles) in the general population across 
different ethnic groups (Tang et al., 2006), and has usually been regarded as a 
polymorphism. The p.Gly160Ser mutation, in heterozygosity, was found in two NSHL cases 
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compatible with dominant HL, reported by Janecke et al. (2002) and Löffler et al. (2001). 
However, the genetic data presented do not allow conclusions to be drawn regarding a role 
of p.Gly160Ser in HL. Some other HL patients, heterozygous for the p.Gly160Ser mutation, 
have been reported (Cheng et al., 2005; Hashemzadeh Chaleshtori, Farhud, & Patton, 2007; 
Santos et al., 2005; Tang et al., 2006) but, considering the presented information, no 
inference about its pathogenicity can be made. On the other hand, the report of hearing-
impaired individuals presenting with NSHL compatible with a recessive mode of inheritance 
and with the c.35delG/p.Gly160Ser or p.Val37Ile/p.Gly160Ser genotypes (Snoeckx, Huygen, 
et al., 2005) could suggest a possible pathogenic effect of the p.Gly160Ser mutation. Further 
genetic data and/or functional studies are needed to help elucidating the role of p.Gly160Ser 
in HL. 
 
 
2. Assessment of GJB2 noncoding regions in HL patients 
 
2. 1. Exon 1, basal promoter and upstream region 
Most of the studies that analysed the GJB2 gene of HL patients have not screened the 
gene beyond its coding region and splice sites. However, the whole exon 1 and the upstream 
region (including the basal promoter) have been analysed in some studies. In spite of the 
fact that these noncoding regions have not been given as much attention as the coding 
region, they are potential locations of pathogenic mutations which might interfere with GJB2 
expression. These mutations could help to elucidate and explain the excess of c.35delG 
monoallelic patients identified in the Portuguese patients analised. 
We have investigated GJB2 donor splice site, exon 1 and basal promoter in a total of 
100 unrelated HL patients, previously analysed as regards the coding region and not 
harbouring any of the GJB6 common deletions (Chapters 3, 4, 5 and 6). Eighteen out of these 
100 patients carried one pathogenic or controversial GJB2 coding mutation. 
As a result of this screening, we have found, in one of the monoallelic patients, above 
reported, a novel GJB2 mutation, c.-259C>T, occurring within a Sp1/Sp3 binding site in the 
GJB2 basal promoter (Chapter 3). This mutation was identified in trans with the c.250G>A 
(p.Val84Met) mutation in a profoundly hearing-impaired individual. The patient’s 
moderately hearing-impaired mother was heterozygous for the p.Val84Met mutation only, 
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while her normal-hearing sister was heterozygous for the basal promoter mutation. The 
location of the mutation in a transcription factor binding site critical for GJB2 basal 
expression, its occurrence in trans with a coding GJB2 mutation in an hearing-impaired 
individual, and its absence in 70 unrelated normal-hearing controls, were suggestive of a 
possible pathogenic effect. Therefore, we have performed a functional study in order to 
assess its functionality (Chapter 3). 
In one other HL patient, carrier of the controversial p.Arg127His, already mentioned 
above, we have identified the c.-23+1G>A donor splice site recessive mutation (Chapter 5). 
The compound genotype was considered as a likely cause of the HL. The same noncoding 
mutation was identified in heterozygosity in one other patient, who didn’t harbour any GJB2 
coding mutation (Chapter 6). The etiology of the HL in that case remained unelucidated. 
One important finding of this study was the identification, for the first time, of a 
normal-hearing individual homozygous for the 10 bp deletion c.-684_-675del (Chapter 6) 
and not carrying the p.Met34Thr mutation, which is in LD with the 10 bp deletion (Zoll et al., 
2003). Whether this deletion has a pathogenic effect on the hearing function has been 
unclear. Although it had been previously found in homozygosity in two hearing-impaired 
individuals, these two sibs were also homozygous for the p.Met34Thr mutation (Houseman 
et al., 2001). The same study reported expression from the allele harbouring both c.-684_-
675del and p.Met34Thr mutations, but this analysis was not quantitative. The normal-
hearing individual homozygous for the 10bp deletion, here reported, provides evidence for 
its non-pathogenicity. To our knowledge, after the first report of the c.-684_-675del by 
Houseman et al. (2001) only the study of Zoll et al. (2003) and our own have considered the 
c.-684_-675del. These three studies revealed considerable allelic frequencies in the British, 
German and Portuguese (this study) control populations (4.9%, 2.8% and 4.4%, respectively). 
We have also identified, in normal-hearing subjects, two previously unreported variants 
in the exon 1 and in the region upstream of the basal promoter (see sequencing traces in 
Chapter 6, Annex fig. 2). 
 
2.2. 3’UTR 
As already mentioned, most of the studies on GJB2 have only analysed the coding 
region. Some of these studies, however, have also analysed the sequence immediately 
downstream of the stop codon (included in the amplified region) but they have not 
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considered the whole 3’UTR. We could find in the literature one study in which the whole 
3’UTR of the GJB2 gene had also been analysed, but only in three patients from a large 
pedigree (Wilch et al., 2006). No putative pathogenic variant in the 3’UTR has been reported 
in that or in any other study.  
The 3’UTRs play, however, important roles in gene expression, being involved in its 
regulation at multiple levels (mRNA 3’-end formation, mRNA polyadenylation, 
stability/degradation, nuclear export, subcellular localisation and translation efficiency), 
through a variety of cis-acting regulatory elements (reviewed in J.-M. Chen, Férec, & Cooper, 
2006a, 2006b). Therefore, 3’UTRs should be considered in the genetic screening of disease-
associated genes. In fact, several sequence variants (including common polymorphisms in 
the general population) within the 3’UTR of other genes have been shown to affect gene 
expression (for instance, by interfering with mRNA 3’-end formation or mRNA stability) 
leading to or being associated with human disease (reviewed in J.-M. Chen, Férec, & Cooper, 
2006a, 2006b). 
Thus, we have sequenced and analysed the whole GJB2 3’UTR in 89 unrelated HL 
patients (who are included in the 100 patients analysed for the GJB2 donor splice site, exon 
1 and basal promoter), who were negative or heterozygous for pathogenic or controversial 
GJB2 coding mutations, as well as in 91 normal-hearing controls. This analysis also included 
the genotyping for ten SNPs within the 3’UTR, and one SNP further downstream, for which 
we observed variability in the patient and/or control samples. 
Polyadenylation of eukaryotic mRNAs is critical for the regulation of mRNA stability 
and translation. In mammalian, three elements define the core polyadenylation signal: a) the 
UCPAS (upstream core polyadenylation signal), a conserved hexamer (AATAAA or a close 
variant), located 10-30 nucleotides upstream the polyadenylation addition site; b) the DCPAS 
(downstream core polyadenylation signal) which is a less conserved U/GU rich element, 
located 10-30 nucleotides downstream the polyadenylation addition site; c) the cleavage site 
(CS), or the polyadenylation addition site (J.-M. Chen, Férec, & Cooper, 2006a). The UPCAS is 
a potential location of pathogenic mutations. In fact, some mutations were shown to disrupt 
this signal in other genes and are associated with human disease (reviewed in Chatterjee & 
Pal, 2009; J.-M. Chen, Férec, & Cooper, 2006a). Furthermore, the identity of the nucleotide 
residues at positions -1 and -2 relative to the CS appear not to be random, since Sheets, Ogg, 
and Wickens (1990) observed that these positions were occupied by an adenine and cytosine 
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residues, respectively, in most of the vertebrate genes they have analysed. Consistent with 
the suggested functional relevance of the two positions immediately upstream of the CS, a 
polymorphism at position -1 relative to the CS of the prothrombin gene (F2) was found to be 
associated with elevated prothrombin levels and with increased risk of venous thrombosis 
(Poort, Rosendaal, Reitsma, & Bertina, 1996). This polymorphism causes increased CS 
recognition, increased 3’-end processing, and increased mRNA accumulation and protein 
synthesis (Danckwardt et al., 2004; Gehring et al., 2001). A sequence variant located 11 
nucleotides downstream of the CS, apparently at a DCPAS, also resulted in increased mRNA 
expression and protein synthesis, and increased efficiency of the 3’-end formation. Both the 
fore mentioned variants resulted in gain-of-function, but loss-of-function mutations may 
conceivably occur at the same functional elements. In fact, J.-M. Chen, Férec, and Cooper 
(2006a) argued that, considering the genetic and clinical data of the patient, two single 
nucleotide substitutions in cis, with one of the two variants occurring at the nucleotide at 
position -2 relative to the CS, might lead to a moderate decrease in the efficiency of CS 
recognition. In this study, the sequences of the three UCPASs of GJB2 gene, and the two 
nucleotides immediately preceding the six inferred CSs (see Chapter 6, Annex fig. 1), were 
invariant in patients and controls. 
The 3’UTR of GJB2 gene contains stretches of four or more T residues localised no 
more than 30 nucleotides downstream of each of the six inferred CS (see Chapter 6, Annex 
fig. 1). Several lines of evidence suggest that pentamers consisting of four U residues and 
any other residue within this pentamer may serve as DCPAS. Pentamers of U residues and A 
or C single point substitutions in any position of the pentamer were able to mediate 
polyadenylation, being the U pentamer the most efficient element (Chou, Chen, & Wilusz, 
1994). Moreover, stretches of four U residues were able to interact with the 64K subunit of 
the CstF (MacDonald, Wilusz, & Shenk, 1994). Consistent with these experimental findings, 
pentamers consisting of four U residues and any other residue within this pentamer, located 
within 30/32 bases downstream of the CS, have been found to occur in the majority of 
mammalian (including human) polyadenylation signals containing AAUAAA/AUUAAA UPCAS 
(F. Chen, MacDonald, & Wilusz, 1995; Zarudnaya, Kolomiets, Potyahaylo, & Hovorun, 2003). 
Thus, the fore mentioned tracts of T residues might well correspond to DCPASs in the GJB2 
pre-mRNA. However, similarly to what was observed with the UCPASs, the sequences of 
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these potential DCPASs (see Chapter 6, Annex fig. 1) were invariant in our patients and 
controls. 
As regards the entire 3’UTR of GJB2 gene, we have found two novel variants in normal-
hearing individuals (see sequencing traces in Chapter 6, Annex fig. 2), but no novel mutation 
was identified in the patients. Noteworthy, we did observe a statistically very significant 
association of two SNPs (which are in strong LD) with HL. This association could be due to a 
pathogenic effect of either or both SNPs, or it could be due to an unidentified pathogenic 
variant in linkage with the two SNPs. We next assessed the possible structural implications of 
both SNPs, by using the mRNA folding prediction program Mfold. Only the SNP c.*168A>G, 
which was also found in homozygosity in one of the patients, was predicted to alter the 
mRNA folding. However, the mRNA folding in silico predictions serve merely as an indication 
and must be considered with caution. Upon conservation analysis we noticed moderately 
conserved regions in the 3’UTR of GJB2, by using the ENCODE database (Birney et al., 2007). 
Both SNPs are localised outside of these regions (see Chapter 6, Annex fig. 3). Nonetheless, 
any of the two SNPs might be functionally relevant in our species, and it would be interesting 
to assess, in other populations, their association with HL. We have also observed an 
increased frequency, in the patient group, of one haplotype comprising four SNPs (CCAC) 
but, due to the low number of subjects, no statistically valid conclusion could be drawn from 
our data. The possible association of this haplotype with HL needs to be assessed in a larger 
sample. 
 
 
3. Functional assessment of three novel pathogenic GJB2 mutations 
 
We investigated the role in hearing impairment of three novel GJB2 mutations, all of 
which had been identified in Portuguese NSSHL patients. 
These mutations, c.-259C>T, c.250G>A (p.Val84Met) and c.487A>C (p.Met163Leu), 
were identified in two nuclear Portuguese families, presenting with NSSHL (Matos et al., 
2008, 2007). The pattern of transmission was compatible either with autosomal dominant or 
mitochondrial inheritance. The presence of the A1555G and A7445G mtDNA mutations, 
associated with HL, and occurring in several populations, was excluded in the two families. 
Screening of the GJB2 coding region in the members of these families revealed the 
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segregation of either one of the two coding mutations with the HL, which further suggested 
an autosomal dominant mode of inheritance of the condition. However, Pandya et al. (2003) 
also reported one profoundly hearing-impaired 17-year-old female heterozygous for 
c.250G>A (p.Val84Met) born to normal-hearing parents. Furthermore, Cheng et al. (2005) 
described one family with apparently recessive HL, in which the affected members 
presented with profound HL and were compound heterozygous for p.Val84Met (the 
mutation at the DNA level was not indicated) and either c.35delG (grandmother) or 
p.Met34Thr (two of the siblings). These genetic data suggested a recessive nature for 
p.Val84Met. Effectively, we found, in the profoundly hearing-impaired proband, a second 
GJB2 mutation (c.-259C>T) in the basal promoter, in trans with c.250G>A (p.Val84Met). The 
basal promoter mutation, not present in the mother, was also identified in heterozygosity in 
the proband’s normal-hearing sister. 
Since the c.-259C>T and the p.Met163Leu mutations had not been reported in any 
other study we have performed functional studies to investigate their suspected 
pathogenicity. Assessment of the functionality of the c.250G>A (p.Val84Met) mutation was 
also pursued, since the genetic data regarding that mutation was restricted to our study and 
two other reports (Cheng et al., 2005; Pandya et al., 2003), from which its pathogenicity 
could not be unequivocally inferred. 
The effects of the two coding mutations, p.Val84Met and p.Met163Leu (localised to 
M2 and in E2, respectively), in the functionality of Cx26, as assessed by our functional assays, 
were distinct. 
 
3.1. The p.Val84Met-Cx26 mutant 
The p.Val84Met-Cx26 mutant protein was able to traffic to the cell membrane, 
forming gap junction-like structures, although apparently displaying an increased retention 
in the cytoplasm, as compared to the wild-type protein (Chapter 3, supp. fig. 2). However, 
the intercellular channels formed solely by p.Val84Met-Cx26 were impermeable to both LY 
and NBN, suggesting loss-of-function of these channels in vivo. We have also observed that 
the p.Val84Met-Cx26 mutant could co-localise with wtCx26 or wtCx30 at gap junctions. This 
fact suggested that this mutant might form mixed channels with wtCx26 and/or wtCx30 in 
vivo. However, the functionality of such channels may be affected to some degree by the 
presence of the defective protein. The possibility that this fact, together with other genetic 
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and/or environmental factors, might be responsible for the moderate HL of the p.Val84Met 
carrier, mother of the c.-259C>T/p.Val84Met proband, cannot be discarded. 
Further considerations regarding the Val84 residue in Cx26 are due. This amino acid 
residue is conserved across mammals (Chapter 3, Annex fig. 3). In addition, the valine 
residue at the corresponding position in other mammalian beta-connexins is invariant 
(Chapter 3, Annex fig. 4). Several mutations affecting this valine residue in human beta-
connexin genes, GJB2 as well as GJB1 (Cx32) and GJB3 (Cx31), were identified in individuals 
presenting with HL or X-linked Charcot-Marie-Tooth (CMTX) disease (Table 1).  
 
Table 1. Non-synonymous mutations affecting the Val84 amino acid residue in human beta-
connexins. 
 
Gene 
Mutation 
Phenotypea Studies 
DNA Protein 
GJB2 (Cx26) 
c.250G>A p.Val84Met HL 
Matos (2002) 
Matos et al. (2003) 
Pandya et al. (2003) 
c.250G>C p.Val84Leu HL 
Kelley et al. (1998) 
Zoll et al. (2003) 
Azaiez et al. (2004) 
Tang et al. (2006) 
Putcha et al. (2007) 
c.250G>T p.Val84Leu HL Putcha et al. (2007) 
c.251T>C p.Val84Ala HL 
H. J. Park, Hahn, 
Chun, Park, and Kim 
(2000) 
Pandya et al. (2003) 
GJB1 (Cx32) c.250G>A p.Val84Ile CMTX Rouger et al. (1997) 
GJB3 (Cx31) c.250G>A p.Val84Ile HL 
J.-J. Yang et al. 
(2010) 
  
a. The condition affecting the individuals harbouring the referred mutations. 
CMTX - X-linked Charcot-Marie-Tooth disease; HL - Hearing loss. 
 
The c.250G>C (p.Val84Leu), in GJB2, have been found segregating with HL compatible 
with a recessive pattern of inheritance (Azaiez et al., 2004; Kelley et al., 1998). Two other 
GJB2 mutations, c.250G>T, also leading to p.Val84Leu, and c.251T>C (p.Val84Ala) have been 
identified in compound heterozygosity with c.35delG (Pandya et al., 2003; Putcha et al., 
 2007). Kenna et al. (2001) reported a patient, with profound HL, homozygous for p.Val84Leu 
(mutation at DNA level was not provided). 
in GJB1 and GJB3 genes, in CMTX and HL patients, respectively
et al., 2010; Y. Yuan et al., 2009)
apparently a polymorphism (Y. Yuan 
that mutations changing the Val84 residue in beta
residues, are not always tolerated.
(Beltramello et al., 2005; Zhang 
their pathogenicity. The p.Val84Leu
IP3 (Beltramello et al., 2005; Zhan
displayed ionic coupling and permeability to LY comparable to wild
(Beltramello et al., 2005; Bruzzone 
channels were impermeable t
substitution of Val84 for the bulkier leucine or methionine is likely to increase the distance 
between M2 and M3 (fig. 1). 
 
 
Figure 1. Representation of relative positions of amino acid 
The spheres represent van der Waals radii. The main chains of Arg143 and Glu147 are in blue, while 
the main chain of the amino acid residue at position 84 (Val84, Leu84 or Met84) is in pink. The side 
chains maintain the color code of Swiss
structure model, led the side chains of both Leu84 and Met84 to contact with the main chains of 
Arg143 and Glu147. The side chain of Leu84 and Met84 also contact the side chain of Phe1
shown, for image clarity). The lowest free
considered. This simulation was based on the Cx26 model 2zw3 
using Swiss-Pdb Viewer v4.0.2 (Guex & Peitsch, 1997)
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et al., 2009). Nonetheless, these genetic data suggest 
-connexins, even if for other hydrophobic 
 Functional characterization of mutations p.Val84Leu 
et al., 2005) and p.Val84Met (this study) further supported 
-Cx26 channels displayed impaired permeability to PI and 
g et al., 2005). However, while p.Val84Leu
et al., 2003; Zhang et al., 2005), the p.Val84Met
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(Maeda et al., 2009)
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The resulting displacement of M2 might, in turn, might cause displacement of the N
terminus helices, which are thought to form a constriction site (the funnel) at the 
cytoplasmic entrance of the pore of the connexon, in its open
2). 
 
 
Figure 2. Structure of a Cx26 connexon, showing the funnel structure (upper panel), and 
representation of the relative positions of amino acid residues Gln7, Leu10 (in N
-state (Maeda 
-
et al., 2009; fig. 
 
-terminus), Leu89 
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and Ala92 (in M2), in a Cx26 subunit, showing their close proximity (lower panel). The differently 
colored ribbons in upper panel represent different connexin subunits within the same connexon. In 
the lower panel, the side chains of Gln7 and Leu10 are in green and those of Leu89 and Ala92 are in 
blue, while the backbones of those amino acid residues maintain the color code of Swiss-Pdb Viewer. 
In the left side image of the lower panel, van der Waals radii are represented as punctate spheres, 
while in the right side image they are rendered as solid spheres. The protein backbone comprised of 
amino acid residues 2 to 7 is in bright green, in both panels. The putative displacement of M2, caused 
by the interaction of leucine or methionine at position 84 (marked in the ribbon in pink) with Arg143 
(in orange in the ribbon), Glu147 (in blue in the ribbon) and Phe146 (in red in backbone) (upper and 
lower panels), likely implies a change in the position of Leu89 and Ala92, the amino acid residues into 
which the first part of the N-terminus seems to fit, through Gln7 and Leu10 (see lower panel). As a 
consequence, such displacement might alter the normal position of the N-terminus, and therefore 
the funnel’s diameter. This simulation was based on the Cx26 model 2zw3 (Maeda et al., 2009) and 
performed using Swiss-Pdb Viewer v4.0.2 (Guex & Peitsch, 1997). 
 
As a result, the diameter of the funnel bottom might be reduced, thus preventing the 
permeation of the fore mentioned tracers or the second messenger IP3. In this hypothesis, 
the reduced electrical coupling associated with p.Val84Met-Cx26 but not with p.Val84Leu-
Cx26 channels, could be due to smaller diameter of the funnel bottom induced by the 
former mutation, since methionine is bulkier than leucine. Alternatively, the greater 
deleterious effect of the p.Val84Met mutation on the permeability properties could arise if 
the displacement of M2 prevented the N-terminus to be in close proximity to the inner wall 
of the channels, and disrupted the factors stabilizing the funnel structure, preventing the 
channel to be in the open state. The factors, that promote the stabilization of the funnel 
structure and the proximity of the N-terminus to the pore wall, could be, as suggested by 
Maeda et al. (2009), the hydrogen bond between Asp2 and Thr5, and the hydrophobic 
interaction of Met34 and Trp3, of adjacent protomers. In fact, disruption of the latter 
interaction was hypothesized to release the N terminus from the pore wall, which would 
then form the occluding “plug” observed within the pore of the Cx26-p.Met34Ala channel (A. 
Oshima, Tani, Hiroaki, Fujiyoshi, & Sosinsky, 2007, 2008; A. Oshima et al., 2011). Therefore, 
such mechanism might explain the observed impermeability to NBN and LY and the reduced 
conductance of the p.Val84Met-Cx26 channels. 
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3.2. The p.Met163Leu-Cx26 mutant 
As regards the p.Met163Leu-Cx26 protein the functional studies performed indicated 
that the mutant protein presented a trafficking defect, when expressed alone, but could 
form gap junction-like structures containing both the mutant and wtCx26 or wtCx30. An 
interesting finding regarding this mutant was that it caused increased cell death. This lethal 
phenotype was only partially rescued by co-expression of the mutant with either wtCx26 or 
wtCx30 in a 1:1 ratio, suggesting a dominant-negative effect of the mutant on both wild-type 
connexins, as regard to cell viability. Co-expression of the mutant with both wild-type 
connexins in a ratio mimicking a p.Met163Leu heterozygote with two functional GJB6 (Cx30) 
alleles, resulted in a cell death rate not statistically different (although slightly higher) from 
that of cells expressing wtCx26 and wtCx30 (1:1 ratio). Notwithstanding, if the distinct and 
graded expression of Cx26 and Cx30 reported in the guinea-pig (Zhao & Yu, 2006) also occurs 
in the human, heterozygosity for p.Met163Leu may explain the HL observed in the patients 
here reported, which affects the higher frequencies more pronouncedly. Interestingly, 
heterozygosity for p.Met163Leu has also been described in an Argentinean patient who 
presented with prelingual, profound NSHL (Dalamón et al., 2010). The more severe 
phenotype of the Argentinean patient might be due to the genetic background that could 
result in: i) a significantly higher cell death rate induced by the mutation; ii) quantitative 
differences in the expression of connexin subunits leading to different number of functional 
channels; iii) a significantly increased susceptibility to the disruption of the gap junction 
network, each factor of which would strongly compromise the whole cochlea and, thus, all 
the frequencies. However, a possible progression of the HL could also account for the more 
severe HL of that patient. 
Our results suggest that the increased cell death phenotype associated to 
p.Met163Leu-Cx26 mutant might not be due to aberrant hemichannel function. By one 
hand, no gap junctions were observed between cells expressing the mutant protein, and the 
protein was apparently retained in the cytoplasm, suggesting a trafficking defect. By another 
hand, high extracellular calcium concentration did not rescue the increased lethality 
phenotype, as was the case of other dominant Cx26 mutations, p.Gly12Arg, p.Asn14Lys, 
p.Ala40Val and p.Gly45Glu (Gerido, DeRosa, Richard, & White, 2007; J. R. Lee, Derosa, & 
White, 2009; Stong, Chang, Ahmad, & Lin, 2006), leading to aberrant hemichannel function 
in Xenopus oocytes (also in HEK-293 mammalian cells, in the case of p.Gly45Glu). It should 
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be mentioned that the increased cell death induced by p.Asp50Asn (a Cx26 syndromic skin 
disease-associated mutation) which could not be rescued by high extracellular calcium 
concentration in this study, has however been rescued by a similarly high extracellular 
calcium concentration in one study using Xenopus oocytes (J. R. Lee et al., 2009). This 
discrepancy might be due to intrinsic cellular physiology differences between both species. 
The amino acid residues Gly12, Asn14 (both localised to the N-terminus), Gly45 and Asp50 
(both localised to the E1) of Cx26 are thought to be pore-lining residues (Maeda et al., 2009) 
and therefore potentially involved in voltage-dependent gating. The Ala40 residue, although 
not contacting the pore lumen, is at the M1/E1 boundary which has been suggested to be 
involved in voltage sensing, and is adjacent to the Lys41 residue which might have a role in 
sensing the voltage field (Maeda et al., 2009). 
Our data suggests that the increased cell death phenotype in human cells induced by 
p.Asp50Asn and p.Met163Leu might be accounted for a different mechanism, other than 
aberrant hemichannel gating. Tattersall, Scott, Gray, Zicha, and Kelsell (2009), using human 
cell lines, provided evidence that endoplasmatic reticulum (ER) stress, leading to the 
unfolded protein response (UPR), and not “leaky” hemichannels, was the main cause of the 
increased cell death observed with erythrokeratodermia variabilis (EKV)-associated Cx31 
mutants, p.Arg42Pro and Cys86Ser, localised to distinct domains (E1 and T2, respectively). 
Interestingly, the pattern of cellular localisation of these EKV mutants, which co-localised 
with upregulated proteasome markers, resembles that of the p.Met163Leu-Cx26, here 
reported. Thus, it is a possibility that the p.Met163Leu mutation causes increased cell death 
due to ER-stress. As far as the three dimensional structure of Cx26 is concerned, the 
p.Met163Leu mutation might lead to clashes between Leu163 and Phe69, and between 
Leu163 and Gln164. A leucine at position 163 could also tangentially contact Val182 (fig. 3). 
Indeed, these interactions might affect folding. 
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Figure 3. Three dimentional structure of E1 and E2 of Cx26, depicting the methionine or 
leucine at position 163, and the amino acid residues putatively contacting Leu163. The leucine 
rotamer here represented is one out of the four possible rotamers (all four rotamers had the same 
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free-energy value). The backbone of the amino acid residue at position 163 is in dark pink, while the 
side chain of that residue is in light pink. Atoms of amino acid residues at positions 69, 164 and 182 
maintain the color code of Swiss-Pdb Viewer. The blue ribbon represents E1 and the yellow ribbon 
represents E2. The images in the left represent van der Waals radii as punctate spheres. In the right-
hand images van der Waals radii are rendered as solid spheres. This simulation was based on the 
Cx26 model 2zw3 (Maeda et al., 2009) and performed using Swiss-Pdb Viewer v4.0.2 (Guex & 
Peitsch, 1997). 
 
3.3. The c.-259C>T mutation 
The c.-259C>T mutation changed a GC box, previously proved to be capable of binding 
to Sp1 and Sp3 transcription factors, and to be critical for GJB2 basal promoter activity since 
it disruption by mutation almost abolished reporter gene activity in two human epithelial cell 
lines (Tu & Kiang, 1998). We have shown that the c.-259C>T mutation greatly impaired 
promoter activity, in two other human cell lines, HEK-293 and Caco-2. The fact that drastic 
impairment of basal promoter activity due to mutations in the fore mentioned GC box was 
consistently observed (four different cell lines), reinforces the notion the Sp1/Sp3-mediated 
activation of GJB2 basal promoter is intrinsically dependent on that particular GC box, in 
spite of the existence of one other GC box, close upstream, also capable of binding to 
Sp1/Sp3 (Tu & Kiang, 1998). Thus, it is reasonable to assume that the c.-259C>T mutation 
might impair the basal promoter activity in the supporting cells of the organ of Corti and/or 
fibrocytes of the spiral ligament and spiral limbus. If this hypothesis is correct, nearly all Cx26 
produced in those cochlear regions, in the c.-259C>T/p.Val84Met proband, is expected to be 
the p.Val84Met-Cx26 mutant form (here shown to impair Cx26 channel function in vitro), 
thereby possibly compromising in vivo the function of Cx26 containing intercellular channels. 
The proband’s normal-hearing sister carries only the c.-259C>T mutation, which is also 
consistent with the functional data. She carries one wild-type GJB2 allele, which suffices to 
ensure normal hearing function. Therefore, the analysis of the genetic and the functional 
data strongly supports that the proband’s genotype is most likely the cause of her HL. 
Noteworthy, pathogenic mutations affecting important regulatory elements have been 
identified in 5’ untranslated and promoter regions of other connexin genes. A GJB1 
mutation, previously found in a family with CMTX, disrupts an internal ribosome entry site 
(IRES) within the 5’UTR of the nerve-specific Cx32 mRNA, abolishing translation (Hudder & 
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Werner, 2000). Two other GJB1 mutations, also identified in CMTX patients, where shown to 
cause a reduction in SOX10-dependent activation of the nerve-specific promoter P2 
(Bondurand et al., 2001; Houlden et al., 2004). Osaka et al. (2010) found, in a patient with 
mild Pelizaeus-Merzbacher-like disease, a GJC2 (Cx47) mutation which completely abolished 
the SOX10 binding and attenuated the promoter activity. 
 
 
4. Concluding remarks 
 
The contribution of GJB2 mutations to NSSHL in Portuguese families has been 
investigated. As in several other Caucasian populations, c.35delG was the most frequent 
GJB2 mutation identified. However, the contribution of GJB2 mutations to the HL and the 
relative proportion of c.35delG homozygous cases were not as high as in other Southern 
European populations. 
We have assessed the functionality of two GJB2 missense mutations and one GJB2 
basal promoter transition mutation, identified in two Portuguese HL families, and for which 
a pathogenic role was suspected. The results obtained further supported a pathogenic role 
for each of the three mutations, thus allowing the molecular diagnosis of GJB2-related HL for 
three affected individuals, with benefits to the respective families, since genetic counselling 
could be provided. 
This work also contributed to extend GJB2 analysis, as regards the role of GJB2 
noncoding regions in HL. We have found the first pathogenic mutation occurring in the basal 
promoter, allowing for the elucidation of the HL of one affected subject. This finding shows 
the relevance of searching for mutations beyond the GJB2 coding region and splice sites, in 
NSSHL cases, especially in monoallelic individuals. Furthermore, we have found a strong 
association of two SNPs in the GJB2 3’UTR with HL. It would be interesting to investigate 
whether this association is also present in other populations. Finally, this work provides 
some relevant annotation regarding known and putative functional elements on the 3’UTR, a 
region neglected in nearly all molecular diagnosis studies, which might be useful for future 
investigation. 
 
 
 5. Future Directions 
 
As already mentioned, and it was also shown in this thesis, the 
be affected not only by mutations occurring in the coding region, but also by mutations in 
noncoding regions, such as the promoter and the donor splice si
patients, noncoding mutations may remain to be identified in other noncoding regions of the 
gene. We have noticed that a ~200 bp stretch within the intron shows some conservation 
(fig. 4), which suggests it might be important for
 
 
Figure 4. Representation of 
derived from ENCODE (Birney et al
of ~200 bp, displaying significant overall conservation 
represents exon 1 plus part of the basal promoter. The basal promoter region shows considerable 
conservation. 
 
As such, pathogenic mutations occurring in that intronic regio
cases. 
 
Considering the results here obtained, we propose that screening of 
promoter, exon 1 and donor splice site should be performed in those Portuguese patients 
harbouring only one pathogenic/controversial 
Since the prevalence of GJB2
NSSHL cases was low, linkage to DFNB1 should be demonstrated in those patients who 
harboured no GJB2 coding mutation and none of the common 
those other patients who harboured only one 
and in whom the screening of the basal promoter, exon 1 and donor splice site had failed to 
identify further mutations. If there is indication of linkage to DFNB1 then the investigation of 
GJB2 sequence should be extended to the other noncoding regions which have been here 
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investigated, as well as to the fore mentioned ~200 bp stretch of the intron, for which 
massive parallel sequencing could be a valuable methodology. 
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